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Abstract
Melissa Whaley
Role of Influenza among Adult Respiratory Hospitalizations: a Systematic Review
(Under the direction of Dr. Lisa Casanova, faculty member)
With the threat of avian influenza, influenza laboratory testing and surveillance capacity
has increased globally. Data from global surveillance activities have been used to identify
circulating influenza strains for vaccine policy decisions, and have provided evidence of
influenza disease among various populations. A recent meta-analysis, which includes
findings from these surveillance efforts, has shown that influenza contributes to 10% of
pediatric respiratory hospitalizations. Although statistical models indicate a high burden
of influenza-associated morbidity among older adults and pandemic studies reveal an
increase in hospitalizations among young adults, the global burden of seasonal influenza
among adults remains unknown. In order to estimate the global burden of seasonal
influenza among adult respiratory hospitalizations, we conducted a systematic review of
the published literature, and identified 48 eligible articles published between January
1996 and June 2012 that met our inclusion criteria. We combined these published
datasets with 29 eligible, unique datasets from year-round, influenza hospital-based
surveillance. These combined data covered 50 countries with varying income and vaccine
policies. Extracting numbers tested and positive for influenza, we calculated crude
median positive proportions and evaluated potential differences in crude proportions
among variables using Kruskal-Wallis non-parametric tests. We observed differences by
data source and country development status when we included the 2009 pandemic year.
With the exclusion of the 2009 pandemic year, we then generated adjusted pooled
estimates using the log binomial model. We found 11% of cases from adult respiratory
hospitalizations worldwide were laboratory-confirmed for influenza. This pooled
estimate was independent of age but increased as country development or income level
decreased. Our findings suggest that influenza is an important contributor to severe acute
respiratory illness among both young and older adult populations. For countries without
reliable influenza data, we provide an estimate that they may use in planning and
allocating resources for the control and prevention of influenza.
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Chapter I Introduction
1.1 Background
Respiratory diseases remain the second leading cause of deaths globally.
Influenza contributes to this global mortality (Ferkol & Schraufnagel, 2014). According
to the World Health Organization (WHO), an estimated 200,000 to 500,000 deaths and 3
to 5 million hospitalizations annually are attributable to influenza (WHO, 2014b). This
burden is due in part to the mutable nature of the influenza virus, which causes seasonal
epidemics and potentially pandemics (CDC, 2012, 2013). The only current means of
influenza prevention is through vaccination (CDC, 2012, 2013; Fiore, Bridges, & Cox,
2009). Although influenza vaccination and other interventions have been associated with
reductions in influenza disease many countries do not have sufficient evidence on the
burden of influenza to support the implementation of such interventions (Bresee et al.,
2013; Partridge & Kieny, 2013; Radin et al., 2012).
High-income, developed countries have found evidence of the high influenza
disease burdens among young children and older adults, through modeling approaches
and hospital-based surveillance (W. W. Thompson, Shay, Weintraub, & et al., 2004;
Zhou et al., 2012). The recent advancement and expansion of both approaches has
afforded developing countries and countries with complicated influenza seasons the
ability to monitor influenza disease (Savy et al., 2013; Simmerman & Uyeki, 2008)
(Gessner, Shindo, & Briand, 2011; Mmbaga et al., 2012; Radin et al., 2012; Savy et al.,
2013). Combining the data from these advancements and from a systematic review, two
meta-analyses have estimated the global burden of seasonal influenza in pediatric
respiratory hospitalizations (Lafond et al., 2014; Nair et al., 2011). The meta-analyses
revealed substantial morbidity among the pediatric population globally (~1 million cases
of severe acute lower respiratory infections, 374,000 to 870,000 hospitalizations), with
school-aged children bearing the highest burden (Lafond et al., 2014; Nair et al., 2011).
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While global burden is not known for adults, certain adult populations are at
higher risk of disease. Adults who care for ill children or patients are at an increased risk
of influenza disease (Kuster et al., 2011; Dena L. Schanzer, Langley, & Tam, 2008a;
Mauskopf, Klesse, Lee, & Herrera-Taracena, 2013). Complications as a result of disease
have been observed in individuals with underlying conditions (C. Cohen et al., 2012;
Gessner et al., 2011; Mauskopf et al., 2013; Dena L. Schanzer et al., 2008a). The
increased risk of influenza disease and complications associated with disease is especially
high during pandemics (CDC, 2013; N. J. Cox & Subbarao, 2000; F. S. Dawood et al.,
2012; Kuster et al., 2011; Dena L. Schanzer et al., 2008a). Similarly to previous
pandemics, an estimated 65% of deaths associated with the 2009 pandemic H1N1
influenza virus was observed globally among adults <65 years old (N. J. Cox &
Subbarao, 2000; F. S. Dawood et al., 2012).
In preparation for future pandemics, WHO is working with country officials and
stakeholders to increase vaccine supply and to encourage influenza vaccine research and
development (Friede et al., 2011). With sufficient supply of effective influenza vaccines,
countries across the global will potentially reduce case-fatalities and prevent the
breakdown of health and social services (Friede et al., 2011). Research and development
will lead to improved treatment options, prevention strategies, and diagnostics (Stohr,
2003; Yu et al., 2014).
Due to competing priorities and limited resources, many countries have not
implemented policies to control and prevent influenza disease (Ayele et al., 2012;
Samaan, McPherson, & Partridge, 2013) leaving their populations susceptible to
influenza disease (Friede et al., 2011; Partridge & Kieny, 2013). Middle and low income
countries without established influenza vaccine policies report the largest burden of
influenza morbidity and mortality within Asia, Africa, and Latin America and the
Caribbean, and among the pediatric population worldwide (Gessner et al., 2011; Lafond
et al., 2014; Nair et al., 2011; Savy et al., 2013; Simmerman & Uyeki, 2008). These high
burden estimates, obtained from hospital-based surveillance and summed through metaanalyses, may provide the needed evidence to advocate for investments in influenza
control and prevention measures, which will in turn improve the global pandemic

3
preparedness and response (Friede et al., 2011; Gordis, 2009; Schoub, 2010; WHO,
2005).
Although current systematic reviews and meta-analyses shed light on the high
influenza burdens in developing countries and within the global pediatric population,
little is known about the global burden of influenza among the adult populations (Gessner
et al., 2011; Kuster et al., 2011; Dena L. Schanzer et al., 2008a). A recent publication
suggests higher incidences of respiratory failure due to influenza among hospitalized
adults than among pediatric patients (Ortiz et al., 2013). Through this systematic review
of published and unpublished influenza-associated hospitalization datasets, we provide an
estimate for the global burden of influenza among adult respiratory hospitalizations. This
estimate may be used to guide influenza policy, assisting the needs assessment for
interventions, in countries without reliable influenza data, and to support global programs
that establish and sustain influenza surveillance, laboratory testing, and vaccine
manufacturing capacity.
1.2 Purpose of study
The purpose of this study is to estimate the global proportion of influenza in adult
acute respiratory hospitalizations through a systematic review.
1.3 Research questions:
1. What is the estimated global proportion of adult (≥18 years old) acute respiratory
hospitalizations due to seasonal influenza?
2. Of these hospitalizations, is a higher influenza-positive proportion observed
among older adults (≥65 years old) than younger adults (18-64 years old)?
3. Do influenza positive proportions differ by WHO regions?
4. Do the positive proportions vary by country income levels and/or developmental
status?
5. Due to the variability of laboratory tests (differences in sensitivity and specificity
between different laboratory tests) and clinical presentations, do the test
performance and/or case definitions impact the positive proportions?
6. How does the pandemic H1N1 data impact the positive proportions?

Chapter II Literature Review
Influenza has caused morbidity and mortality throughout the centuries globally. The
first documented influenza pandemic was in 1580 (CDC, 2012). An estimated 20-30
million or more deaths resulted from the Spanish influenza pandemic in 1918 (CDC,
2012). In 2009, approximately 60 million cases of pandemic influenza A (H1N1) were
reported in the United States alone (CDC, 2012). Of these cases, 270,000 were
hospitalized and 12,500 died (CDC, 2012). Other influenza pandemics occurred in 1957
(H2N2) and 1968 (H3N2, WHO 2005). During non-pandemic years, “seasonal” influenza
viruses contribute to morbidity and mortality worldwide (L. Simonsen et al., 1997).
Viboud et al. estimated that 1 million annual deaths worldwide are attributable to
influenza (Cécile Viboud, Alonso, & Simonsen, 2006).
2.1 Influenza Viruses
Influenza is a single-stranded RNA virus of the Orthomyxovirus family (CDC, 2012).
Three types of influenza cause disease in humans—type A, B, and C (CDC, 2012). Type
C is thought to be the least virulent, typically causing subclinical infections in children
and young adults (CDC, 2012; Greenbaum, Morag, & Zakay-Rones, 1998; White &
Fenner, 1994). Greenbaum et al and others report sporadic cases of influenza type C
during influenza types A and B outbreaks (Greenbaum et al., 1998; Taylor, 1951).
In recent years, the burden of influenza type B illness has reportedly increased in the
United States and the United Kingdom (W.P. Glezen, Schmier, Kuehn, Ryan, & Oxford,
2013). Type B viruses are divided into two genetic lineages, Victoria and Yamagata
(CDC, 2012, 2013). These lineages may co-circulate (CDC, 2013). In vitro analysis
suggests that type B is a more stable virus, with a slower mutation rate than type A
(CDC, 2013; W.P. Glezen et al., 2013); the same lineage (Victoria) included in the
trivalent vaccine for last 10 years (CDC, 2013). Five of those ten years, the vaccine
lineage was predominant (CDC, 2013). While lineage is the same, the vaccine strain
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changes similarly to type A subtypes (WHO, 2014c). Generally, type B infections are
primarily found in children (CDC, 2013).
Type A is categorized into subtypes by surface antigens, hemagglutinin (HA) and
neuraminidase (NA) (CDC, 2012, 2013; White & Fenner, 1994). HA (H1-16) promotes
viral attachment to host cell, while NA allows the virus to penetrate the cell (CDC, 2012,
2013; White & Fenner, 1994). HA in human flu viruses are genetically similar to those
isolated from birds and pigs (CDC, 2013). In 2013, human cases of H7N9, resulting from
a triple assortment, were identified and thought to be associated with open markets
selling birds (Liu et al., 2014).
Influenza viruses undergo frequent antigenic change during viral replication
(CDC, 2013). Small changes occur within the genes coded for the antigen-binding sites
of the virus, known as antigenic drift (CDC, 2012, 2013). Antigenic drift may lead to
epidemics, since these changes may result in a new, unrecognizable virus to the host’s
immune system (CDC, 2012). Epidemics are reported annually for types A and B (CDC,
2012, 2013; W.P. Glezen et al., 2013). In the United States, annual influenza epidemics
account for 114,000 hospitalizations and 20,000 deaths (Brammer et al., 2002). Type A
viruses experience antigenic drift more frequently and more rapidly than types B (CDC,
2013). Type A viruses may also undergo recombination events, where not seen before
surface antigens arise (CDC, 2012, 2013; White & Fenner, 1994). This phenomenon is
known as antigenic shift (CDC, 2012, 2013; White & Fenner, 1994). Antigenic shift
promotes the greatest change potentially resulting in pandemics where little or no preexisting immunity exists and when the new virus effectively transmits from human to
human (CDC, 2013). Antigenic shifts are thought to occur approximately every 20 years,
while antigenic drifts occur all the time (CDC, 2012). Pandemics have higher attack rates
than epidemics (CDC, 2012, 2013). Gordan et al found attack rates doubled for
pandemic H1N1 (20.1%) in comparison to the 2007 seasonal influenza (11.7%) among
children in Nicaragua (Gordon et al., 2010). While severe disease during annual
epidemics often disproportionately affects certain age groups (<5 and ≥65 years old) and
individuals with comorbidities, pandemics have a wider impact across age groups and
health statuses, including healthy young individuals (CDC, 2012; WHO, 2012a).
However, seasonal epidemics can occasionally cause spikes in severe respiratory illness
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in young, healthy individuals as well, as observed in the 2003-2004 season (CDC, 2014a;
WHO Collaborating Center for Surveillance et al., 2004).
2.2 Transmission, Clinical Presentations, and Diagnosis
The main mode of influenza transmission is through direct or indirect, via
contaminated object, contact with respiratory droplets from an infected individual
(Weinstein, Bridges, Kuehnert, & Hall, 2003). One to four days after contact, newly
infected individuals may exhibit the classic influenza symptoms: abrupt onset of fever,
myalgia, sore throat, nonproductive cough, and/or headache (CDC, 2012). These
symptoms are often used to describe other pathogenic infections (CDC, 2012; Harper et
al., 2009; Weinstein et al., 2003). Influenza infections are generally self-limiting and can
be asymptomatic (Harper et al., 2009). In fact, 50% of influenza-infected individuals
present symptoms (CDC, 2012). The clinical course of influenza infections depend on the
individual’s health as well as on the circulating influenza strain (CDC, 2012). Influenza
infections may progress to severe pneumonia, primary influenza pneumonia or secondary
bacterial pneumonia (Bader & McKinsey, 2005; CDC, 2012). Influenza was identified as
one of the leading causes of community acquired pneumonia hospitalizations among
adults in Vietnam and acute respiratory illness case-fatalities among adults in Guatemala
(Takahashi et al., 2013; Verani et al., 2013). Influenza infections have led to the
exacerbations of underlying medical conditions, such as myocarditis and chronic
pulmonary diseases (CDC, 2012; Harper et al., 2009; Dena L. Schanzer, Langley, &
Tam, 2008b).
As influenza illness presents similarly to many other respiratory pathogens and
cannot be diagnosed by clinical presentation alone, infection needs to be confirmed
through laboratory testing (Weinstein et al., 2003). These laboratory tests may include
viral culture, direct or indirect immunofluorescence, serology (such as antigen
complement fixation assay, hemagglutination inhibition assay, and enzyme-linked
immunosorbent assays), single or multiplex polymerase chain reaction (PCR), and rapid
antigen tests (Kumar & Henrickson, 2012; Talbot & Falsey, 2010). Laboratory tests vary
in required technical skills and/or specialized equipment, turnaround times, as well as
sensitivity and specificity for influenza detection (Kumar & Henrickson, 2012; Talbot &
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Falsey, 2010). Despite these differences, all tests are limited in their ability to detect
influenza virus by the time from illness onset to of specimen collection as peak shedding
occurs early in infection, and by the handling and storage of specimen (Lau et al., 2010)
(Carrat et al., 2008; Kumar & Henrickson, 2012).
2.3 General Epidemiology
Circulation of influenza viruses
The dominant circulating influenza type and/or subtype may change from year to
year and vary in disease severity. Prior to pandemic H1N1, higher influenza-associated
mortality rates were reported when type A H3N2 predominately circulated than when
type A H1N1 or type B predominately circulated (CDC, 2010; Kyncl et al., 2005; L.
Simonsen et al., 1997; W. W. Thompson et al., 2009). Following the pandemic H1N1 in
2009, in 2010, influenza B was the virus type in eastern Asia, and northern and eastern
Europe (WHO, 2010). In Southeast Asia and in Africa, pandemic type A (H1N1)
remained predominant with type B and type A H3N2 co-circulating (WHO, 2010).
Influenza peaks during the winter months in temperate regions (November
through March in the northern hemisphere and April through September in the southern
hemisphere); these periods are marked by an increase in medical visits for classic
influenza-like symptoms (fever and cough and/or sore throat) (CDC, 2012; N. J. Cox &
Subbarao, 2000). This may be due to the fact that the influenza virus survives longer
outside of the host in cold and dry weather (Cécile Viboud et al., 2006; WHO, 2014b).
Peaks of influenza occur year-round in tropical and subtropical regions (CDC, 2012; N. J.
Cox & Subbarao, 2000; Cécile Viboud et al., 2006).
Risk factors associated with severe outcomes due to seasonal influenza
Influenza viruses cause disease in all ages (CDC, 2013). Illness due to influenza,
as described earlier, is generally mild, not requiring medical attention (CDC, 2012,
2013). Some cases, however, do lead to severe outcomes, such as hospitalization and/or
death. From influenza mortality and morbidity rates, studies have shown that certain age
groups and people with comorbidities are at an increased risk of severe influenzaassociated outcomes (CDC, 2012, 2013).
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During a typical influenza season, a U-shaped distribution curve is observed
among the age groups, where the highest number of influenza-attributable
hospitalizations and deaths are reported for children <5 years old and adults ≥65 years old
(CDC, 2013; C. Viboud et al., 2004). Functionality of the host immune system may play
a role; young children lack immunity while older adults are unable to mount adequate
protective immune response against the circulating influenza virus (CDC, 2013; Haq &
McElhaney, 2014; Sambhara & McElhaney, 2009). Immune functionality is further
decreased in children and adults with underlying medical conditions (CDC, 2013).
Medical conditions, such as chronic cardiovascular disease and chronic
respiratory disease, may worsen when individuals become ill due to influenza (Madjid,
Aboshady, Awan, Litovsky, & Casscells, 2004; Mauskopf et al., 2013; Dena L. Schanzer
et al., 2008a; Siriwardena, 2012). Within 3 days of influenza infection, individuals with
cardiovascular disease are 4-times more likely to experience myocardial infarction and
stroke (Smeeth et al., 2004). Influenza infections increase the incidence of secondary
bacterial infections in patients with chronic obstructive pulmonary disease (COPD),
leading to longer hospitalization stays and greater lung impairment (Mallia & Johnston,
2007). Influenza infections exacerbate wheezing and asthma in young children (Patria,
Tenconi, & Esposito, 2012). Neurological diseases, diabetes, chronic renal disease,
morbid obesity, and compromised or suppressed immune systems due to HIV,
transplants, or chemotherapy have also been linked to influenza-related complications
(CDC, 2013; C. Cohen et al., 2012; Mauskopf et al., 2013).
Pregnant or recently pregnant women have also shown to be at increased risk of
complications due influenza infections (CDC, 2013; Laibl & Sheffield, 2005; WHO,
2012a). Secondary bacterial infections are common among pregnant women in their third
trimester and postpartum women within 4 weeks after delivery (Laibl & Sheffield, 2005).
Some studies report increased delivery complications in pregnant women hospitalized for
influenza infection (CDC, 2013).
Due to the nature of their job, healthcare workers are at an increased risk of
influenza infections (CDC, 2013; Kuster et al., 2011). Kuster et al calculated this risk as
a 2.5 fold increase in healthcare workers compared to adults not working in the
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healthcare field (Kuster et al., 2011). Healthcare workers may also spread influenza to
vulnerable patients (Kuster et al., 2011).
Prevention
Although good hygiene assists in preventing influenza transmission, the only and
most effective method of influenza prevention is through vaccination (CDC, 2010, 2013;
Fiore et al., 2009). Current vaccines available in the United States are the inactivated
influenza vaccine (administered to anyone ≥6months without contradictions); live,
attenuated, cold adapted influenza vaccine (LAIV, administered via nasal spray to only
children 2-8 without aspirin-regiments or respiratory conditions (asthma or wheezing));
the inactivated influenza vaccine with a higher dose of hemagglutinin (available as
another option for adults >65 years old); and trivalent recombinant influenza vaccine and
cell-based inactivated influenza vaccine (as options for individuals with an egg allergy)
(Fiore et al., 2009; Grohskopf et al., 2014). Inactivated influenza vaccines may be
formulated to protect against three (trivalent) or four (quadrivalent) different influenza
viruses (CDC, 2014b; Grohskopf et al., 2014). Vaccine effectiveness is not 100%; it
depends on age, immune status, and the antigenic similarity between the circulating and
vaccine strains (Harper et al., 2009). Reduction in vaccine effectiveness has been
reported in older adults, >65 years old, with or without comorbidities, and
immunocompromised patients (Jansen, Sanders, Hoes, van Loon, & Hak, 2007; Lenglet
et al., 2007; Mauskopf et al., 2013; Sambhara & McElhaney, 2009). Despite the reduced
effectiveness, studies have shown that immunizing older adults reduced influenzaassociated hospitalizations (Jansen et al., 2007; Jefferson et al., 2010). This effectiveness
is only seen when vaccine strains antigenically match the strains in circulation (Fiore et
al., 2009). Due to the constant antigenic changes that influenza viruses undergone, one or
more strains included in the vaccine change annually (CDC, 2012, 2013).
Treatment
Although treatment is not usually recommended for self-limited influenza
infection, antivirals are available and recommended for influenza-infected individuals
who are at high risk of developing complications (Harper et al., 2009). Early treatment,
within 48 hours of onset, with antivirals has shown to reduce severity and duration of
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influenza infections (CDC, 2010; Harper et al., 2009). Current antivirals target viral
infection, the release of viral particles and viral replication (Gu, Liu, & Wei, 2013;
Michiels, Van Puyenbroeck, Verhoeven, Vermeire, & Coenen, 2013). Neuraminidase
inhibitors, oseltamivir and zanamivir, are the only antivirals available in the United States
(CDC, 2012). Studies show that oseltamivir and zanamivir are effective against influenza
types A and B (CDC, 2012; Harper et al., 2009). Their effectiveness against type A
viruses may be subtype-specific (Harper et al., 2009). M2 proton channel inhibitors,
amantadine and rimantadine, have been used in the past to treat non-pandemic A
(H1N1viruses) (Harper et al., 2009). Since strains circulating in the United States and
worldwide have shown resistance to amantadines and rimantadines, these antivirals are
not currently recommended (CDC, 2012). The decision to use antivirals for the
prophylaxis or treatment of influenza-like-illness often depends on if the benefits
outweigh the risks (virus strain resistance, side-effects, and financial costs) (Michiels et
al., 2013).
2.4 Burden of Influenza Disease
Burden of disease is the measure of impact that a pathogen has on a population
(Gordis, 2009). This impact includes morbidity and mortality—from the very mild
disease to severe disease to death (Gordis, 2009). Different methods and tools are used to
quantify this impact (Gordis, 2009; Lozano et al., 2012; Parashar, Hummelman, Bresee,
Miller, & Glass, 2003).Quantifying the burden allows leaders to see if efforts or
additional efforts are needed in developing interventions (Gordis, 2009; Lozano et al.,
2012; Parashar et al., 2003).
Influenza disease severity varies. Most often, influenza disease is self-limiting and
does not require medical attention (CDC, 2012; Harper et al., 2009). To capture these
mild cases, epidemiologists issue household or serum surveys (CDC, 2012). Sudden
increases in outpatient visits usually coincide with annual influenza epidemics (CDC,
2012, 2013; N. J. Cox & Subbarao, 2000; W. P. Glezen, Payne, Snyder, & Downs, 1982).
Surveillance systems may be developed to systematically collect, analyze, and interpret
outpatient, inpatient, and mortality data (CDC, 2012; Gordis, 2009). From the synthesis
of the influenza surveillance data, epidemiologists calculate the estimates of excess
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influenza-associated mortality, influenza-associated hospital morbidity, and direct and
indirect costs associated with medical care and/or loss time due to influenza infections
(CDC, 2012).
Excess influenza-associated mortality
Influenza infections may go untested, undiagnosed, and underreported for various
reasons (Azziz-Baumgartner et al., 2013). Testing can be resource intensive (Layne,
2006; Schoub, 2010). When testing is completed, the results are not always available for
clinical management, and a positive test may not alter the treatment plan, especially for
mild cases (Azziz-Baumgartner et al., 2013). Due to incomplete identification and
varying severity of influenza infections, epidemiologists rely on statistic modeling for
estimating disease burden of influenza (CDC, 2010; Lopez-Cuadrado, de Mateo,
Jimenez-Jorge, Savulescu, & Larrauri, 2012; L. Simonsen et al., 1997). This approach
was introduced by William Farr during the 1847-1848 influenza epidemic in London (L.
Simonsen et al., 1997). Early epidemiologists, such as William Farr, calculated simple
excess mortality estimates as differences in the number of deaths between time periods
where influenza is present and where influenza is absent (L. Simonsen et al., 1997).
Initially, these modeling techniques were limited to regions with defined influenza
seasons and countries with established vital statistics (Cécile Viboud et al., 2006). Since
influenza often circulates throughout the year in tropical and subtropical regions, it is
more difficult to establish a baseline, a period of non-influenza activity, which is essential
for this approach (Cécile Viboud et al., 2006). Influenza-associated deaths are obtained
from deaths coded for pneumonia or influenza by the International Classification of
Diseases, ICD-10: J00-J99 for instance (Gordis, 2009; D. L. Schanzer, Sevenhuysen,
Winchester, & Mersereau, 2013), although alternative approaches also include deaths due
to respiratory and circulatory diseases, and in some cases, all-cause deaths accounting for
severe influenza infections complicated by underlying conditions and secondary bacterial
infections. Vital registration records, however, do not capture all the deaths (Lozano et
al., 2012). In 2005, 18.8 million of 51.7 million deaths were recorded (Lozano et al.,
2012). Coding regulations and categories change often, which may lead to inaccurate
estimations of influenza-associated deaths (Barker & Mullooly, 1981; W. P. Glezen et al.,
1982).
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Since 1889, the United States and Western Europe have been tracking influenzaassociated mortality (Monto, 2004). Earlier modeling techniques did not account for
deaths due to co-circulating pathogens, such as respiratory syncytial virus, and lacked
confirmation of influenza infection (Yang, Chiu, et al., 2011). With advancements in
diagnostics, surveillance networks were established and reliable influenza activity
became available (Lopez-Cuadrado et al., 2012; Yang, Chiu, et al., 2011). Serfling
regression, poisson regression, negative binomial regression, and generalized linear
regression are models used to calculate influenza-associated mortality (Lopez-Cuadrado
et al., 2012; W. W. Thompson et al., 2009). The Poisson or generalized linear regression
models allowed epidemiologists to account for changes in population size, to incorporate
other factors (such as temperature or co-circulating pathogens), and to assess disease
severity by virus type and/or subtype (Freitas et al., 2013; Lopez-Cuadrado et al., 2012;
W. W. Thompson, Comanor, & Shay, 2006; W. W. Thompson et al., 2009). These
advanced statistical models require consistent, robust weekly viral surveillance data and
at least 5 years of mortality data (W. W. Thompson et al., 2009). The quality and quantity
of available mortality data and influenza surveillance data vary by region and country
(Gordis, 2009; D. L. Schanzer et al., 2013; W. W. Thompson et al., 2009). Other
statistical models, such as rate difference and autoregressive integrated moving average
(ARIMA), do not require virological data or manually setting baselines (W. W.
Thompson et al., 2009). Rate difference and ARIMA may serve as options for countries
with limited viral surveillance and complex influenza seasons (W. W. Thompson et al.,
2009). In a comparison of four different models using the same data, Thompson et al
found that annual influenza-associated death estimates were similar among the models
except for summer-season rate difference model and ARIMA, which were consistently
higher (W. W. Thompson et al., 2009). Schanzer et al found that different models of
Poisson regression (multiplicative, additive, negative binomial distribution) produced
almost identical results (D. L. Schanzer et al., 2013). Influenza-associated mortality
estimates from various models and regions are listed in the table below.
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Table of Influenza-associated Excess Mortality
Country
Study
Statistical Method
period

Southern Brazil
(Freitas et al.,
2013)
Singapore
(Chow, Ma,
Ling, & Chew,
2006)

19802008

Hong Kong (C.M. Wong, Chan,
Hedley, & Peiris,
2004)

19961999

USA (CDC,
2010)

19762007

South Africa
(Cheryl Cohen et
al., 2010)
Argentina
(AzzizBaumgartner et
al., 2013)

19982003

East and
Southeast Asia
(Guangzhou,
Hong Kong, and
Singapore)(Yang,
Ma, et al., 2011)

20042006

19962003

20022009

Underlying
pneumonia/
influenza (per
100,000 personyears)

Serfling regression
model using monthly
number of deaths
Negative binomial
regression using
monthly number of
deaths and monthly
proportion of
influenza-positive test
result
Poisson regression
model using weekly
number of deaths and
weekly proportion of
influenza-positive test
result
Poisson regression
model using weekly
number of deaths and
weekly influenzapositive proportion
Serfling regression
model using monthly
number of deaths
Linear regression
model/Serfling using
deaths

All ages: 1.4
≥60yr: 10.0

Underlying
respiratory/
circulatory
deaths (per
100,000 personyears)
All ages: 9.2
≥60yr: 86.6

All ages: 2.9
≥65yr: 46.9

All ages: 11.9
≥65yr: 155.4

All ages: 4.1
≥65yr: 39.3

All ages: 12.4
≥65yr: 102.0

All ages: 2.4
<19yrs: 0.1
19-64yrs: 0.4
≥65yr: 17.0

All ages: 9.0
<19yrs: 0.2
19-64yrs: 1.5
≥65yrs: 66.1

Poisson regression
model using weekly
number of deaths
(natural spline
smoothing function of
time, temperature, and
relative humidity)

Guangzhou
All ages: 1.0

≥65yr: 42.0

All ages: 6.0
men≥65yr: 37
women ≥65yr:
36
men <65yr: 2
women <65yr: 1
2009 H1N1,
<65: 8
(compared to
seasonal periods,
3)

Hong Kong
All ages: 4.6
Singapore
All ages: 2.8

All ages: 21.4
men≥65yr: 171
women ≥65yr:
136
men <65yr: 4
women <65yr: 2
2007 (H3N2), all
ages: 34
flu A (H1N1) or
flu B seasons, all
ages: 11.4 to
23.4
Guangzhou
All ages: 9.8
>65yr: 104.1
Hong Kong
All ages: 9.5
>65yr: 78.7
Singapore
All ages: 5.3
>65yr: 46.0

All-cause
deaths
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Country

Study
period

Statistical Method

Underlying
pneumonia/
influenza (per
100,000 personyears)

Canada (D. L.
Schanzer et al.,
2013)

19922009

Poisson regression
model using weekly
deaths (vital statistics)
and hospitalization
discharge records

All ages: 11.3
(fluA H3N2,
H1N1, and
pH1N1)
Only pH1N1
All ages: 1.7
<65 yrs: 0.9
65+ yrs: 0.6

Canada (Dena L.
Schanzer et al.,
2008a)

1994 –
2000

Poisson regression
model using weekly
death (vital statistics)
and hospital discharge/
admission records and
database (identified
individuals with
comorbidities)

Spain (LopezCuadrado et al.,
2012)

1999 –
2005

Serfling using only
national vital statistics;
Poisson regression
model using vital
statistics and viral
surveillance

USA (W. W.
Thompson et al.,
2003)
Portugal (Nunes
et al., 2011)
Czech Republic
(Kyncl et al.,
2005)

Italy (Rizzo et
al., 2007)

1980 –
2004
1982 –
2000

1969 –
2000

Serfling
>44yrs:2.68
45-64yrs: 0.33
>64yrs: 15.25
GLM
>44yrs:1.08
45-64yrs: 0.18
>64yrs: 6.00

All ages: 1.45
Serfling with poisson
distribution using
weekly number of
deaths (vital statistics)
and viral surveillance
data

Underlying
respiratory/
circulatory
deaths (per
100,000 personyears)

All-cause
deaths

All ages: 14
<50yrs: 0.3
50-54yrs: 3
55-59yrs: 4
60-65yrs:10
65-69yrs: 2
70-74yrs: 34
75-79yrs: 89
80-84yrs: 175
85-89yrs: 387
90+yrs: 831
65+yrs: 96
Serfling
>44yrs:30.42
45-64yrs:
3.77
>64yrs:
164.10
GLM
>44yrs:10.97
45-64yrs:
2.31
>64yrs: 57.05
All ages: 19.6

All ages: 13
All ages:
25.99

All ages: 3

Influenza-associated excess mortality rates vary by age and health status. The
highest influenza-associated excess mortality rates are observed among adults older than
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65 years of age. In fact, 90% of influenza-associated deaths reported in the United States
were identified in the older age group (CDC, 2010).Singapore also reported an 11.3 times
higher risk for influenza-related mortality in older adults than in the general population
(Simmerman & Uyeki, 2008). Schanzer et al found that age as well as underlying
conditions, especially chronic lung or heart disease, contributed independently to elevate
risks of influenza-associated mortality (Dena L. Schanzer et al., 2008a). Estimated excess
influenza-associated mortality were also elevated in individuals infected with human
immunodeficiency (C. Cohen et al., 2012), 94-146/100,000 estimated excess influenzaassociated mortality compared to 0.9-1.0 in general population between 25-64 years of
age and 64-70 deaths in adults ≥65 years old (CDC, 2010).
Influenza-associated hospital morbidity
Mortality only accounts for a small portion of severe influenza cases (Lenglet et
al., 2007; Lone Simonsen, Fukuda, Schonberger, & Cox, 2000). Hospitalizations make up
an important component of influenza disease burden, and these individuals may present
atypical influenza symptoms and therefore are not tested for influenza (Lenglet et al.,
2007; W. W. Thompson et al., 2004; Yang, Chiu, et al., 2011; Zhou et al., 2012). Since
testing for influenza is not routine, even hospitalized patients with influenza symptoms
may not be tested for influenza (Wang et al., 2012; Yang, Chiu, et al., 2011; Zhou et al.,
2012). In attempts to overcome these limitations and indirectly estimate the burden of
influenza hospitalizations, modeling approaches similar to those used to estimate excess
influenza-associated mortality, can be used (Kim, Kilgore, Lee, Nyambat, & Ki, 2011;
Yang, Chiu, et al., 2011). The total number of hospitalizations during and outside of an
influenza season can be obtained from hospital or health insurance discharge databases
(Gordis, 2009; Kim et al., 2011). These databases are usually unavailable in lower-middle
and low income countries (Gordis, 2009). Since hospital discharge records utilize a
similar international coding system as death certificates, they are subject to the same
coding changes, possible misclassifications, and differences in usage by various
healthcare systems (Jansen, Sanders, Hoes, van Loon, & Hak, 2007; Kim et al., 2011;
Perrotta, Decker, & Glezen, 1985). Records may be incomplete in the description of
patient conditions, excluding underlying conditions, possible co-infections, and vaccine
status (Gordis, 2009; Kim et al., 2011; Zhou et al., 2012). To limit underestimations of
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influenza-associated hospitalizations as a result of incomplete records, some models
expanded the list of codes used to define an influenza-associated hospitalization,
‘pneumonia and influenza’ to ‘respiratory and circulatory diseases’ for example. These
models and other models may have included viral surveillance data for confirming
influenza seasons and for taking into account co-circulating viruses (Kim et al., 2011;
Jansen, Sanders, Hoes, van Loon, & Hak, 2007). The table below presents influenzaassociated hospitalization rates resulting from these various models.
Table of Influenza-associated Hospitalizations
Country
Study
Data Source
(source)
Period
Hong Kong
1996Hospital
(C. M. Wong
2000
discharge
et al., 2009)
diagnoses from
14 acute
hospitals

Method

Estimated Hospitalization Rates

Poisson
regression
weekly
counts
(control for
RSV)

29.3 excess pneumonia & influenza per
100,000 (all age groups)
11.6% of all hospitalizations
Excess influenza-associated
hospitalizations coded as acute respiratory
disease
0-14yrs: 163.3 (135.2, 189.7)
15-39yrs: 6.0 (2.7, 8.9)
40-64yrs: 14.9 (10.7, 18.8)
65-74yrs: 83.8 (61.2, 104.2)
75+ yrs: 266 (198.7, 330.2)
All: 60.6 (52.8, 67.2)
Seasonal rates of excess influenzaassociated hospitalizations
Pneumonia/influenza Acute Respiratory
0-5yrs: 23%
12.8%
6-17yrs: 18.3%
15.5%
18-39yrs: 9.5%
10.4%
40-64yrs: 6.8%
8.3%
65-74yrs: 6.3%
7.1%
75+yrs: 6.2%
6.7%
All ages: 8.5%
8.8%
Excess pneumonia & influenza
hospitalizations
8.6% of all hospitalizations
<5yrs: 18.5/100,000
5-49yrs: 6.8/100,000
50-64yrs: 37.9/100,000
65-74yrs: 97.3/100,000
75+yrs: 344.1/100,000
All ages: 36.8/100,000
Excess influenza-associated
hospitalizations coded for respiratory and
circulatory diseases
<5yrs: 107.5/100,000
5-49yrs: 20.8/100,000
50-64yrs: 83.3/100,000
65-69yrs: 189.7/100,000
70-74yrs: 321.2/100,000
75-79yrs: 431.1/100,000

Hong Kong
(C. M. Wong
et al., 2012)

20052010

Electronic
hospital
discharge
records from 41
hospitals

quasiPoiss
on
regression
models

United States
(W. W.
Thompson et
al., 2004)

1979 2001

National
Hospital
Discharge
Survey data and
WHO
Collaborating
Labs influenza
Surveillance
data

Poisson
regression
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Country
(source)
United States
(W. W.
Thompson et
al., 2004)
United States
(Lone
Simonsen et
al., 2000)
United States
(Zhou et al.,
2012)

Study
Period
1979 2001

Data Source

1970 1995

Netherlands
(Jansen,
Sanders, Hoes,
van Loon, &
Hak, 2007)

19972003

National
Hospital
Discharge
Survey Data
Statewide
hospital
discharge
database (13
states, 40% of
population);
influenza and
RSV viral
surveillance data
hospitalization
discharge (viral
surveillance for
flu and RSV)

Finland (Jacks,
Ollgren,
Ziegler, &
Lyytikainen,
2012)

19962009

Annual national
discharge
register
(including
weekly reports
of seasonality,
RSV, M. pna)

Negative
binomial
regression
model

South Korea
(Kim et al.,
2011)

20022005

National health
insurance
databases

Ratedifference
models

Spain (Lenglet
et al., 2007)

20002004

Hospitalization
discharge

Poisson
regression
model

1993 2008

Method

Estimated Hospitalization Rates

Poisson
regression

80-84yrs: 686.1/100,000
85+yrs: 1194.9/100,000
All ages: 88.4/100,000
~3 million excess P&I hospitalizations
≥65yrs: 174/100,000
<65yrs: 33/100,000

Negative
binomial
regression
model
weekly

Excess influenza-associated respiratory
and circulatory hospitalizations
<1yrs: 151/100,000
1-4yrs: 38.8/100,000
5-49yrs: 16.8/100,000
50-64yrs: 65.6/100,000
65+yrs: 309.1/100,000
All ages: 63.5/100,000

Ratedifference
models

Rates of hospitalizations for influenzaassociated all-cause mortality
0-17yrs: 14%
18-49yrs: 12%
50-64yrs: 23%
65yrs+: 51%
(H3N2 most seasons, 2000/01 H1N1)
Rates = “pneumonia & influenza
coded”/100,000 of age group pop/week
2009
Pre-pandemic (1996-2009)
0-4yrs: 16.6
15.2
5-24yrs: 3.5
2.3
25-64yrs: 6.7
5.1
≥65yrs: 46.5
47.3
All ages: 13.4
11.5
Rates of hospitalizations coded for
pneumonia & influenza per year (all ages
groups): 4.61% (2002), 4.47% (2003),
4.46% (2004), 4.64% (2005)
Per 1000
2002:
2003:
2004:
<5yrs: 36.7
41.2
45.8
5-14yrs: 3.3
5
3.2
15-49yrs: 0.9
0.9
0.9
50-64yrs: 3.1
3
3.5
65-74yrs: 8.4
8.4
10.4
≥75yrs: 15.6
16.9
21.6
All ages: 4.6
5.1
5.3
Influenza-associated hospitalization for
all-caused mortality
All ages by season:
2001/02: 24.7/100,000
2002/03: 18/100,000
2003/04: 17.7/100,000
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Country
(source)
Canada (Dena
L. Schanzer et
al., 2008b)

Study
Period
19942000

Data Source

Method

Estimated Hospitalization Rates

Hospitalization
database
including
clinical
diagnostics

Poisson
regression
model

Canada (D. L.
Schanzer et
al., 2013)

19922009

Hospitalization
discharge
records

Poisson
regression
model

Argentina
(AzzizBaumgartner
et al., 2013)

20052008

Governmentoperated hospital
discharge forms

Serfling
model (P/I)
Linear
regression
model
(R/C)

Hospitalizations coded for influenza &
pneumonia
20-49yrs: 1-2/100,000
50-64yrs: 5-7/100,000
65+yrs: 37-36/100,000
20+yrs: 6-8/100,000
Hospitalizations coded for influenza &
pneumonia
Seasonal average due to H3N2, H1N1,
pH1N1
All ages: 39.5/100,000
Hospitalizations coded for influenza &
pneumonia (P/I)
All ages: 2.0
Hospitalizations coded for respiratory and
circulatory disease (R/C)
All ages: 5.7/100,000
2007 (H3N2), all ages: 8.4/100,000

From the studies included in the summary table above, the highest rates of
influenza-associated hospitalizations were commonly observed among older adults (>65
years of age) and young children, <5 years of age. Severity of disease was dependent on
type or subtype; hospitalization rates increased when multiple influenza types or subtype
H3N2 were in circulation (Azziz-Baumgartner et al., 2013; Dao et al., 2010; W. W.
Thompson et al., 2004). To validate these influenza-associated hospitalization rates, Zhou
et al suggested conducting large studies testing hospitalized patients prospectively using
PCR (Zhou et al., 2012).
In recent years, laboratory-testing capacity has grown globally (Mmbaga et al.,
2012; Nair et al., 2011; WHO, 2013). The number of countries in Africa completing
influenza surveillance using PCR has increased from 5 to 15 from the year 2006 to 2011
(Radin et al., 2012). This increased capacity has improved the understanding of influenza
epidemiology, allowing for the establishment of influenza seasonality and detection of
novel influenza circulating strains with pandemic potential (WHO, 2011b). The increased
capacity has also increased the recognition of influenza infections among children and
adults in developing countries, adding to the evidence of disease worldwide (Nair et al.,
2011; Takahashi et al., 2013; Verani et al., 2013). Along with increased laboratory
capacity, the Global Influenza Hospitalization Surveillance Network was recently
established to evaluate influenza burden among hospitalized patients matching a
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standardized case definition, to quantify virus type and subtype distribution, and to
measure vaccine effectiveness (Puig-Barbera et al., 2014). With the expansion of
laboratory capacity and support of network surveillance, countries have calculated
laboratory-confirmed influenza-associated hospitalization rates (Chadha et al., 2013; Dao
et al., 2010; Yu et al., 2014) examples of rates are seen in the following table.
Country-specific, laboratory-confirmed influenza-associated hospitalization rates
Influenza
Overall
Country
Age-group specific estimates
Seasons
estimates
USA (Dao
18-49yrs
50-64yrs
65-74yrs
75+yrs
et al.,
2005-2006
9.9/100,000
3.6/100,000 7.8/100,000
22.9/100,000 65.1/100,000
2010)1
2006-2007
4.8/100,000
2.5/100,000 4.2/100,000
10.6/100,000 22.3/100,000
2007-2008
18.7/100,000 7.3/100,000 14.8/100,000 37.6/100,000 116.6/100,000
Mean
4.5/100,000 8.9/100,000
23.7/100,000 68/100,000
China (Yu
65+yrs
et al.,
2010-2011
141/100,000
2014)
2011-2012
89/100,000
India
Entire study 44.1/10,000
15-29yrs
30-44yrs
45-59yrs
60+
(Chadha et 2009-2010
67.1/10,000 25.2/10,000
18.3/10,000
11.6/10,000
al., 2013)2
2010-2011
58.3/10,000 23.3/10,000
28.8/10,000
18.7/10,000
1
Dao et al study population represents 7% of US population ≥18 years old and from only urban hospitals.
2
Chadha et al study may not reflect the typical influenza season, since it includes pandemic H1N1.

As seen in the above table, estimated rates based on laboratory-confirmed
influenza hospitalizations are generally lower than rates estimated by models discussed
earlier. Models may account for severe influenza cases, especially those with atypical
symptoms, not tested for influenza, where laboratory-confirmed influenza surveillance
does not. Depending on the sources used, models may underestimate or overestimate
influenza associated hospitalizations, either by not accounting for influenza
hospitalizations due to not fully developed or widespread use of hospital administrative
databases or including hospitalizations not confirmed for influenza and potentially caused
by other co-circulating pathogens (Azziz-Baumgartner et al., 2013). In attempt to
overcome the limitations of earlier models and by laboratory-confirmed surveillance,
Reed, Biggerstaff, and colleagues have created the multiplier model for estimating local
influenza morbidity (Biggerstaff et al., 2013; Reed et al., 2009). The multiplier model
adjusts the laboratory-confirmed cases for the portion of population with influenza who
did not seek care or provide a specimen, for specimens not sent to the public health
laboratory or tested for influenza, and for mishandled specimens and/or the delay in
collection of specimens (Biggerstaff et al., 2013; Reed et al., 2009). These adjustments
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rely on prior knowledge of population health-seeking behaviors, and influenza testing
procedures and policies (Biggerstaff et al., 2013; Reed et al., 2009).
In addition to modeling, systematic reviews provide an assessment of the
available knowledge to estimate influenza-associated morbidity and mortality (Gessner et
al., 2013; W.P. Glezen et al., 2013; Savy et al., 2013; Simmerman & Uyeki, 2008).
Gessener et al summarized literature findings on seasonal influenza in sub-Saharan
Africa from 1980 to 2009 (Gessner et al., 2013). Gessner and colleagues found that
influenza viruses contribute substantially to respiratory infection morbidity and mortality
for all ages, although little was reported about children older than five years old and
adults (Gessner et al., 2013). They also noted an eight times greater risk of influenza
mortality and morbidity when a child was co-infected with the human immunodeficiency
virus (Gessner et al., 2013). Savy et al completed a similar literature review for Latin
America and the Caribbean (Savy et al., 2013). According to literature from 1980 to
2008, Savy et al also found substantial morbidity and mortality due to seasonal influenza
infections (Savy et al., 2013). Although the percentage of specimens received by testing
centers was low during this time period, 4.7 to 15.4%, Savy et al calculated 36,080
influenza-like illnesses per 100,000 annually with a mean hospital stay of 5.8 to 12.9
days and a mean direct cost of $575 US dollars per confirmed case (Savy et al., 2013).
Savy et al noted low vaccine uptake in the region (Savy et al., 2013). Low vaccine uptake
was also observed in East and Southeast Asia, according Simmerman and Uyeki who
summarized literature findings for this region from 1980 to 2006 (Simmerman & Uyeki,
2008). Due to high variability between studies, using different case definitions and data
collection methods, they were unable to aggregate data and calculate estimates
(Simmerman & Uyeki, 2008). Simmerman and Uyeki, however, found evidence of
influenza disease throughout the region (Simmerman & Uyeki, 2008). Middle and high
income countries, with improved and sustained laboratory capacity and surveillance,
reported the largest burden of influenza morbidity and mortality (Simmerman & Uyeki,
2008). Higher proportions of the known influenza burden were observed in young
children and adults >65 years old (Simmerman & Uyeki, 2008).
To explore the role of influenza in pediatric respiratory hospitalizations globally,
Nair et al and Lafond et al completed meta-analyses of published and surveillance data
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(Lafond et al., 2014; Nair et al., 2011). Nair et al estimated 1 million cases of
hospitalized severe acute respiratory infections in children under five-years-old were
attributed to influenza each year (Nair et al., 2011). Using the rate-based approach, they
estimated 28,000 to 111,000 annual influenza-associated deaths (Nair et al., 2011).
Lafond et al calculated pooled estimates and found that 9.5% of pediatric respiratory
hospitalizations were due to seasonal influenza infections during the 1996 to 2012 time
period (Lafond et al., 2014). A higher proportion of influenza associated hospitalizations
were observed in school-age children (16%) compared to children <5 years-old (6%)
(Lafond et al., 2014). During seasonal influenza epidemics, adults also experience severe
outcomes from influenza-related respiratory infections (CDC, 2013; N. J. Cox &
Subbarao, 2000; F. Dawood et al., 2012). Although Dawood et al found 65% of
pandemic H1N1 deaths globally were adults 18 to 64 years old in 2009, no global
estimates for seasonal influenza currently exist for adults (F. Dawood et al., 2012; Kuster
et al., 2011; Dena L. Schanzer et al., 2008a).
Economic impact of influenza infections
After estimating excess mortality and hospital morbidity, a cost analysis
associated with the disease burden of influenza and with the impact of the targeted
interventions can be conducted (Azziz-Baumgartner et al., 2013; Szucs, 1999). Influenza
disease has direct and indirect costs (CDC, 2010; Molinari et al., 2007; Monto, 2004; Ott
et al., 2013; Peasah, Azziz-Baumgartner, Breese, Meltzer, & Widdowson, 2013; Ryan,
Zoellner, Gradl, Palache, & Medema, 2006; Szucs, 1999). Physician visits and hospital
admissions due to influenza infections contribute to high direct costs (Szucs, 1999). In
France, the use of healthcare services for influenza infections totaled appropriately $300
million in 1989; the United States reported higher annual direct costs with totals of $1-3
billion (Szucs, 1999). A larger price tag, however, was observed for indirect costs among
high income countries (Peasah et al., 2013; Szucs, 1999). Indirect costs, such as
productivity losses and school or work absenteeism, due to influenza infections totaled
$2.3 billion in France and $10-15 billion per year in the United States (Szucs, 1999).
Indirect costs were 50% less than direct costs in Hong Kong and Thailand (Peasah et al.,
2013). Influenza accounts for 10-12% of all sick-related absentees among workers (Ryan
et al., 2006; Szucs, 1999). An average of 3.7 to 5.9 working days were lost due to
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laboratory-confirmed influenza infections among healthy working adults (Karve,
Misurski, Meier, & Davis, 2013; Keech & Beardsworth, 2008). The magnitude of direct
and indirect costs sharply increases among high risk groups. Influenza infections among
older adults, for an example, contribute to 64% of the economic burden due to seasonal
influenza in the United States (Menec, Black, MacWilliam, & Aoki, 2003; Molinari et
al., 2007). School or work absenteeism was reported highest among closely living
communities with young children (Szucs, 1999). Individuals with comorbidities
experience severe influenza outcomes, hospitalizations and deaths, more frequently than
healthy adults (Dena L. Schanzer et al., 2008a; Szucs, 1999). Interventions, specifically
influenza vaccination programs, targeting high risk groups have shown to be costeffective in the United States and China (Ott et al., 2013; Ryan et al., 2006; Szucs, 1999).
Vaccinating older adults reduced rates of influenza disease severity (Szucs, 1999). After
vaccinating healthy adults, rates of absenteeism decreased by 43% and 25% less upper
respiratory infections were reported (Szucs, 1999).
Many factors contribute to the cost-effectiveness of influenza vaccination. As
previously mentioned, vaccine effectiveness varies among age groups and from year to
year (Fiore et al., 2009; Ott et al., 2013). The timing of vaccination, location of vaccine
administration, and duration of vaccine protection also impact cost-effectiveness and
cost-benefit analyses (Ott et al., 2013). Influenza vaccination has been shown to be most
cost-effective when administrated early in the season (Ott et al., 2013). Due to vaccine
limitations, lower efficacy in older adults and antigenic differences between vaccine and
circulating strains, other interventions, such as antivirals, may need to be considered
(Szucs, 1999).
Influenza infections have a substantial economic impact (Karve et al., 2013;
Szucs, 1999). Cost analyses of influenza burden and the impact of its interventions aid in
policy decisions (Ott et al., 2013; Peasah et al., 2013). High income, temperate-climate
countries have provided the majority of currently available cost evaluations (Ott et al.,
2013; Peasah et al., 2013). A few publications on cost analysis come from middle income
countries (Ott et al., 2013; Peasah et al., 2013). Evaluations in lower middle income and
low income countries are lacking (Ott et al., 2013; Peasah et al., 2013). Since cost
analyses are lacking despite the evidence of substantial influenza disease burden, middle
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and low income countries do not have sufficient evidence to support the establishment of
influenza vaccine policies or recommendations (Ott et al., 2013; Peasah et al., 2013)
(Samaan et al., 2013).
Applications of influenza burden estimates
Burden estimates provide evidence of disease and improve the understanding of
influenza epidemiology. Prior to the expansion of surveillance and laboratory capacity,
many developing countries were unaware of the impact of influenza (Katz et al., 2012;
Muyembe Tamfum et al., 2012; Nyatanyi et al., 2012; Schoub, 2010; Steffen et al.,
2012). Influenza, in fact, may have been misdiagnosed as malaria or as other diseases
with nonspecific symptoms (Muyembe Tamfum et al., 2012; Schoub, 2010). Using
laboratory diagnostics has confirmed the presence of influenza in circulation and as a
cause of morbidity and mortality for all ages worldwide (Layne, 2006; Nyatanyi et al.,
2012; WHO, 2011b).
One key aspect of influenza epidemiology is seasonality and timing of virus
circulation each year. A peak of influenza confirmed cases may occur during the same
time period for multiple years in a particular region or country (L. Simonsen et al., 1997).
Studying this trend or occurrence may reveal the seasonality of influenza disease (L.
Simonsen et al., 1997). Knowing when influenza occurs allows leaders to plan and
implement control and prevention measures, and to potentially evaluate those measures
over time (Muyembe Tamfum et al., 2012)
In addition to detection, some laboratory diagnostics permit further characterization
of strains, such as the identification of virus types and/or subtypes (Layne, 2006). The
coordinating centers for the World Health Organization (WHO) rely on such work to
evaluate strain variability and to inform their recommendations for the annual vaccine
strain selection (CDC, 2012; WHO, 2014c). To ensure coverage of vaccine strains, it is
essential to have good, reliable global surveillance (Layne, 2006; Schoub, 2010). Not all
countries have the capacity to implement and maintain influenza surveillance systems
(Schoub, 2010). In developing countries, surveillance systems often depend on additional
financial support from donors (Layne, 2006; Lutwama et al., 2012). Evidence provided
by burden estimates may draw attention to the public health needs for controlling and
preventing influenza and advocate for further country and donor support (Gordis, 2009).
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Beyond routine surveillance for seasonal influenza viruses, increased surveillance
efforts support detection of novel influenza viruses with pandemic potential (Ayele et al.,
2012; Monto, 2004; Radin et al., 2012). During pandemics, burden estimates are
generally high, and in many regions of the world too high, to supply the necessary care in
both treating ill individuals and protecting healthy individuals within the population
(Ayele et al., 2012; WHO, 2009). Early detection of pandemic viruses through global
surveillance may lessen the impact if countries are prepared and equipped to recognize
and manage disease (Layne, 2006; WHO, 2009). Countries with limited resources and
competing priorities are often forced to rebuild capacity (Lutwama et al., 2012). Global
estimates of seasonal influenza may provide evidence to support the need to sustain that
testing capacity.
In addition to observing seasonal trends of influenza and the high burden of disease
during pandemics, epidemiologists may also observe an increased number of influenzaassociated hospitalizations and deaths among certain individuals in the population. By
identifying the individuals at risk, those who experience the greatest burden of influenza
disease, countries can create targeted campaigns (Azziz-Baumgartner et al., 2013; Dena
L. Schanzer et al., 2008a). While countries, such as Canada, have observed reductions in
influenza-associated mortality and morbidity after the implementation of a universal
immunization program, other countries with limited resources may be able to provide
similar reductions in disease through targeted campaigns that allow prioritization and
effective allocation of resources (Fuller et al., 2013; Kwong et al., 2008; Monto, 2004).
Once these campaigns are implemented, recalculated burden estimates may be used to
confirm the effectiveness and drive future improvement.
Through the examination of burden estimates on a global scale, epidemiologists can
compare and evaluate the effectiveness of interventions against influenza in different
settings, among diverse populations, and in relation to other pathogens. Even though
vaccination is considered the only effective means of preventing influenza infections,
introducing the vaccine may not be cost-effective in certain settings, particularly when
disease burdens are greater for other pathogens and resources are limited (CDC, 2010,
2012, 2013; Fiore et al., 2009; WHO, 2005). Over time, this may change, especially if
disease burdens for influenza and related infections increase (WHO, 2005). In
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populations with a high prevalence of human immunodeficiency virus (HIV), severe
outcomes as a result of influenza infections are four to eight times as likely (C. Cohen et
al., 2012; Gessner et al., 2013; Gessner et al., 2011). The severity of influenza infections
in HIV patients appears to decline when patients receive antiretroviral therapy along with
the influenza vaccine (C. Cohen et al., 2012). As individuals recover from influenza
infections, they may become susceptible to secondary infections (Shrestha et al., 2013).
Shrestha et al have shown that influenza infections increase a patient’s susceptibility to
pneumococcal pneumonia by approximately 100-fold (Shrestha et al., 2013). Vaccines
and other interventions against influenza may assist in reducing the morbidity and
mortality associated with other pathogens (Shrestha et al., 2013). However, the
interaction between influenza and other pathogens is complex. In one hospital setting in
the US where influenza vaccine coverage is high (78%), researchers observed an increase
in hospitalizations due to other circulating respiratory viruses in adults ≥ 65 years old
(Widmer et al., 2012).
Despite interventions such as vaccines, burden estimates may remain high. To
uncover the reasons why, further research is needed to monitor trends and severity in
disease, and to develop new ways to control and prevent disease. Country leaders and
health planners rely on burden estimates to prioritize investments in health and research
(Chadha et al., 2013; W. W. Thompson et al., 2009; Yu et al., 2014). Developing
vaccines that target conserved regions of the influenza virus may lead to broad protection
and a universal vaccine (Schotsaert & Garcia-Sastre, 2014). Diagnostics with high
sensitivity and specificity for the influenza could lead to the reduction of nosocomial
infections and the unnecessary use of antibiotics (W. P. Glezen et al., 1982; Widmer et
al., 2012). Leaders may also use burden estimates to guide policy and medical practice,
such as the use of antivirals in hospitalized patients, which have shown to increase the
chances of survival, and the development of a standardized influenza case definition to
improve identification and treatment (Jain et al., 2009; Kyncl et al., 2005; Mytton, Rutter,
& Donaldson, 2012).
With the recent expansion of sentinel surveillance for influenza infections in
healthcare facilities of developing countries, more data for influenza-associated
hospitalizations is available and not yet summarized. A summary of this data as it
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pertains to the adults provides the needed evidence to inform and guide the global public
health community in discussions of polices and interventions targeted at influenzaassociated hospitalizations.

Chapter III
Methods and Procedures
3.1 Data Sources
We derived our study data from two sources: a systematic review of the published
literature of influenza in hospitalized adults and unpublished data from a working group
of partners conducting influenza surveillance among hospitalized adults.
Systematic Literature Search
To identify eligible articles, we searched Pubmed, Embase, Web of Science, Global
Health, LILACS, IndMed, CINAHL, WHOLIS, and CNKI using the following search
terms and respiratory illness keywords: “Influenza” or “viral etiology;” respiratory (tract)
infection/disease/illness; pneumonia, bronchiolitis, bronchitis, “influenza-like illness:” and
case definitions for ILI (influenza-like illness), SARI (severe acute respiratory illness),
ARI (acute respiratory illness), ARLI (acute respiratory like illness), LRTI (lower
respiratory tract illness), or CAP (community acquired pneumonia). We conducted our
search on all databases simultaneously, over one week. We limited our search to articles
published between January 1, 1996 and June 30, 2012. Our search was not restricted by
language or location. We relied on multilingual professionals who either worked in the
Influenza Division (CDC) or had basic knowledge of influenza and epidemiology to assist
in the screening and abstracting of data from non-English papers. Additional papers,
outside of the citation search, were identified from the bibliographies of eligible articles.
Supplemental Unpublished Data
In addition to the systemic review of published literature, we invited international
collaborators who complete year-round influenza testing of hospitalized adults to
participate in the study. Together these collaborators cover most if not all WHO regions
and different World Bank income levels. Some collaborators have participated in the
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SARI, severe acute respiratory infection, network, and have collected influenza testing
for both pediatric and adult populations.

3.2 Data collection
Published Data
After identifying potentially eligible publications in our search, we followed a multistep process for collecting data. We first reviewed the titles and abstracts from the list of
citations captured by our search strategy. We eliminated any review articles or articles
unrelated to the influenza virus. We continued to screen the articles deemed eligible by
our citation review.
In our screening, we utilized a standard set of inclusion criteria (summarized in box
1). These criteria were defined prior to project implementation and based on previous
research (Nair et al., 2011; Lafond et al., 2014; Gessner et al., 2011; Simmerman &
Uyeki, 2008). The purpose of the criteria was to identify comparable data sources that
provided the percent of adult inpatients that tested positive for influenza viruses (our
primary outcome), and compare the effects of factors such as year, age group, location,
case definition, or influenza diagnostic tool on the positive influenza-tested percentage
(secondary outcomes). Article must provide total number tested for influenza and among
those tested the total number of influenza positive for adult inpatients. Articles must have
data for inpatients. We defined inpatients as patients admitted into the hospital.
Emergency room department admissions were considered outpatients unless later
specified that patients required hospitalization. Studies collected data for adults only or
reported by age group. Individuals 18 years or older were considered adults if not
otherwise noted. To ensure that we included a dataset only once, original research was
required. Authors either collected and used data or were the only ones to use data for
investigating positive influenza inpatients. Since we are interested in the circulation of
influenza among the general population, healthcare-acquired influenza infections were
excluded. The circulation of influenza tends to be seasonal in most regions. To control for
this seasonality, studies completed at least 12 months of continuous influenza testing.
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We required laboratory confirmation of influenza for ensuring accuracy of our primary
outcome. Inpatients may present onset and symptoms similar to influenza but do not have
an influenza infection according to laboratory test. In light of diagnostic differences in
sensitivity and specificity, studies listed the influenza confirmation test. Studies tested a
minimum of fifty inpatients for influenza, in attempts to maintain adequate power for
estimation and limit type I errors.
Box 1. Inclusion Criteria
1. Adult inpatient data
2. Original research
3. Community-acquired influenza
4. 12 months of continuous influenza testing
5. Laboratory confirmation of influenza
6. Diagnostic test description
7. Total number tested for influenza
8. Total number of influenza positive for adult inpatients
9. Minimum of fifty inpatients for influenza
Once we confirmed that screened article matched the criteria, we abstracted and
recorded the outcome measurements and related factors (listed in box 2).
Box 2. Recorded Outcome Measurements
1. Positive percentage of influenza
 What is the total of patients tested for influenza?
 Of this total, how many are positive for influenza, positive for influenza type A
and/or influenza type B?
2. Year
 When did the study occur? What are start and end dates?
 Was the study completed during a pandemic or seasonal influenza season?
3. Adult age range
 What is the age range of the adult inpatients tested for influenza?
 If influenza testing results were given by age group, what is the total tested and total
positive for the following age groups: 18-45, 45-64, and ≥65?
4. Location
 Where did the studies and testing occur, where were the patients enrolled (city or
town, and country)?
 Which WHO region did the study’s or working group collaborator’s country belong
to?
 According to the World Bank income standards, would this country be described as
high, middle-high, middle-low, or low income?
 Also, would this country during the testing timeframe be described as industrial or
undeveloped?
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Box 2. Recorded Outcome Measurements
5. Case definition
 What guidelines are used to direct hospital admission and laboratory testing?
 How do authors/work group collaborators define influenza disease in their
studies/populations?
6. Influenza diagnostic tool
 What laboratory test was used to confirm suspected cases?
 What type of specimen was collected and tested?
Two or more reviewers completed each step, ensuring that articles were at least
doubly reviewed and screened, and that data was doubly abstracted. Any discrepancies
between reviewers were discussed. If discussion did resolve discrepancies, reviewers
were asked to re-screen and abstract data. Data collection tools were piloted, tested and
results evaluated by reviewers, prior to implementation and for training purposes. We
found that piloting the collection tools allowed us to ensure that approach by all
reviewers was consistent, utilizing the same definitions, and to confirm that our tools
captured our outcomes of interest. We also completed a bias assessment, study and
outcome level on the eligible articles (box 3).
Box 3. Bias Assessment
Yes = (score)
1. Selection
i. Was a standard criteria, such as a case definition, used in selecting inpatients
for influenza testing? (1)
ii. Was the method for selecting inpatients for influenza testing unclear or
undefined? (0)
2. Comparability
i. Within the case definition, does the article describe or list symptoms or signs?
(1)
ii. Does the article list a syndrome (such as LRTI or community-acquired
pneumonia) without describing symptoms (0)?
3. Outcome
a. Reporting
i. Do the authors clearly provide total number of inpatients tested for influenza
and of those tested, the number of inpatients who were positive for influenza?
(1)
ii. Do authors not clearly provide the total influenza tested and the total positive
for influenza? (0)
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Unpublished Data
We used a template for collecting standard outcome data from working group
participants. Participants provided a basic description of their surveillance system. This
basic description includes start year, age group testing, lists of inpatient surveillance sites,
case definition used and start time of using definition, sampling strategies used for
influenza testing during influenza and non-influenza seasons, type of sample collected
and tested, and the diagnostic method used in influenza testing (method, percentage of
samples used with each method used, and when method was used). The template also
captured influenza testing by year (start and end date for each testing year, from 2005 to
2012), age group (18-49, 50-64, 65-74, and 75+), and serotype (pH1N1, H3N2, B, and
seasonal H1N1). Optionally, participants provided site-level results for influenza-testing
by age group. No individual patient data was collected.
3.3 Data Management and Analysis
For analysis, we used Stata and SAS version 9.3 software. We divided our datasets
into seasonal, pre- and post-pandemic, and pandemic timeframes. We defined pandemic
as datasets with data collected during the 2009 year. Seasonal datasets excluded 2009year data. Our analysis excluded datasets that combined seasonal and pandemic
timeframes. We also used two age groups, 18-64 and 65+, for our analysis. We
completed descriptive analysis, stratifying by data source (published articles or working
group submissions), using SAS. We calculated crude median results for outcomes of
interest—number tested, number of influenza positive, and percent positive—using nonparametric tests for difference by Kruskal Wallis, rank sum.
To determine if timeframe influenced our crude proportions, we stratified the datasets
by timeframe. We observed differences between age groups, data sources, case
definitions, and income levels with the inclusion of pandemic datasets. Due to this
observation, we restricted the meta-analysis to seasonal datasets. Using seasonal datasets,
we generated adjusted pooled estimates and 95% confidence intervals for the proportion
of specimens testing positive for influenza by key age groups, study population types,
geographical region, and income and development status. These adjusted pooled
estimates and confidence intervals were calculated through the use of the log binomial
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model in SAS, accounting for random effects at the dataset level. When the SAS model
did not converge or there were insufficient data points, we used the Stata random-effects
model, DerSimonian-Laird method, for the adjusted pooled estimates and confidence
intervals. If a seasonal dataset provided data by year, we treated each year of data as a
single observation in the model and defined datasets as clusters. Due to the known
varying sensitivity of influenza diagnostic tests, we also stratified the pooled estimates by
polymerase chain reaction (PCR) testing, the gold standard of influenza laboratory
confirmation, and compared the stratified estimates to the estimates including all testing
methods used.
3.4 Exploratory Analysis
We also conducted exploratory analyses on potential impact of bias, calendar year
2010 data, partial-years data, and multipathogen detection on our crude and pooled
estimates. For our calculations of estimates, we used rank sum non-parametric tests and
the SAS binomial log regression model.
In our exploratory analysis of bias, we defined total bias as the sum of selection,
comparability, and outcome bias. As mentioned earlier, we completed the bias
assessment by scoring each published dataset for the three components, using 0 for not
meeting the criteria or 1 for meeting the criteria. A total bias of 3 was considered the
highest level of quality, while a total bias of 0 was considered the lowest. We explored
the impact of article quality on positive proportions.
Since pandemic H1N1 remained in circulation during 2010, we removed 2010-year
data and reanalyzed the seasonal datasets. We observed in earlier analysis that the
inclusion of pandemic datasets showed variation among key variables. To ensure that our
crude and pooled estimates were reliable and we have accounted the full time period in
which the pandemic H1N1 influenced our estimates, we calculated and compared the
crude and pooled estimates of seasonal datasets without 2010-year data to the estimates
including all seasonal datasets.
We defined partial-years data as datasets which completed ongoing influenza testing
beyond a 12-month period, such as 15 and 26 months. Datasets with partial years may
potentially include multiple peaks of influenza circulation and as a result of this
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inclusion, inflate our pooled and crude estimates. We stratified datasets by whether they
contained partial years of data and compared the estimates.
We considered datasets which tested for other pathogens in addition to influenza type
A and B as datasets completing multipathogen detection. Other viruses frequently cocirculate with influenza. These viruses as well as bacteria can co-exist with influenza in
the human hosts and may increase the severity of the infection. To explore whether
datasets that tested for other pathogens in addition to influenza were likely to have higher
or lower crude proportions and pooled estimates, we stratified the published datasets by
multipathogen testing.
3.5 Human Subjects Considerations
In our study, we used published data and aggregated data from consenting
collaborators. No individual patient data was collected. Due to the nature of our sources,
no human subject investigational review was required.

Chapter IV Results
4.1 Description of data sources
Figure 1 describes the number of eligible publications for each step in the literature
review and the number of eligible surveillance datasets included in analysis. For full
details of each search and more information about datasets, refer to appendices 1-3.
Figure 1. Flow diagram of data sources identified for systematic review of influenza testing among
hospitalized adults (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA,
(Moher, Liberati, Tetzlaff, Altman, & The, 2009))
49,603 records identified through
database searches

53 additional records identified
through other sources

38,032 records after duplicates removed

38,032 records screened

37,129 records excluded, not
relevant to topic

903 full-text articles assessed for
eligibility

855 full-text articles excluded
782 did not meet inclusion criteria
25 duplicate datasets

48 full-text articles included in
qualitative synthesis
29 unpublished surveillance datasets
identified for inclusion
77 studies included in
qualitative synthesis

68 studies included in
quantitative synthesis (metaanalysis)
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We described the data by source in table 1. Published and unpublished datasets
together covered 31 years, 1981 to 2012. The majority of datasets, whether published or
unpublished, was one to two years in duration and had a population size of 100 to 500
individuals. Six published articles and three unpublished datasets only provided
combined pre-pandemic/pandemic data (data not provided by year) and were excluded
from analyses, which were split into seasonal and pandemic periods. Between the two
sources, good global representation was seen for all World Health Organization (WHO)
regions. China and Spain provided the most datasets (5 each) followed by Thailand (4),
Australia (3), Germany (3), and Italy (3). All income levels and country developmental
status, as defined by the World Bank and United Nations Population Division
respectively, were covered by the two sources. Data sources did differ as we described in
the following paragraphs.
By study design, published datasets were heterogeneous. Age ranges varied and
were often not matched with the number of enrollees. Many datasets described the age of
their study population as “adult,” ≥14 years of age. Published datasets were older than
unpublished datasets. Most publications were from the pre-pandemic (pre-2009)
timeframe. In confirming influenza, published datasets most commonly used polymerase
chain reaction (PCR) with other diagnostic tests. Some of the other tests may include
serology, culture, and immunofluorescence. Serology, both single and paired serum,
followed PCR for testing. These tests were performed on individuals meeting the preset
case definition. The most common influenza case definition was pneumonia; the case
definition for severe acute respiratory infection (SARI, (WHO, 2013) was not used in any
of the published datasets. Published datasets were predominately from the European
region, and more frequently from high income, industrialized countries. One-fourth of the
datasets targeted special populations (chronic obstructive pulmonary disease, COPD;
immunocompromised; ICU patients; and acute asthma patients). Many datasets also
provided results for pathogens other than influenza, most commonly for respiratory
syncytial virus (RSV) and parainfluenza. Little information was provided for vaccine
status. Majority of published datasets provided comorbidity information, although less
than half of the studies provided severity data, percentage of mortality and ICU
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admissions among their study populations. From these studies, we calculated a median
mortality percentage of 7% and median percentage of ICU admissions of 9%.
Using the influenza surveillance collection form, unpublished datasets captured
outcome measures by pre-defined age groups (18-49 years, 50-64 years, 65-74years, and
75+ years). For our analysis, we used two age groups, 18-64 and 65+. The number of
unpublished datasets increased with time; years with the largest number of unpublished
datasets were those following the pandemic (particularly 2010 and 2011). Unpublished
datasets used PCR alone or with other tests as the primary influenza diagnostic test.
Pneumonia was not used as the case definition. Instead, unpublished datasets most
frequently identified cases using the severe acute respiratory illness (SARI) definition.
These datasets provided more data from the Africa, Western Pacific, and Southeast Asia
regions. The data were more frequently from lower middle income; all surveillance
datasets were from developing countries. Unpublished datasets were from influenza
surveillance platforms that did not target special populations, and due to the design of the
working group data collection form, data was not collected from working group partners
on comorbidities or vaccine status, or on the detection of pathogens other than influenza
types A and B.

Table 1. Characteristics of published studies and surveillance data sources about influenza-associated
respiratory illness among hospitalized adults, 1981-2012
48
29
Published studies n= Unpublished studies n=
(%)
(%)
Date of studies
1981 to 2010
2003 to 2012
Age group in years*
≥14
44(92%)
29(100%)
18 – 64
5(10%)
26(90%)
≥65
9(19%)
17(59%)
Study duration in years
1–2
38(79%)
13(45%)
3–4
6(13%)
10(34%)
5+
4(8%)
6(21%)
Timeframe for outcome data
Pre-2009**
42(87.5%)
6(14%)
During 2009 ("pandemic")
0%
9(21%)
Post-2009
0%
26(59%)
Total cases tested
50–99
15(31%)
8(28%)
100–499
31(65%)
10(34%)
500+
2(4%)
11(38%)
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Diagnostic test
Polymerase Chain Reaction (PCR) only
Immunofluorescence only
Culture only
Serology only
Multiple diagnostic tests, incl. PCR
Multiple diagnostic tests, excl. PCR
Case definition‡
Acute Respiratory Infection
Acute Lower Respiratory Infection
Pneumonia
Severe Acute Respiratory Illness
Other§
Study population
General adult population
COPD
Immunocompromised
Otherǁ
WHO region
African
Americas
Eastern Mediterranean
European
Southeast Asian
Western Pacific
World Bank income level¶
Low Income
Lower Middle Income
Upper Middle Income
High Income
Development status†
Developing
Industrialized
Comorbidity Data Provided
Influenza Vaccine Status Data Provided
Multipathogen Detection Data Provided
Bacteria₮
Respiratory syncytial virus
Parainfluenza
Adenovirus
Rhinovirus
Human metapneumovirus
Other viruses¥

48
Published studies n=
(%)

29
Unpublished studies n=
(%)

9(19%)
1(2%)
2(4%)
13(27%)
18(38%)
5(10%)

11(38%)
0%
0%
0%
18(62%)
0%

4(8%)
1(2%)
29(60%)
0%
14(29%)

1(3%)
3(10%)
0%
23(79%)
2(7%)

36(75%)
7(15%)
2(4%)
3(6%)

29(100%)
0%
0%
0%

1(2%)
5(10%)
2(4%)
25(52%)
2(4%)
13(27%)

8(28%)
5(17%)
1(3%)
2(7%)
6(21%)
7(24%)

1(2%)
3(6%)
6(13%)
38(79%)

9(31%)
15(52%)
5(17%)
0%

13(27%)
35(73%)
40(83.3%)
12(25%)

29(100%)
0%
0%
0%

38(79%)
40(83%)
40(83%)
35(73%)
24(50%)
20(42%)
31(65%)

0%
0%
0%
0%
0%
0%
0%

*Age groups include datasets that use subset within the given range, e.g., "≥14 Years" includes datasets of adults 30 years and older, but not those
restricted to 40 and older. However, each age-based estimate is only included in one grouping. See supplement for a full description of age ranges.
**Pandemic defined as calendar year 2009. Six published articles and three working group datasets only provided combined pre-pandemic/pandemic
estimates.
‡Case definitions as defined per individual study criteria
§ Includes: acute febrile illness, respiratory infection, acute exacerbation of chronic illness
ǁ Includes: ICU patients only, acute asthma patients
¶Obtained from http://siteresources.worldbank.org/DATASTATISTICS/Resources/OGHIST.xls
†Source: United Nations Population Division (UNPD), 2012 World Population Prospects Report
₮ Testing for Bacteria Includes: Streptococcus pneumoniae, Haemophilus Influenzae, Legionella pneumophila, Coxiella burnetti, Mycoplasam
pneumoniae, Chlamydophila pneumonia, C. psittaci, Pseudomonas spp, Klebsiella, other Enterobacteriaceae spp, Staphylococcus aureus, Pasteurella
spp, β-haemolytic Streptococcus, and Mycobacterium, Moraxella catarrhalis, Bacillus subtilis, Leptospira
¥Other viruses include: enterovirus, coronavirus, herpes simplex
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4.2 Median Crude Influenza-positive Proportions
4.2a. Crude proportions for all (eligible) datasets
In table 2, we provided crude estimates of respiratory samples from hospitalized
adults testing positive for influenza by a number of key variables, including age range,
study population type, income level, case definition, diagnostic test, WHO region,
country development, documented comorbidities, and influenza vaccine status among
both published and unpublished datasets. All eligible datasets conducted testing for both
influenza type A and B, and provided data for populations at 14 years of age or older. A
limited number of datasets used immunofluorescence and culture as their only diagnostic
tool. Eastern Mediterranean was the least represented WHO region. The most common
age range for the influenza-tested individuals was between 18 and 64 years of age. The
median number of tested individuals was larger for unpublished datasets. The largest
median number tested for influenza was diagnosed using the acute respiratory infection
case definition. The immunocompromised population and culture only diagnostic also
had a large median influenza-tested population, although they both were among the
lowest median percent influenza-positive proportion. We noted a low median percent
influenza-positive proportion for industrialized countries and when using pneumonia as
the case definition. Although not significant by Kruskal-Wallis, the European WHO
region had the lowest positive proportion when compared to other regions. We observed
the largest median influenza-positive proportion for the pandemic (2009) timeframe
followed by datasets which used multiple diagnostics excluding PCR. ICU patients and
acute asthma patients together, labeled as “other,” had a large median influenza-positive
proportion. According to Kruskal-Wallis or Wilcoxon rank sum, there were significant
differences in the median percent influenza-positive by a number of key variables: study
types (published vs non-published), timeframes (pre- and post- vs during pandemic), and
UN country developmental statuses.
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Table 2. Crude proportion of respiratory samples from hospitalized adults testing positive for influenza by
age group, study design, and population including all datasets*§
No. of
Median
studies
Median Percent Positive (IQR) p-value**
Number (IQR)
(n=)
Tested
Positive
Age group in years
≥14
64
258(147, 753)
21(11, 72)
10% (0.06, 0.18) 0.1254
18 to 64
26
605(285, 1235)
72(33, 356)
14% (0.09, 0.19)
≥45
27
300(107, 718)
27(9, 92)
10% (0.08, 0.16)
≥65
23
159(76, 482)
20(7, 55)
11% (0.06, 0.15)
Type of study
Unpublished
26
760(317, 1538)
80(37, 388)
13% (0.08, 0.24) 0.0094
surveillance
Published
39
190(107, 283)
14(7, 21)
8% (0.04, 0.17)
Timeframe for outcome data
Pre-2009†
47
190(107, 290)
14(7, 22)
8% (0.04, 0.16)
0.0004
During 2009
9
501(123, 835)
162(52, 187) 23% (0.14, 0.34)
("pandemic")
Post-2009
26
618(218, 1065)
55(27, 151)
12% (0.08, 0.20)
Diagnostic test
PCR only
15
510(205,849)
37(21, 81)
14% (0.06, 0.22) 0.2597
Immunofluorescence
1
130
9
7%
only
Culture only
1
785
11
1%
Serology Only
10
240(135, 308)
14(4, 22)
6% (0.04, 0.16)
Multiple diagnostic
33
266(179, 720)
21(9, 110)
9% (0.05, 0.17)
tests, incl. PCR
Multiple diagnostic
5
84(79, 157)
15(6, 20)
20% (0.07, 0.22)
tests, excl. PCR
Case definition
Acute Respiratory
4
534(262, 1481)
16(10, 205)
6% (0.02, 0.13)
0.0724
Infection
Acute Lower
206(107,
3
37(14, 1324) 13% (0.10, 0.18)
Respiratory Infection
12779)
Pneumonia
24
189(124, 250)
14(7, 20)
7% (0.04, 0.10)
Severe Acute
21
720(317, 1457)
80(52, 211)
13% (0.08, 0.26)
Respiratory Illness
Other
13
198(90, 510)
20(7, 37)
16% (0.06, 0.22)
Study population
General adult
54
296(193, 800)
29(13, 80)
10% (0.06, 0.18) 0.1680
population
COPD
6
98(85, 148)
12(3, 22)
12%(0.02, 0.22)
Immunocompromised
2
457(128, 785)
7(2, 11)
1% (0.01, 0.02)
Other
3
107(79, 187)
19(7, 20)
18% (0.04, 0.25)
WHO region
African
8
338(217, 632)
23(14, 64)
8% (0.05, 0.14)
0.4600
Eastern
2
422(124, 720)
112(13, 211) 20% (0.10, 0.29)
Mediterranean
European
22
239(135, 324)
14(7, 34)
8% (0.02, 0.16)
Americas
8
262(162, 1261)
18(9, 154)
10%(0.05, 0.17)
Southeast Asian
7
748(199, 2438)
57(7, 558)
10% (0.06, 0.24)
Western Pacific
18
208(92, 804)
28(19, 72)
14% (0.08, 0.18)
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No. of
studies
(n=)
World Bank income level
Low
Lower Middle
Upper Middle
High
Development Status
Developing
Industrialized
Percent Comorbidity‡
<65%
≥65% and <100%
100%
no data
Vaccine Coverage‡
<40%
≥40%
no data

Median
Number (IQR)

Median Percent Positive (IQR)
Tested

Positive

p-value**

10
15
8
32

464 (228, 800)
783(268, 1498)
211(130, 1462)
187(107, 283)

54(29, 80)
110(14, 468)
29(12, 254)
14(7, 22)

12% (0.06, 0.17)
14% (0.06, 0.26)
13% (0.08, 0.19)
8% (0.03, 0.14)

0.0850

35
30

626(205, 1394)
198(107, 296)

55(15, 211)
14(6, 21)

13% (0.07, 0.20)
7% (0.02, 0.13)

0.0028

8
6
10
43

160(121, 258)
250(130, 296)
107(85, 148)
359(206, 1065)

11(6, 22)
9(6, 16)
15(3, 20)
37(15, 120)

8% (0.04, 0.10)
7% (0.03, 0.08)
12% (0.02, 0.22)
12% (0.06, 0.19)

0.8279

5
5
57

198(137, 211)
217(148, 304)
283(130, 800)

16(4, 26)
7(5, 29)
21(13, 80)

8% (0.02, 0.19)
8% (0.04, 0.10)
10% (0.06, 0.18)

0.7540

*Six eligible articles provided data for influenza A only, and were excluded from the overall positive analyses
§These crude estimates include all datasets: pre-pandemic, pandemic, and post-pandemic.
**Kruskal-Wallis/Wilcoxon rank sum test.
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. Since data was provided by year in
the unpublished datasets, three unpublished datasets were included in two timeframes; six unpublished datasets were in all three timeframes.
‡Data only available in published studies. Fifteen studies provided approximate totals for percent comorbidity and one study for vaccine coverage. These
were excluded from analysis. Kruskal Wallis or Wilcoxon rank sums of defined groups; excluded no data.

4.2b.Crude positive proportions by year and virus type or subtype
We used boxplots to present the total proportion of positive influenza by year and
by virus type or subtype in figure 2. Since unpublished datasets were the only source to
provide data by year and by virus type or subtype, we constructed the boxplots using the
unpublished datasets. Although unpublished datasets covered 2003 to 2012, we limited
our analysis to years with more than one dataset. We had one dataset for each of the
following years: 2003, 2004, 2005, 2006, and 2012. Virus type A was most commonly
detected during 2007 to 2011. The largest subtype-specific median influenza-positive
proportion was seen in 2009 for influenza A (H1N1) pandemic virus. Pandemic H1N1
decreased in 2010, but was still high. In 2011, pandemic H1N1further decreased. Cases
of seasonal influenza A (H1N1) were the least commonly detected subtype, and were
only detected in 2009. Influenza A (H3N2) virus was detected from 2008 through 2011,
when it had its highest proportion positive among these datasets. Influenza type B cases
were confirmed and reported throughout the time period (2007 to 2011) with u-shaped
positive proportion distribution, decreasing in 2009 and increasing in 2010.
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Figure 2. Boxplot of the proportion of adult respiratory samples testing positive for influenza virus by year
and virus

2007 (n=3)

2008 (n=6)

2009 (n=9)

2010 (n=20)

2011 (n=18)

Year (Number of GRIPP Datasets)
Virus Type/Subtype
Influenza A

A/H3N2

A/H1N1 pandemic

A/H1N1 seasonal

Influenza B

excludes outside values

4.2c. Crude positive proportions by population characteristics
Some publications provided more details about their study populations, such as
the percentage of study participants with comorbidities and those who have received the
influenza vaccine within the last twelve months. In table 2 and 3, we observed a slight
increase in median percent influenza-positive proportions as the percentage of vaccine
coverage and comorbidities among the study population increases. This increase,
however, as calculated by Kruskal-Wallis or Wilcoxon rank sums, is not statistically
significant (p-values >0.05). It is important to note that majority of studies (49 to 65 of
the 77 studies) lacked comorbidity and vaccine coverage information. Of the
comorbidities reported, lung disease was the most common.
4.2d. Pandemic and seasonal crude proportions
To determine whether the data from the pandemic period was influencing the
trends in the median positive proportion by other key variables, we removed data from
this timeframe from the crude analyses, and observed a decrease in statistical significance
in median positive proportions for timeframe variable. In table 3, we showed the crude
estimates with seasonal (pre and post pandemic) data only. After removing the pandemic
timeframe from analysis, statistical significance diminished for all groupings, except for
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UN country development status and timeframe. The highest median influenza-positive
proportion slightly decreased from 23% to 20%. Studies which used multiple diagnostics
excluding PCR had the highest median positive proportion. This decrease in median
positive proportion was observed for many variables, such as age group 18-64 (14% all
datasets to 12% seasonal datasets only) and developing countries (13% all to 10%
seasonal). By the number of datasets, we noted that most seasonal datasets used either
SARI or pneumonia as their case definition, tested individuals using multiple tests
including PCR, and came from the European WHO region, high or lower middle income
levels, and developing countries. Datasets, which used acute lower respiratory infection
as the case definition, had the largest median number of individuals tested for influenza
(1662, median range = 84 to 1662) and the largest median number of individuals with
positive influenza laboratory results (164, median range = 7 to 164). Datasets which used
culture or immunofluorescence as their primary diagnostic test had the lowest median
number of laboratory-confirmed positive influenza cases.
We also stratified crude proportions by pandemic datasets alone (appendix 4).
Pandemic datasets were smaller and lacked power. Generally, when pandemic data was
available for variables, the pandemic crude proportions were larger than seasonal crude
proportions (12-42%). None of the published datasets in our systematic review focused
on the pandemic year alone. We observed a slight statistical difference between case
definitions, acute lower respiratory infection versus severe acute respiratory infection, in
the pandemic datasets (p-value by Kruskal-Wallis = 0.0404). No other subgroupings were
statistically differed by Kruskal-Wallis or Wilcoxon rank sum test.
Table 3. Seasonal crude proportions of respiratory samples from hospitalized adults testing positive for
influenza by age group, study design, and population*§
No. of
Median
studies
Median Percent Positive (IQR)
p-value**
Number (IQR)
(n=)
Tested
Positive
Age group in years
≥14
61
209(124, 473)
19(9, 46)
10% (0.05, 0.15)
0.3099
18 to 64
25
199(112, 528)
22(12, 75)
12% (0.06, 0.16)
≥45
26
176(86, 558)
18(7, 74)
10% (0.07, 0.14)
≥65
20
149(88, 441)
16(7, 50)
10% (0.06, 0.15)
Type of study
Unpublished
25
232(136, 805)
26(13, 109)
11% (0.06, 0.15)
0.2124
surveillance
Published
39
190(107, 283)
14(7, 21)
8% (0.04, 0.17)
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No. of
studies
(n=)
Diagnostic test
PCR only
Immunofluorescence
only
Culture only
Serology Only
Multiple diagnostic
tests, incl. PCR
Multiple diagnostic
tests, excl. PCR
Case definition
Acute Respiratory
Infection
Acute Lower
Respiratory Infection
Pneumonia
Severe Acute
Respiratory Illness
Other
Study population
General adult
population
COPD
Immunocompromised
Other
WHO region
African
Eastern
Mediterranean
European
Americas
Southeast Asian
Western Pacific
World Bank income level
Low
Lower Middle
Upper Middle
High
Development Status
Developing
Industrialized
Percent Comorbidity‡
<65%
≥65% and <100%
100%
no data
Vaccine Coverage‡
<40%
≥40%
no data

Median
Number (IQR)

Median Percent Positive (IQR)
Tested

Positive

164(117, 401)

20(13, 36)

13% (0.07, 0.17)

15

130

9

7%

1
10

785
240(135, 308)

11
14(4, 22)

1%
6% (0.02, 0.16)

32

229(136, 551)

19(8, 70)

8% (0.04, 0.13)

5

84(79, 157)

15(6, 20)

20% (0.07, 0.22)

4

566(283, 785)

21(11, 99)

9% (0.03, 0.13)

24

1662(826,
2019)
189(124, 250)

20

3

164(40, 237)

p-value**

0.1486

0.3623

13% (0.09, 0.14)

14(7, 20)

7% (0.04, 0.10)

192(117, 401)

17(9, 41)

10% (0.06, 0.15)

14

198(90, 510)

20(7, 36)

16% (0.04, 0.22)

53

228(135, 510)

19(9, 52)

10% (0.06, 0.15)

6
2
3

98(85, 148)
457(128, 785)
107(79, 187)

12(3, 22)
7(2, 11)
19(7, 20)

12%(0.02, 0.22)
1% (0.01, 0.02)
18% (0.04, 0.25)

8

177(111, 233)

14(8, 27)

8% (0.06, 0.14)

1

124

13

10%

22
8

14(8, 25)
18(9, 46)

8% (0.03, 0.15)
10%(0.05, 0.14)

85(16, 236)

12% (0.06, 0.17)

18

198(123, 250)
233(133, 437)
1130(143,
1680)
203(109, 401)

22(6, 30)

10% (0.05, 0.18)

10
14
8
32

184 (92, 358)
250(140, 955)
566(130, 1462)
187(107, 283)

16(13, 28)
26(8, 115)
68(15, 120)
14(7, 22)

10% (0.06, 0.15)
10% (0.04, 0.16)
12% (0.08, 0.17)
8% (0.03, 0.14)

0.4555

34
30

208(123, 800)
198(107, 296)

24(13, 84)
14(6, 21)

10% (0.06, 0.16)
7% (0.02, 0.13)

0.0492

8
6
10
42

160(122, 258)
250(130, 296)
107(85, 148)
231(136, 582)

11(6, 22)
9(6, 16)
15(3, 20)
21(13, 81)

8% (0.04, 0.10)
7% (0.03, 0.08)
12% (0.02, 0.22)
10% (0.06, 0.16)

0.8279

5
5
56

198(137, 211)
217(148, 304)
208(117, 536)

16(4, 26)
7(5, 29)
19(9, 41)

8% (0.02, 0.19)
8% (0.04, 0.10)
10% (0.06, 0.15)

0.7540

7

*Six eligible articles provided data for influenza A only, and were excluded from the overall positive analyses

0.1505

0.9136
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§These crude estimates include all datasets: pre-pandemic, pandemic, and post-pandemic.
**Kruskal-Wallis/Wilcoxon rank sum test.
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. Since data was provided by year in
the unpublished datasets, three unpublished datasets were included in two timeframes; six unpublished datasets were in all three timeframes.
‡Data only available in published studies. Fifteen studies provided approximate totals for percent comorbidity and one study for vaccine coverage. These
were excluded from analysis. Kruskal Wallis or Wilcoxon rank sums of defined groups; excluded no data.

4.3 Pooled estimates of adult influenza respiratory hospitalizations
Using the binomial regression model in SAS, we calculated pooled estimates for
the positive proportion of adult influenza hospitalizations by age range, study population
type, country developmental status, WHO region, and country income level (table 4). We
included sample size and 95% CI. Due to statistical, significant differences observed in
key variables when including pandemic datasets, we used only seasonal datasets in our
pooled estimate calculations. We calculated an overall pooled estimate of 11% (95% CI,
0.09-0.12). Pooled estimates ranged from 7% to 16%. Whether restricting analysis to
PCR only or including all tests, we calculated similar median positive pooled estimates
for both overall and stratified estimates. We observed very little change in median
influenza-positive crude proportions and median positive pooled estimates for age
groups. We noted consistent results, across stratified estimates, for country
developmental status and country income level. Lower income countries, where PCR was
used exclusively, had a higher median positive pooled estimate than higher income
countries. Developing countries had a higher (11-12%) median positive pooled estimate
than industrialized countries (8%).

Table 4: Pooled estimates of global adult influenza-associated hospitalizations, by age group, study
population, income level and WHO region
PCR
PCR tested Pooled %
Pooled % Positive
N†
Tested N*
Positive (95% CI)
(95% CI)†
Age group in years
≥14
62
11% (0.09, 0.13)
88
11% (0.09, 0.12)
18 to 64
44
12% (0.09, 0.15)
50
12%(0.10, 0.15)
≥45
33
10% (0.09, 0.11)
41
10% (0.09, 0.11)
≥65
23
10% (0.10, 0.10)
31
10% (0.10, 0.10)
Study population
General adult
59
11% (0.09, 0.13)
80
11% (0.09, 0.13)
population
Special population**
5
9% (0.03, 0.30)
9
7% (0.03, 0.16)
WHO region
African
14
9% (0.07, 0.12)
15
9% (0.07, 0.12)
Americas
3
9% (0.03, 0.23)
12
11% (0.08, 0.15)
Eastern Mediterranean
one
dataset‡
European
12
16% (0.08, 0.34)
24
10% (0.06, 0.18)
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WHO region
Southeast Asian
Western Pacific
Income level
Low Income
Lower Middle Income
Upper Middle Income
High Income
Development status†
Developing
Industrialized

PCR
Tested N*

PCR tested Pooled %
Positive (95% CI)

N†

Pooled % Positive
(95% CI)†

14
21

13% (0.08, 0.19)
11% (0.08, 0.14)

14
25

12% (0.08, 0.19)
11% (0.08, 0.14)

17
25
7
15

13% (0.10, 0.17)
12% (0.08, 0.18)
10% (0.07, 0.16)
9% (0.06, 0.12)

18
31
10
32

13% (0.10, 0.16)
12% (0.09, 0.17)
10% (0.07, 0.14)
8% (0.06, 0.11)

51
13

11% (0.09, 0.14)
8% (0.06, 0.12)

61
30

12% (0.10, 0.14)
8% (0.05, 0.10)

*Number of data points included in model, including multiple individual years from a single dataset, when available
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients
†All diagnostic tests included
‡no PCR data
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients

4.4. Assessment of the impact of dataset quality on influenza-positive proportions
Exploring the impact of article quality on our outcome of interest, we found no
significant difference in the median influenza-positive proportions among published
datasets by total bias score (p-value = 0.9255; appendix 5). In our assessment, we
evaluated selection, comparability, and outcome bias, giving each dataset a bias score of
0 (undefined) or 1 (clearly defined). Total bias was the sum of this assessment, with
larger totals correlating with the higher quality. This assessment was limited to published
datasets. Thirty-eight percent of published datasets were of high quality with total bias
score of 3. Slightly more datasets were of medium quality, total bias scores of 2 (43%). A
small subset of datasets had a total bias score of ≤1 (19%). When we stratified the
published datasets by PCR testing, we observed a statistical difference in median
proportion positive by selection bias score (p-value = 0.0394); datasets with high quality
scores, bias score of 1, had a larger median positive proportion (11% compared to 5% for
datasets with a selection bias score of 0). The statistical difference seen in selection bias
after stratifying datasets by PCR testing did not influence the overall bias assessment (pvalue = 0.1866). We also noted a larger median positive proportion for datasets where
PCR was the primary diagnostic test, and published PCR datasets tended to be of high
quality with a total bias score of 3 (of 3). After we stratified by timeframe, we noted that
the pandemic datasets had larger median positive proportions as the total bias score
increased (14% when total bias score equaled 3 and 5% when total bias score equaled 2).
Seasonal datasets exhibited little to no change in median positive proportion with varying
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bias assessment scores (10% positive proportion for datasets with total bias score of 0 or
1, 7% positive proportion for datasets with total bias score of 2, and 8% positive
proportion for datasets with total bias of 3).
4.5 Exploratory Analyses
4.5a. Impact of pandemic H1N1in 2010 calendar year
To evaluate the possible influence of other factors on the calculated crude
proportions and pooled estimates, we conducted several post-hoc exploratory analyses.
The first factor we evaluated was inclusion of calendar year 2010 data in seasonal
influenza (non-pandemic) estimates. In our primary analyses, we defined pandemic
datasets as datasets including the 2009 year. However, as seen in figure 2, pandemic
H1N1 continued to circulate in 2010. As we previously described in table 3, we observed
a decrease in statistical differences among key variables when we removed 2009-year
data. To explore whether 2010-year data influenced crude proportions and/or pooled
estimates for seasonal influenza, we reanalyzed the seasonal data, excluding data points
from 2010 and compared these findings to the main results (appendix 6). When reviewing
the datasets without 2010-year data, we observed slight decreases in crude proportions
(1-20%; examples include 6% without 2010 vs 9% in seasonal for acute respiratory
infection case definition). The ≥65 age group crude proportions increased after removal
of 2010 data (10% to 11%). No statistical significance was noted among the crude
proportions by Kruskal-Wallis or Wilcoxon rank sums in the datasets without 2010-year
data. Pooled estimates were similar prior to and after stratification, typically 1% to 3%
lower after 2010-year data was removed. Highest pooled estimate, before and after
stratification, was for datasets from the European WHO region which used PCR as the
primary diagnostic test (16%).
4.5b. Potential impact of testing timeframe and detection of other pathogens
4.5bi. Partial year influenza testing stratification
In this study, some datasets collected data for one or more full 12-month periods,
while others had a time frame of data collection exceeding a multiple of 12 months of
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ongoing influenza testing (such as 18 or 30 months). We referred to these datasets as
datasets with partial years of influenza data (appendix 7). To ensure that the datasets with
partial years did not inflate our pooled and crude estimates due to their potential inclusion
of multiple peaks of influenza circulation, we stratified the datasets by whether they
contained partial years of data and compared the estimates. After stratifying the datasets,
we noticed that there were less datasets with partial-year data than with data completed
during 12-month periods (36 partial-year datasets had data for the ≥14 year-old age
group, while 73 full-year datasets included data for the same age group variable, for an
example). A few variables were specific to datasets with or without partial years.
Datasets that used immunofluorescence as the only diagnostic test or were from the
Eastern Mediterranean WHO region completed influenza testing ongoing beyond a
multiple of 12 months; using culture only or multiple diagnostic testing excluding PCR
were only seen in datasets without partial-year data.
Overall, datasets with partial years had similar positive crude proportions, 0-19%,
compared to datasets without partial years, 0-20%. The multiple tests excluding PCR
variables remained the largest crude proportions in the datasets without partial years
(20%). The PCR only datasets with partial-year data had a crude proportion of 19%. This
crude proportion decreased by 8% when datasets with partial-year data were excluded
and by 6% when analyzing all eligible seasonal datasets. We noted similar levels of
decrease in crude proportions after removing partial-year datasets for COPD study
population (16% partial-year to 8% full-year), Western Pacific WHO region (17%
partial-year to 9% full-year), and industrialized countries (10% partial-year to 5% fullyear). Increases in crude proportions were observed in datasets without partial-year data.
Datasets from the Americas WHO region increased 5% after the removal of datasets with
partial-year data.
As calculated by Kruskal-Wallis or Wilcoxon rank sums, we observed statistical
differences for case definition in partial-year datasets (p-value = 0.032). We noted more
statistical differences for crude proportions in datasets without partial years (pre- and
post-pandemic timeframe, p-value = 0.038; and development status, p-value = 0.0464).
When we evaluated the pooled estimates by partial year stratification, datasets
with partial years versus datasets with full years, we observed little difference in
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estimates between partial and full year datasets including all diagnostic tests (9-20% and
4-21% respectively). Pooled estimates for special populations decreased when we
removed partial-year datasets (20% partial-year to 4% full-year datasets). We also
noticed a decrease in pooled estimates for datasets from the Southeast Asian WHO region
after the removal of partial-year datasets (17% partial-year to 11% full-year). European
WHO region datasets increased from 11% with partial-year datasets to 21% without
partial-year datasets.
4.5bii. Multipathogen Detection
Other viruses frequently co-circulate with influenza. These viruses as well as
bacteria can co-exist with influenza in the human hosts and may increase the severity of
the infection. To explore whether datasets that tested for other pathogens in addition to
influenza were likely to have higher or lower crude proportions and pooled estimates, we
stratified the published datasets by multipathogen testing (appendix 8). Only one
published, seasonal dataset did not test for other pathogens in addition to influenza type
A and B. Comparing the crude and pooled estimates from the multipathogen testing
datasets, published only, to those in the seasonal datasets, published and unpublished, we
noted little change in the estimates (0-6% difference seen among the key variables). The
overall pooled estimate for the multipathogen testing datasets was 8% (compared to the
seasonal, 11%). Similar to the seasonal datasets, developing countries had higher pooled
estimates than industrialized countries (12% vs 7%) in the multipathogen testing datasets.
We were unable to calculate pooled estimates for three of the six WHO regions (African,
Eastern Mediterranean, and Southeast Asia), and for low and lower middle income levels
using the multipathogen testing datasets. With the seasonal datasets, we calculated pooled
estimates for all variables of interest; we included data from lower income countries and
all WHO regions in our analysis by supplementing the literature review with surveillance
data. No statistical significance was observed in the crude proportions for the
multipathogen testing datasets.
To evaluate whether testing for a specific pathogen in addition to influenza
influenced the influenza-positive crude proportions and/or total tested for influenza, we
stratified the crude proportions in the multipathogen testing datasets by other pathogen
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testing. We found that influenza-positive crude proportions increased when excluding
datasets that tested for RSV, adenovirus, or bacteria (8% prior to stratification; 11%
without RSV, 22% without adenovirus, and 14% without bacteria). The crude proportions
further increased when we restricted the analysis to PCR data (17% without bacteria, for
example). We observed larger median totals tested for influenza when we excluded
datasets that tested for RSV; parainfluenza; bacteria; or enterovirus, coronavirus, and
herpes simplex. Totals increased when we included datasets that tested for adenovirus or
rhinovirus.

Chapter V Discussion
5.1 Summary of findings
By combining findings from the published literature with additional unpublished
surveillance data, we obtained influenza testing results from 50 countries with varying
income levels, country development status, vaccine policies, and health-seeking
behaviors over a 31-year period of time. We estimated that 11% (95% CI, 0.09 – 0.12) of
global adult respiratory hospitalizations were associated with seasonal (non-pandemic)
influenza. This pooled estimate increased as country income level decreased and as
country development status decreased (8% (0.06, 0.11) for high income, 10% (0.07, 0.14)
for upper middle income, 12% (0.09, 0.17) for lower middle income, and 13% (0.10,
0.14) for low income; 8% (0.05, 0.10) for industrialized countries and 12% (0.10, 0.14)
for developing countries). The crude (median) proportions were influenced by the
pandemic time period, with the largest proportion positive (23% IQR 0.14-0.34) occurred
during 2009. The crude proportion positive for influenza during non-pandemic periods
was not statistically different by age group, data source, case definition, or country
income level.
5.2 Evaluation of potential impact on estimates by key variables or with inclusion of
pandemic virus
Impact of country income level and development status
Country income and development status had an inverse relationship with the
influenza-positive pooled estimate and seasonal crude proportions, with increasing
prevalence of influenza as country income decreased. Comparing the datasets by country
development status, we notice that majority of datasets provided by developing countries
were unpublished, used PCR as their main diagnostic test, and were collected post 2009
pandemic. Timeframe at which specimens were collected and analyzed may influence the
positive-influenza proportion. At times of heightened awareness of influenza, enrollment
increases (Ayele et al., 2012). Perhaps, more individuals with influenza seek care and
50
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tested positive for influenza after than before 2009. Prior to 2009, influenza data from
developing, low-income countries was limited, as seen with our meta-analysis and others
(Briand, Mounts, & Chamberland, 2011; Gessner et al., 2011; Peasah et al., 2013; Savy et
al., 2013; Simmerman & Uyeki, 2008). With the later time period of testing, developing
countries were able to use more sensitive methods such as PCR (Das, Spackman, PantinJackwood, & Suarez, 2009; Kumar & Henrickson, 2012; Pasick, 2008; WHO, 2011a).
Industrialized countries included our meta-analysis used other tests
(immunofluorescence, cell culture, and immunoassays), which may have lower
sensitivity or require advanced technical skill, in addition to PCR (Harper et al., 2009;
Kumar & Henrickson, 2012). Depending on the testing algorithm and interpretation of
results, some influenza cases may have been missed (Harper et al., 2009; Kumar &
Henrickson, 2012).
While industrialized countries have well-established influenza vaccination programs,
high vaccine coverage (≥60% among adults ≥65 years old), and in many cases stockpiles
of vaccines available, developing countries, low and middle income countries struggle to
have influenza vaccine recommendations or policies established (Mereckiene et al., 2010;
MIV, 2005; Oshitani, Kamigaki, & Suzuki, 2008; Samaan et al., 2013). During our study
timeframe, the influenza vaccine available may have provided sufficient protection
against circulating strains and as result, countries distributing the vaccine to their
population were able to prevent influenza disease, decreasing the number of individuals
who tested positive for influenza. Although influenza vaccine effectiveness was reported
low during the 2003-2004 season in the United States (Herrera et al., 2007), the increased
vaccine coverage during 2010-2011 and 2012-2013 seasons averted more influenza
illness and hospitalizations (Bresee et al., 2013; Kostova et al., 2013).
Differences in host immunity and virulence of influenza may contribute to the
variation in influenza positive proportions among developing, lower income countries
and industrialized, high income countries (Freitas et al., 2013; Yang, Chiu, et al., 2011;
Yu et al., 2014). Influenza disease may lead to more severe outcomes in developing
countries due to higher prevalence of HIV and malnutrition (Freitas et al., 2013; Tempia
et al., 2014). Adults infected with HIV are at greater risk of influenza-associated
hospitalizations (C. Cohen et al., 2012; Gessner et al., 2013). In addition to increased risk
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of severe influenza disease, immunocompromised adults shed seasonal influenza virus
detectable by PCR for longer periods of time than immunocompetent adults (Klimov et
al., 1995; van der Vries et al., 2013; Weinstock, Gubareva, & Zuccotti, 2003). Prolonged
shedding of pandemic H1N1 virus was detected in both immunocompromised and
immunocompetent adults (Fleury et al., 2009). The variation of co-circulating viruses and
bacteria between developing and industrialized countries may also contribute to the
difference in disease severity (Madhi & Klugman, 2004; Morens, Taubenberger, & Fauci,
2008). Environmental factors, such as crowded living conditions with close proximity to
animals, temperature, and humidity, may increase likelihood of influenza transmission
and/or promote viral survival in developing, lower income countries (Freitas et al., 2013;
Yang, Chiu, et al., 2011). Sutanto et al observed a decrease in influenza severe outcomes
when accessibility to health care increased (Sutanto et al., 2002). Developing, low
income countries often have insufficient number of nurses and doctors on staff, hospital
beds available, and medical supplies (Oshitani et al., 2008). A low income country with
large populations, such as Bangladesh, have modest health care infrastructure (Homaira
et al., 2012). With this lack of access to adequate medical care and modest health
infrastructures, developing countries experience higher mortality rates due to influenza
than industrialized countries, according Oshitani and colleagues (Oshitani et al., 2008).
Impact of pandemic H1N1
As we noticed in our analysis, the pandemic H1N1 season was very different from
other influenza seasons. The largest positive proportions were seen during the pandemic.
Globally, H1N1 contributed to 201,000 respiratory deaths and 83,300 cardiovascular
deaths (F. Dawood et al., 2012). When examining the positive proportions by age group,
we observed slightly higher positive proportions in younger adults, 18-64 years old, than
older adults, 65 years or older (not statistically significant). This finding is consistent
with surveillance studies of influenza-associated hospitalizations conducted in the United
States and India (Chadha et al., 2013; C. M. Cox et al., 2012; N. J. Cox & Subbarao,
2000). During the pandemic in the United States, influenza-associated hospitalizations
among younger adults increased 6-folds, in comparison to the average number of
hospitalizations in this age group during the prior four influenza seasons (C. M. Cox et
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al., 2012). In India, the highest number of hospitalizations due to pandemic H1N1 was
among individuals 5-29 years old (Chadha et al., 2013). Although hospitalizations among
younger adults increased during the pandemic, hospitalizations among adults ≥75 years
old decreased (C. M. Cox et al., 2012). A large portion of older adults had pre-existing,
cross-reactive antibodies to pandemic H1N1, according to a serological survey of adult
serum prior to 2009; these antibodies provided immune protection (Hancock et al., 2009).
Impact of age
After the removal of pandemic H1N1 data (2009 year data), we observed no
difference in positive proportions by age group (12% (IQR, 0.06-0.16) for 18-64 year
olds and 10% (IQR, 0.06, 0.15) for 65+). Behbehani et al described this lack of difference
in their published dataset, when they conducted a year-long study to evaluate the causes
of community-acquired pneumonia in hospitalized adults in Kuwait (Behbehani et al.,
2005). Earlier studies show that complications, hospitalizations, and deaths due to season
influenza were greatest among adults ≥65 years of age (CDC, 2010). Due to the higher
risk for severe outcomes, existing influenza vaccination policies for adults typically target
this age group (CDC, 2013; Mereckiene et al., 2010; MIV, 2005; WHO, 2012a, 2012b).
According to recent studies, a large portion of adults ≥65 years old are receiving the
vaccine (Mereckiene et al., 2010). This increase in vaccine uptake among this age group
may have prevented disease, if the received vaccine induced an adequate immune
response in vaccinees against circulating influenza strain(s) (CDC, 2010). Vaccine
effectiveness, however, is known to be lower in older adults than younger adults due
dysregulation of the immune system, termed immunosenescence (Reber et al., 2012).
Older adults may have acquired immunity to circulating strains through prior exposure,
as seen in the pandemic timeframe (Hancock et al., 2009; Hardelid et al., 2010; Miller et
al., 2010; Talbot & Falsey, 2010). On the other hand, the datasets included in our study
may have missed influenza cases in older adults due to atypical presentation, not fitting
the case definitions, or the inability to collect specimens (Talbot & Falsey, 2010;
Babcock, Merz, Dubberke, & Fraser, 2008). Influenza often presents without fever in
older adults and patients with COPD (Talbot & Falsey, 2010). When comparing
laboratory-confirmed influenza cases, younger adults matched the influenza-like-illness
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case definitions more frequently than older adults (Babcock et al., 2008; Radin et al.,
2012). Older adults tend to have less secretions and increased nasal dryness; both of
which increase the difficulty of collecting specimens and may result in more discomfort
during the collection process (Talbot & Falsey, 2010). As found from community
surveys, health-seeking behaviors depend on socioeconomic status, disease severity, and
age. Children were more likely to be treated than adults in New Mexico, United States
(D. L. Thompson et al., 2013). During the 2005-2010 influenza seasons in Hong Kong,
Wang et al observed an increase in excess influenza-related hospitalizations among
children and young adults and a decrease among adults ≥65 years old (Wang et al., 2012).
Heighten public awareness of respiratory viruses due to SARS may explain the change in
health-seeking behavior among parents and young adults (Wang et al., 2012). Older
adults and adults with underlying conditions usually seek care for influenza-likesymptoms only after the illness worsens (Biggerstaff et al., 2014). Since influenza illness
can lead to secondary infections and/or complications of underlying conditions, older
adults and adults with underlying conditions may go undiagnosed and not tested for
influenza (Biggerstaff et al., 2014). If even tested for influenza, these patients may not be
shedding virus at the time of receiving care (Biggerstaff et al., 2014). The differences in
age distribution among the study populations may also explain the lack of difference
between the age groups. In developing countries, especially in countries with high
prevalence of HIV and malnutrition, life expectancy is lower than industrialized countries
(Gordon et al., 2010; Radin et al., 2012; Takahashi et al., 2013). As a result, the
population proportion of elderly in Vietnam, for example, is lower than the proportion of
the population living in the United States (Takahashi et al., 2013). Because our age cutoffs primarily reflect the unpublished surveillance data, which was collected from
developing countries only, the older age group may not be well-represented.
Impact of diagnostic tests used
In our analysis, diagnostic test used did not influence the pooled estimates and
positive proportions. Influenza diagnostic tests have varying sensitivity and specificity
(Leekha et al., 2013; Sawatwong et al., 2012; Talbot & Falsey, 2010). When respiratory
specimens are collected soon after onset and stored properly, PCR is considered the most
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sensitive test, even for adults ≥ 65 years old (Ellis & Curran, 2011; Hopkins, Moorcroft,
Correia, & Hart, 2011; Leekha et al., 2013; Sawatwong et al., 2012; Talbot & Falsey,
2010). PCR datasets from a similar meta-analysis of children hospitalized due to
respiratory infections had higher influenza-positive crude and pooled estimates than nonPCR datasets (Lafond et al., 2014). In our study, majority of the datasets (100%
unpublished datasets and 50% published datasets) used PCR alone or with other tests.
Our analysis may have been limited by the number of datasets not using PCR (56 PCR vs
21 non-PCR). Of those not using PCR, 86% used paired or single serum serology. While
paired serum serology measures fold-rise in antibody titers from initial exposure (vaccine
or infection) to recovery, single serum serology measures one point in time with preestablished limits (Broor, Chahar, & Kaushik, 2009; Kumar & Henrickson, 2012). These
pre-established limits do not account for pre-existing antibodies due to prior exposure or
recent vaccination, which may result in false positives (Broor et al., 2009; Kumar &
Henrickson, 2012). Prior exposure to certain influenza virus types and/or subtypes is
common in adults, especially older adults (Talbot & Falsey, 2010). We found a 20%
influenza positive proportion among datasets that used multiple tests excluding PCR in
our crude analysis; some of these datasets included single serum serology. False positives
may also result from PCR. Due to its high sensitivity, PCR detects virus in environmental
contaminants and after the virus no longer replicates (Hopkins et al., 2011; Sawatwong et
al., 2012). The use of multiple tests may provide a more accurate picture of true
infections (Sawatwong et al., 2012; Talbot & Falsey, 2010).
Impact of case definition
Case definitions change over time to improve sensitivity and specificity of
influenza detection. The exclusion of difficulty breathing or shortness of breath, replacing
the terms with cough, improved the sensitivity and specificity of the SARI case definition
among hospitalized patients (Gupta et al., 2013; Hirve et al., 2012; Nachtnebel et al.,
2012). Authors who evaluated the pneumonia case definition in three states reminded the
readers that influenza hospitalizations are associated with other diseases (circulatory,
neurological, etc.) in addition to pneumonia, and restricting to the use of the pneumonia
case definition alone may underestimate the burden of influenza hospitalizations (Ortiz et
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al., 2014). Although case definitions are often subjective and may have differing levels of
sensitivity and specificity (Nichol & Mendelman, 2004), we did not observe statistically
significant differences, through non-parametric testing, between case definitions in our
eligible datasets.
Impact of WHO region
In addition to World Bank and UN development status, WHO region is another
method of defining a global region (WHO, 2014a). WHO created six regions to ease
disease reporting and disease data analysis (WHO). Differences in influenza seasonality
and disease severity have been observed among the WHO regions. The pandemic H1N1
remained in circulation longer in the Southeastern Asia and African WHO regions than in
the other four regions, for example (WHO, 2010). Despite differences, we observed no
statistically significant differences in positive crude proportions for our datasets between
the WHO regions, implying that WHO regions in our study does not impact positive
proportions. To improve the estimate for the Eastern Mediterranean WHO region, only
one dataset was available from this region, more research is needed.
5.3 Limitations and exploratory analysis
Our study is subject to several limitations. Our data were heterogeneous due to
variability in data sources’ time frames, testing criteria or case definitions, and testing
procedures. Diagnostic tests also vary in sensitivity and specificity (Leekha et al., 2013;
Sawatwong et al., 2012; Talbot & Falsey, 2010). As the timing between disease onset and
specimen collection increases, the ability to detect influenza viruses decreases, especially
in adults who shed less virus than children (W. P. Glezen, Greenberg, Atmar, Piedra, &
Couch, 2000; Leekha et al., 2013; Sawatwong et al., 2012; Talbot & Falsey, 2010).
Further, hospital admission relied on care-seeking behavior and hospital or healthcare
facility admission policies (Gordis, 2009; Parashar et al., 2003), which may have
increased or decreased enrollment and did not necessarily influence the percent positive
for influenza. The severity of influenza may vary by population (Gordis, 2009). We may
not have accounted for all severe influenza cases, especially in resource-limited areas and
when patients had non-respiratory presentations of influenza (Freitas et al., 2013;
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Oshitani et al., 2008; Radin et al., 2012). We assumed that influenza caused the
hospitalization and do not account for co-infections and underlying conditions in our
entire study population. Other viruses, such as respiratory syncytial virus and
parainfluenza virus, often co-circulate with influenza (Zhou et al., 2012). While all but
two published datasets tested for other pathogens, we are unaware of whether
surveillance sites considered other pathogens as the cause of illness. When other
pathogens in addition to influenza were detected in patients among published datasets,
the main pathogen contributing to the hospitalization was unknown. Co-infections and
certain underlying conditions have shown to increase the severity of influenza infections
(Dena L. Schanzer et al., 2008a). Severity of influenza disease is unknown due to the lack
of patient outcome data in the majority of study datasets. We may have a reduced
likelihood of publication bias for influenza results in our findings due to the inclusion of
published datasets which tested for other pathogens in addition to influenza or found no
confirmed cases of influenza. Also, according to the Campbell Collaboration Reviews,
we may have removed or at least decreased the effect of publication bias by including
unpublished datasets (C2, 2014). From our quality assessment, 81% of published datasets
were of median to high quality. To minimize our study limitations, we used a randomized
effect model and stratified our data by potential factors—the detection of pandemic
H1N1 during the 2010 calendar year, data collected during multiple influenza seasons,
and the detection of other pathogens that co-circulate with influenza.
We found no indication that 2010 calendar year data, partial year data, and multipathogen testing data impacted the overall seasonal pooled estimates (0-19%). Beginning
in April 2009, public health officials across the globe began to identify pandemic H1N1
cases (WHO, 2010). The report further described the decreased number of cases due to
pandemic H1N1 in most countries and the increased rates of cases due to influenza type
B (WHO, 2010). Our boxplot demonstrated this trend. As we described earlier, the
inclusion of pandemic data (from calendar year 2009) impacted our crude and pooled
estimates. While the pandemic virus, continued to circulate after 2009, it did not have the
same impact in 2010, as seen in our crude and pooled estimates when stratifying seasonal
results to include or exclude 2010 calendar year data.
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Datasets with partial year data (e.g., >12 months but <24 months) could have
potentially over- or under-estimated the proportion of hospitalizations due to influenza if
they over-represented or under-represented months with peak influenza circulation.
Although some datasets in our study included partial year data, we did not see this impact
our global pooled estimates. We also included countries with subtropical and tropical
climates where influenza occurs year-round (Simmerman & Uyeki, 2008; Cécile Viboud
et al., 2006). The Southeast Asian WHO region includes some subtropical countries
(Simmerman & Uyeki, 2008). Even though we found slightly higher crude and pooled
estimates for this region when including datasets with partial years, we are limited in
drawing conclusions due to the small number of datasets with partial year data from this
region and not knowing whether influenza-positive cases increased after the completion
of the study.
5.5 Closing remarks
In this first attempt to summarize the global burden of severe influenza infection
among both younger and older adults, we found 11% of cases from adult respiratory
hospitalizations worldwide were laboratory-confirmed for influenza. This estimate
indicates that all adults, independent of age and country origin, are affected by influenza.
For countries without reliable influenza data, we provide an estimate that they may use in
planning and allocating resources for the control and prevention of influenza in their
adult populations. From a global health perspective, it is important to understand how to
use this estimate for health planning and strategy; this will require further discussion. In
calculating this estimate, we focused on the most recognizable presentation of influenza
in hospitalized patients, respiratory infections (CDC, 2010; Hirve et al., 2012). Although
influenza has been identified in patients who are admitted for other reasons (circulatory
and even all-causes according to the hospital admission forms), these patients are not
typically tested for influenza due to high costs and labor demands (W. W. Thompson et
al., 2009). Vaccine status of hospitalized patients and the use of other interventions are
not often recorded. As more data becomes available, researchers will be able to evaluate
the effectiveness of influenza vaccines and other interventions on preventing and
reducing influenza hospitalizations. Since influenza is a mutable virus, the global
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estimate is likely to vary from year to year, depending on the virus type in circulation and
the occurrence of a pandemic (CDC, 2013). The interaction between influenza and other
pathogens is complex and may contribute to severe outcomes (Rothberg, Haessler, &
Brown, 2008). Evaluating this interaction may provide some insight for preventing such
outcomes. Currently, annual influenza vaccination is the main method of prevention
(CDC, 2013; Couch, 2000). The use of a universal vaccine, especially if it provides longlasting broad coverage and is effective in adults with aging immune systems, will likely
lead to reductions in influenza hospitalizations (McElhaney, 2005; Schotsaert & GarciaSastre, 2014). In effort to identify the circulating influenza virus and potentially improve
the selection of vaccine strains, it is important to continue supporting the increased
capacity of influenza testing and vaccine production in developing countries (Friede et
al., 2011; Mmbaga et al., 2012; Partridge & Kieny, 2013). Many developing countries
cannot afford to vaccinate (Oshitani et al., 2008); efforts to decrease vaccine costs and to
determine more feasible vaccination approaches for developing countries are needed.
Whether living in a developing or industrialized country, adults of all ages are affected by
influenza. Severity of disease varies and the burden of this severity as seen with
hospitalizations will change with time. With strengthen surveillance systems and the
continuation of collecting and publishing data, burden estimates will become more
robust.

References
Ayele, W., Demissie, G., Kassa, W., Zemelak, E., Afework, A., Amare, B., . . . Jima, D.
(2012). Challenges of establishing routine influenza sentinel surveillance in
Ethiopia, 2008-2010. J Infect Dis, 206 Suppl 1, S41-45. doi: 10.1093/infdis/jis531
Azziz-Baumgartner, E., Cabrera, A. M., Cheng, P.-Y., Garcia, E., Kusznierz, G., Calli,
R., . . . Echenique, H. (2013). Incidence of influenza-associated mortality and
hospitalizations in Argentina during 2002-2009. Influenza Other Respir Viruses,
7(5), 710-717. doi: 10.1111/irv.12022
Babcock, H., Merz, L., Dubberke, E., & Fraser, V. (2008). Case‐Control Study of
Clinical Features of Influenza in Hospitalized Patients •. Infection Control and
Hospital Epidemiology, 29(10), 921-926. doi: 10.1086/590663
Bader, M. S., & McKinsey, D. S. (2005). Viral infections in the elderly. The challenges
of managing herpes zoster, influenza, and RSV. Postgrad Med, 118(5), 45-48, 5144.
Barker, W. H., & Mullooly, J. P. (1981). Underestimation of the role of pneumonia and
influenza in causing excess mortality. Am J Public Health, 71(6), 643-645.
Behbehani, N., Mahmood, A., Mokaddas, E. M., Bittar, Z., Jayakrishnan, B., Khadadah,
M., . . . Chugh, T. D. (2005). Significance of atypical pathogens among
community-acquired pneumonia adult patients admitted to hospital in Kuwait.
Med Princ Pract, 14(4), 235-240. doi: 10.1159/000085741
Biggerstaff, M., Jhung, M. A., Reed, C., Fry, A. M., Balluz, L., & Finelli, L. (2014).
Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt
during the 2010–11 influenza season — United States. Journal of Infectious
Diseases. doi: 10.1093/infdis/jiu224
Biggerstaff, M., Reed, C., Epperson, S., Jhung, M. A., Gambhir, M., Bresee, J. S., . . .
Finelli, L. (2013). Estimates of the Number of Human Infections With Influenza
A(H3N2) Variant Virus, United States, August 2011–April 2012. Clinical
Infectious Diseases, 57(suppl 1), S12-S15. doi: 10.1093/cid/cit273
Brammer, T. L., Murray, E. L., Fukuda, K., Hall, H. E., Klimov, A., & Cox, N. J. (2002).
Surveillance for influenza--United States, 1997-98, 1998-99, and 1999-00
seasons. MMWR Surveill Summ, 51(7), 1-10.
Bresee, J., Reed, C., Kim, I. K., Fry, A., Chaves, S. S., Burns, E., . . . Santibanez, T. A.
(2013). Estimated influenza illnesses and hospitalizations averted by influenza
vaccination - United States, 2012-13 influenza season. MMWR Morb Mortal Wkly
Rep, 62(49), 997-1000.
60

61
Briand, S., Mounts, A., & Chamberland, M. (2011). Challenges of global surveillance
during an influenza pandemic. Public Health, 125(5), 247-256. doi:
10.1016/j.puhe.2010.12.007
Broor, S., Chahar, H., & Kaushik, S. (2009). Diagnosis of influenza viruses with special
reference to novel H1N1 2009 influenza virus. Indian Journal of Microbiology,
49(4), 301-307. doi: 10.1007/s12088-009-0054-5
C2, T. C. C. (2014). What is a systematic review? Retrieved January 10, 2014, 2014,
from http://www.campbellcollaboration.org/what_is_a_systematic_review/
Carrat, F., Vergu, E., Ferguson, N. M., Lemaitre, M., Cauchemez, S., Leach, S., &
Valleron, A.-J. (2008). Time Lines of Infection and Disease in Human Influenza:
A Review of Volunteer Challenge Studies. Am J Epidemiol, 167(7), 775-785. doi:
10.1093/aje/kwm375
CDC, Centers for Disease Control and Prevention (2010). Estimates of deaths associated
with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly
Rep, 59(33), 1057-1062.
CDC, Centers for Disease Control and Prevention (2012). Epidemiology and Prevention
of Vaccine-Preventable Diseases The Pink Book: Course Textbook Retrieved
from http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/flu.pdf
CDC, Centers for Disease Control and Prevention (2013). Prevention and control of
seasonal influenza with vaccines. Recommendations of the Advisory Committee
on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep,
62(Rr-07), 1-43.
CDC, Centers for Disease Control and Prevention (2014a). CDC Reports Flu Hit
Younger People Particularly Hard This Season [Press release]
CDC, Centers for Disease Control and Prevention (2014b). Quadrivalent Influenza
Vaccine. Retrieved December 5, 2014, 2014, from
http://www.cdc.gov/flu/protect/vaccine/quadrivalent.htm
Chadha, M. S., Hirve, S., Dawood, F. S., Lele, P., Deoshatwar, A., Sambhudas, S., . . .
Mishra, A. C. (2013). Burden of seasonal and pandemic influenza-associated
hospitalization during and after 2009 A(H1N1)pdm09 pandemic in a rural
community in India. PLoS ONE, 8(5), e55918. doi:
10.1371/journal.pone.0055918
Chow, A., Ma, S., Ling, A. E., & Chew, S. K. (2006). Influenza-associated deaths in
tropical Singapore. Emerg Infect Dis, 12(1), 114-121. doi:
10.3201/eid1201.050826
Cohen, C., Simonsen, L., Kang, J.-W., Miller, M., McAnerney, J., Blumberg, L., . . .
Viboud, C. (2010). Elevated Influenza-Related Excess Mortality in South African

62
Elderly Individuals, 1998–2005. Clinical Infectious Diseases, 51(12), 1362-1369.
doi: 10.1086/657314
Cohen, C., Simonsen, L., Sample, J., Kang, J. W., Miller, M., Madhi, S. A., . . . Viboud,
C. (2012). Influenza-related mortality among adults aged 25-54 years with AIDS
in South Africa and the United States of America. Clin Infect Dis, 55(7), 9961003. doi: 10.1093/cid/cis549
Couch, R. B. (2000). Prevention and Treatment of Influenza. New England Journal of
Medicine, 343(24), 1778-1787. doi: doi:10.1056/NEJM200012143432407
Cox, C. M., D'Mello, T., Perez, A., Reingold, A., Gershman, K., Yousey-Hindes, K., . . .
Network, f. t. E. I. P. (2012). Increase in Rates of Hospitalization Due to
Laboratory-Confirmed Influenza Among Children and Adults During the 2009–
10 Influenza Pandemic. Journal of Infectious Diseases, 206(9), 1350-1358. doi:
10.1093/infdis/jis517
Cox, N. J., & Subbarao, K. (2000). Global Epidemiology of Influenza: Past and Present.
Annu Rev Med, 51(1), 407.
Dao, C. N., Kamimoto, L., Nowell, M., Reingold, A., Gershman, K., Meek, J., . . .
Finelli, L. (2010). Adult hospitalizations for laboratory-positive influenza during
the 2005-2006 through 2007-2008 seasons in the United States. J Infect Dis,
202(6), 881-888. doi: 10.1086/655904
Das, A., Spackman, E., Pantin-Jackwood, M. J., & Suarez, D. L. (2009). Removal of realtime reverse transcription polymerase chain reaction (RT-PCR) inhibitors
associated with cloacal swab samples and tissues for improved diagnosis of Avian
influenza virus by RT-PCR. J Vet Diagn Invest, 21(6), 771-778.
Dawood, F., Iuliano, A., Reed, C., Meltzer, M., Shay, D., Cheng, P., . . . Buchy, P.
(2012). Estimated global mortality associated with the first 12 months of 2009
pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect
Dis, 12, 687 - 695.
Dawood, F. S., Iuliano, A. D., Reed, C., Meltzer, M. I., Shay, D. K., Cheng, P. Y., . . .
Widdowson, M. A. (2012). Estimated global mortality associated with the first 12
months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study.
Lancet Infect Dis, 12(9), 687-695. doi: 10.1016/s1473-3099(12)70121-4
Ellis, J. S., & Curran, M. D. (2011). Simultaneous molecular detection and confirmation
of influenza AH5, with internal control. Methods Mol Biol, 665, 161-181. doi:
10.1007/978-1-60761-817-1_10
Ferkol, T., & Schraufnagel, D. (2014). The Global Burden of Respiratory Disease.
Annals of the American Thoracic Society, 11(3), 404-406. doi:
10.1513/AnnalsATS.201311-405PS

63
Fiore, A. E., Bridges, C. B., & Cox, N. J. (2009). Seasonal influenza vaccines. Curr Top
Microbiol Immunol, 333, 43-82. doi: 10.1007/978-3-540-92165-3_3
Fleury, H., Burrel, S., Balick Weber, C., Hadrien, R., Blanco, P., Cazanave, C., & Dupon,
M. (2009). Prolonged shedding of influenza A(H1N1)v virus: two case reports
from France 2009. Euro Surveill, 14(49).
Freitas, F. T. M., Souza, L. R. O., Azziz-Baumgartner, E., Cheng, P. Y., Zhou, H.,
Widdowson, M. A., . . . Araujo, W. N. (2013). Influenza-associated excess
mortality in southern Brazil, 1980–2008. Epidemiology & Infection, 141(08),
1731-1740. doi: doi:10.1017/S0950268812002221
Friede, M., Palkonyay, L., Alfonso, C., Pervikov, Y., Torelli, G., Wood, D., & Kieny, M.
P. (2011). WHO initiative to increase global and equitable access to influenza
vaccine in the event of a pandemic: Supporting developing country production
capacity through technology transfer. Vaccine, 29(S1), A2-A7. doi:
http://dx.doi.org/10.1016/j.vaccine.2011.02.079
Fuller, J. A., Summers, A., Katz, M. A., Lindblade, K. A., Njuguna, H., Arvelo, W., . . .
Feikin, D. R. (2013). Estimation of the national disease burden of influenzaassociated severe acute respiratory illness in Kenya and Guatemala: a novel
methodology. PLoS ONE, 8(2), e56882. doi: 10.1371/journal.pone.0056882
Gessner, B. D., Brooks, W. A., Neuzil, K. M., Vernet, G., Bright, R. A., Tam, J. S., . . .
Monto, A. S. (2013). Vaccines as a tool to estimate the burden of severe influenza
in children of low-resourced areas (November 30-December 1, 2012, Les
Pensieres, Veyrier-du-Lac, France). Vaccine, 31(32), 3222-3228. doi:
10.1016/j.vaccine.2013.05.017
Gessner, B. D., Shindo, N., & Briand, S. (2011). Seasonal influenza epidemiology in subSaharan Africa: a systematic review. Lancet Infect Dis, 11(3), 223-235. doi:
10.1016/s1473-3099(11)70008-1
Glezen, W. P., Greenberg, S. B., Atmar, R. L., Piedra, P. A., & Couch, R. B. (2000).
Impact of respiratory virus infections on persons with chronic underlying
conditions. Jama, 283(4), 499-505.
Glezen, W. P., Payne, A. A., Snyder, D. N., & Downs, T. D. (1982). Mortality and
influenza. J Infect Dis, 146(3), 313-321.
Glezen, W. P., Schmier, J. K., Kuehn, C. M., Ryan, K. J., & Oxford, J. (2013). The
Burden of Influenza B: A Structured Literature Review. American Journal of
Public Health, 103(3), e43-e51. doi: 10.2105/AJPH.2012.301137
Gordis, L. (2009). Epidemiology (J. H. Merritt, Andy; Sinclair, Joan; Harris, Gene Ed.
4th edition ed.). Philadelphia, PA: Saunders Elsevier.
Gordon, A., Saborio, S., Videa, E., Lopez, R., Kuan, G., Balmaseda, A., & Harris, E.
(2010). Clinical attack rate and presentation of pandemic H1N1 influenza versus

64
seasonal influenza A and B in a pediatric cohort in Nicaragua. Clin Infect Dis,
50(11), 1462-1467. doi: 10.1086/652647
Greenbaum, E., Morag, A., & Zakay-Rones, Z. (1998). Isolation of Influenza C Virus
during an Outbreak of Influenza A and B Viruses. J Clin Microbiol, 36(5), 14411442.
Grohskopf, L. A., Olsen, S. J., Sokolow, L. Z., Bresee, J. S., Cox, N. J., Broder, K. R., . .
. Walter, E. B. (2014). Prevention and control of seasonal influenza with vaccines:
recommendations of the Advisory Committee on Immunization Practices (ACIP)
-- United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep,
63(32), 691-697.
Gu, R.-X., Liu, L. A., & Wei, D.-Q. (2013). Structural and energetic analysis of drug
inhibition of the influenza A M2 proton channel. Trends in Pharmacological
Sciences, 34(10), 571-580. doi: 10.1016/j.tips.2013.08.003
Gupta, V., Dawood, F. S., Rai, S. K., Broor, S., Wigh, R., Mishra, A. C., . . . Krishnan, A.
(2013). Validity of clinical case definitions for influenza surveillance among
hospitalized patients: results from a rural community in North India. Influenza
Other Respir Viruses, 7(3), 321-329. doi: 10.1111/j.1750-2659.2012.00401.x
Hancock, K., Veguilla, V., Lu, X., Zhong, W., Butler, E. N., Sun, H., . . . Katz, J. M.
(2009). Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza
virus. N Engl J Med, 361(20), 1945-1952. doi: 10.1056/NEJMoa0906453
Haq, K., & McElhaney, J. E. (2014). Ageing and respiratory infections: The airway of
ageing. Immunol Lett. doi: 10.1016/j.imlet.2014.06.009
Hardelid, P., Andrews, N. J., Hoschler, K., Stanford, E., Baguelin, M., Waight, P. A., . . .
Miller, E. (2010). Assessment of baseline age-specific antibody prevalence and
incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess,
14(55), 115-192. doi: 10.3310/hta14550-03
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., .
. . Zimmerman, R. K. (2009). Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management:
clinical practice guidelines of the Infectious Diseases Society of America. Clin
Infect Dis, 48(8), 1003-1032. doi: 10.1086/598513
Herrera, G. A., Iwane, M. K., Cortese, M., Brown, C., Gershman, K., Shupe, A., . . .
Bridges, C. B. (2007). Influenza vaccine effectiveness among 50-64-year-old
persons during a season of poor antigenic match between vaccine and circulating
influenza virus strains: Colorado, United States, 2003-2004. Vaccine, 25(1), 154160. doi: 10.1016/j.vaccine.2006.05.129
Hirve, S., Chadha, M., Lele, P., Lafond, K. E., Deoshatwar, A., Sambhudas, S., . . .
Mishra, A. (2012). Performance of case definitions used for influenza surveillance

65
among hospitalized patients in a rural area of India. Bull World Health Organ,
90(11), 804-812. doi: 10.2471/blt.12.108837
Homaira, N., Luby, S. P., Alamgir, A. S., Islam, K., Paul, R., Abedin, J., . . . AzzizBaumgartner, E. (2012). Influenza-associated mortality in 2009 in four sentinel
sites in Bangladesh. Bull World Health Organ, 90(4), 272-278. doi:
10.2471/blt.11.095653
Hopkins, M. J., Moorcroft, J. F., Correia, J. B., & Hart, I. J. (2011). Using the full
spectral capacity (six channels) of a real-time PCR instrument can simplify
diagnostic laboratory screening and typing protocols for pandemic H1N1
influenza. Influenza Other Respir Viruses, 5(2), 110-114. doi: 10.1111/j.17502659.2010.00178.x
Jacks, A., Ollgren, J., Ziegler, T., & Lyytikainen, O. (2012). Influenza-associated
hospitalisations in Finland from 1996 to 2010: unexpected age-specific burden
during the influenza A(H1N1)pdm09 pandemic from 2009 to 2010. Euro Surveill,
17(38).
Jain, S., Kamimoto, L., Bramley, A. M., Schmitz, A. M., Benoit, S. R., Louie, J., . . .
Finelli, L. (2009). Hospitalized Patients with 2009 H1N1 Influenza in the United
States, April–June 2009. New England Journal of Medicine, 361(20), 1935-1944.
doi: doi:10.1056/NEJMoa0906695
Jansen, A. G., Sanders, E. A., Hoes, A. W., van Loon, A. M., & Hak, E. (2007).
Influenza- and respiratory syncytial virus-associated mortality and
hospitalisations. Eur Respir J, 30(6), 1158-1166. doi:
10.1183/09031936.00034407
Jefferson, T., Di Pietrantonj, C., Al-Ansary, L. A., Ferroni, E., Thorning, S., & Thomas,
R. E. (2010). Vaccines for preventing influenza in the elderly. Cochrane
Database Syst Rev(2), Cd004876. doi: 10.1002/14651858.CD004876.pub3
Karve, S., Misurski, D. A., Meier, G., & Davis, K. L. (2013). Employer-incurred health
care costs and productivity losses associated with influenza. Hum Vaccin
Immunother, 9(4), 841-857. doi: 10.4161/hv.23413
Katz, M. A., Lebo, E., Emukule, G., Njuguna, H. N., Aura, B., Cosmas, L., . . . Breiman,
R. F. (2012). Epidemiology, seasonality, and burden of influenza and influenzalike illness in urban and rural Kenya, 2007-2010. J Infect Dis, 206 Suppl 1, S5360. doi: 10.1093/infdis/jis530
Keech, M., & Beardsworth, P. (2008). The impact of influenza on working days lost: a
review of the literature. Pharmacoeconomics, 26(11), 911-924.
Kim, S. A., Kilgore, P. E., Lee, S. Y., Nyambat, B., & Ki, M. (2011). Trends in
pneumonia and influenza-associated hospitalizations in South Korea, 2002-2005.
J Health Popul Nutr, 29(6), 574-582.

66
Klimov, A. I., Rocha, E., Hayden, F. G., Shult, P. A., Roumillat, L. F., & Cox, N. J.
(1995). Prolonged Shedding of Amantadine-Resistant Influenza A Viruses by
Immunodeficient Patients: Detection by Polymerase Chain Reaction-Restriction
Analysis. Journal of Infectious Diseases, 172(5), 1352-1355. doi:
10.1093/infdis/172.5.1352
Kostova, D., Reed, C., Finelli, L., Cheng, P.-Y., Gargiullo, P. M., Shay, D. K., . . .
Bresee, J. S. (2013). Influenza Illness and Hospitalizations Averted by Influenza
Vaccination in the United States, 2005–2011. PLoS ONE, 8(6), e66312. doi:
10.1371/journal.pone.0066312
Kumar, S., & Henrickson, K. J. (2012). Update on influenza diagnostics: lessons from the
novel H1N1 influenza A pandemic. Clin Microbiol Rev, 25(2), 344-361. doi:
10.1128/cmr.05016-11
Kuster, S. P., Shah, P. S., Coleman, B. L., Lam, P. P., Tong, A., Wormsbecker, A., &
McGeer, A. (2011). Incidence of influenza in healthy adults and healthcare
workers: a systematic review and meta-analysis. PLoS ONE, 6(10), e26239. doi:
10.1371/journal.pone.0026239
Kwong, J. C., Stukel, T. A., Lim, J., McGeer, A. J., Upshur, R. E., Johansen, H., . . .
Manuel, D. G. (2008). The effect of universal influenza immunization on
mortality and health care use. PLoS Med, 5(10), e211. doi:
10.1371/journal.pmed.0050211
Kyncl, J., Prochazka, B., Goddard, N. L., Havlickova, M., Castkova, J., Otavova, M., &
Kriz, B. (2005). A study of excess mortality during influenza epidemics in the
Czech Republic, 1982-2000. Eur J Epidemiol, 20(4), 365-371.
Lafond, K., Nair, H., Whaley, M., Garguillo, P., Azziz-Baumgartner, E., Bresee, J., . . .
Group, G. R. D. I. P. P. G. W. (2014). Role and Burden of Influenza in Global
Pediatric Hospitalizations for Respiratory Disease: A Systematic Review and
Meta-Analysis. Centers for Disease Control and Prevention (CDC) and University
of Edinburgh.
Laibl, V. R., & Sheffield, J. S. (2005). Influenza and pneumonia in pregnancy. Clin
Perinatol, 32(3), 727-738. doi: 10.1016/j.clp.2005.04.009
Lau, L. L. H., Cowling, B. J., Fang, V. J., Chan, K.-H., Lau, E. H. Y., Lipsitch, M., . . .
Leung, G. M. (2010). Viral Shedding and Clinical Illness in Naturally Acquired
Influenza Virus Infections. Journal of Infectious Diseases, 201(10), 1509-1516.
doi: 10.1086/652241
Layne, S. P. (2006). Human influenza surveillance: the demand to expand. Emerg Infect
Dis, 12(4), 562-568. doi: 10.3201/eid1204.051198
Leekha, S., Irish, C. L., Schneider, S. K., Fernholz, E. C., Espy, M. J., Cunningham, S.
A., . . . Sampathkumar, P. (2013). Viral detection using a multiplex polymerase

67
chain reaction-based assay in outpatients with upper respiratory infection. Diagn
Microbiol Infect Dis, 75(2), 169-173. doi: 10.1016/j.diagmicrobio.2012.10.016
Lenglet, A. D., Hernando, V., Rodrigo, P., Larrauri, A., Donado, J. D., & de Mateo, S.
(2007). Impact of flu on hospital admissions during 4 flu seasons in Spain, 20002004. BMC Public Health, 7, 197. doi: 10.1186/1471-2458-7-197
Liu, B., Havers, F., Chen, E., Yuan, Z., Yuan, H., Ou, J., . . . Li, Q. (2014). Risk factors
for influenza A(H7N9) disease--China, 2013. Clin Infect Dis, 59(6), 787-794. doi:
10.1093/cid/ciu423
Lopez-Cuadrado, T., de Mateo, S., Jimenez-Jorge, S., Savulescu, C., & Larrauri, A.
(2012). Influenza-related mortality in Spain, 1999-2005. Gac Sanit, 26(4), 325329. doi: 10.1016/j.gaceta.2011.09.033
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., . . . Hoen, B.
(2012). Global and regional mortality from 235 causes of death for 20 age groups
in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study
2010. The Lancet, 380(9859), 2095-2128. doi: http://dx.doi.org/10.1016/S01406736(12)61728-0
Lutwama, J. J., Bakamutumaho, B., Kayiwa, J. T., Chiiza, R., Namagambo, B., Katz, M.
A., & Geissler, A. L. (2012). Clinic- and hospital-based sentinel influenza
surveillance, Uganda 2007-2010. J Infect Dis, 206 Suppl 1, S87-93. doi:
10.1093/infdis/jis578
Madhi, S. A., & Klugman, K. P. (2004). A role for Streptococcus pneumoniae in virusassociated pneumonia. Nat Med, 10(8), 811-813. doi: 10.1038/nm1077
Madjid, M., Aboshady, I., Awan, I., Litovsky, S., & Casscells, S. W. (2004). Influenza
and cardiovascular disease: is there a causal relationship? Tex Heart Inst J, 31(1),
4-13.
Mallia, P., & Johnston, S. L. (2007). Influenza infection and COPD. Int J Chron Obstruct
Pulmon Dis, 2(1), 55-64.
Mauskopf, J., Klesse, M., Lee, S., & Herrera-Taracena, G. (2013). The burden of
influenza complications in different high-risk groups: a targeted literature review.
J Med Econ, 16(2), 264-277. doi: 10.3111/13696998.2012.752376
McElhaney, J. E. (2005). The unmet need in the elderly: Designing new influenza
vaccines for older adults. Vaccine, 23, Supplement 1(0), S10-S25. doi:
http://dx.doi.org/10.1016/j.vaccine.2005.04.019
Menec, V. H., Black, C., MacWilliam, L., & Aoki, F. Y. (2003). The impact of influenzaassociated respiratory illnesses on hospitalizations, physician visits, emergency
room visits, and mortality. Can J Public Health, 94(1), 59-63.
Mereckiene, J., Cotter, S., D'Ancona, F., Giambi, C., Nicoll, A., Levy-Bruhl, D., . . .
O'Flanagan, D. (2010). Differences in national influenza vaccination policies

68
across the European Union, Norway and Iceland 2008-2009. Euro Surveill,
15(44).
Michiels, B., Van Puyenbroeck, K., Verhoeven, V., Vermeire, E., & Coenen, S. (2013).
The value of neuraminidase inhibitors for the prevention and treatment of
seasonal influenza: a systematic review of systematic reviews. PLoS ONE, 8(4),
e60348. doi: 10.1371/journal.pone.0060348
Miller, E., Hoschler, K., Hardelid, P., Stanford, E., Andrews, N., & Zambon, M. (2010).
Incidence of 2009 pandemic influenza A H1N1 infection in England: a crosssectional serological study. Lancet, 375(9720), 1100-1108. doi: 10.1016/s01406736(09)62126-7
MIV, T. M. o. I. V. S. G. (2005). The macroepidemiology of influenza vaccination in 56
countries, 1997–2003. Vaccine, 23(44), 5133-5143. doi:
http://dx.doi.org/10.1016/j.vaccine.2005.06.010
Mmbaga, V. M., Mwasekaga, M. J., Mmbuji, P., Matonya, M., Mwafulango, A., Moshi,
S., . . . Katz, M. A. (2012). Results from the first 30 months of national sentinel
surveillance for influenza in Tanzania, 2008-2010. J Infect Dis, 206 Suppl 1, S8086. doi: 10.1093/infdis/jis540
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The, P. G. (2009). Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med, 6(7), e1000097. doi: 10.1371/journal.pmed.1000097
Molinari, N. A., Ortega-Sanchez, I. R., Messonnier, M. L., Thompson, W. W., Wortley,
P. M., Weintraub, E., & Bridges, C. B. (2007). The annual impact of seasonal
influenza in the US: measuring disease burden and costs. Vaccine, 25(27), 50865096. doi: 10.1016/j.vaccine.2007.03.046
Monto, A. S. (2004). Global burden of influenza: what we know and what we need to
know. International Congress Series, 1263(0), 3-11. doi:
http://dx.doi.org/10.1016/j.ics.2004.02.049
Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2008). Predominant role of bacterial
pneumonia as a cause of death in pandemic influenza: implications for pandemic
influenza preparedness. J Infect Dis, 198(7), 962-970. doi: 10.1086/591708
Muyembe Tamfum, J. J., Nkwembe, E., Bi Shamamba, S. K., Bankoshi, F., Ilunga, B. K.,
Katz, K. A., . . . Wemankoy, E. O. (2012). Sentinel surveillance for influenza-like
illness, severe acute respiratory illness, and laboratory-confirmed influenza in
Kinshasa, Democratic Republic of Congo, 2009-2011. J Infect Dis, 206 Suppl 1,
S36-40. doi: 10.1093/infdis/jis537
Mytton, O. T., Rutter, P. D., & Donaldson, L. J. (2012). Influenza A(H1N1)pdm09 in
England, 2009 to 2011: a greater burden of severe illness in the year after the
pandemic than in the pandemic year. Euro Surveill, 17(14).

69
Nachtnebel, M., Greutelaers, B., Falkenhorst, G., Jorgensen, P., Dehnert, M., Schweiger,
B., . . . Hellenbrand, W. (2012). Lessons from a one-year hospital-based
surveillance of acute respiratory infections in Berlin- comparing case definitions
to monitor influenza. BMC Public Health, 12, 245. doi: 10.1186/1471-2458-12245
Nair, H., Brooks, W. A., Katz, M., Roca, A., Berkley, J. A., Madhi, S. A., . . . Campbell,
H. (2011). Global burden of respiratory infections due to seasonal influenza in
young children: a systematic review and meta-analysis. Lancet, 378(9807), 19171930. doi: 10.1016/s0140-6736(11)61051-9
Nichol, K. L., & Mendelman, P. (2004). Influence of clinical case definitions with
differing levels of sensitivity and specificity on estimates of the relative and
absolute health benefits of influenza vaccination among healthy working adults
and implications for economic analyses. Virus Res, 103(1-2), 3-8. doi:
10.1016/j.virusres.2004.02.005
Nunes, B., Viboud, C., Machado, A., Ringholz, C., Rebelo-de-Andrade, H., Nogueira, P.,
& Miller, M. (2011). Excess mortality associated with influenza epidemics in
Portugal, 1980 to 2004. PLoS ONE, 6(6), e20661. doi:
10.1371/journal.pone.0020661
Nyatanyi, T., Nkunda, R., Rukelibuga, J., Palekar, R., Muhimpundu, M. A., Kabeja, A., .
. . Karema, C. (2012). Influenza sentinel surveillance in Rwanda, 2008-2010. J
Infect Dis, 206 Suppl 1, S74-79. doi: 10.1093/infdis/jis574
Ortiz, J. R., Neuzil, K. M., Cooke, C. R., Neradilek, M. B., Goss, C. H., & Shay, D. K.
(2014). Influenza Pneumonia Surveillance among Hospitalized Adults May
Underestimate the Burden of Severe Influenza Disease. PLoS ONE, 9(11),
e113903. doi: 10.1371/journal.pone.0113903
Ortiz, J. R., Neuzil, K. M., Rue, T. C., Zhou, H., Shay, D. K., Cheng, P. Y., . . . Goss, C.
H. (2013). Population-based incidence estimates of influenza-associated
respiratory failure hospitalizations, 2003 to 2009. Am J Respir Crit Care Med,
188(6), 710-715. doi: 10.1164/rccm.201212-2341OC
Oshitani, H., Kamigaki, T., & Suzuki, A. (2008). Major issues and challenges of
influenza pandemic preparedness in developing countries. Emerg Infect Dis,
14(6), 875-880. doi: 10.3201/eid1406.070839
Ott, J. J., Klein Breteler, J., Tam, J. S., Hutubessy, R. C., Jit, M., & de Boer, M. R.
(2013). Influenza vaccines in low and middle income countries: a systematic
review of economic evaluations. Hum Vaccin Immunother, 9(7), 1500-1511. doi:
10.4161/hv.24704
Parashar, U. D., Hummelman, E. G., Bresee, J. S., Miller, M. A., & Glass, R. I. (2003).
Global illness and deaths caused by rotavirus disease in children. Emerg Infect
Dis, 9(5), 565-572.

70
Partridge, J., & Kieny, M. (2013). Global production capacity of seasonal influenza
vaccine in 2011. Vaccine, 31, 728 - 731.
Pasick, J. (2008). Advances in the molecular based techniques for the diagnosis and
characterization of avian influenza virus infections. Transbound Emerg Dis,
55(8), 329-338. doi: 10.1111/j.1865-1682.2008.01047.x
Patria, M. F., Tenconi, R., & Esposito, S. (2012). Efficacy and safety of influenza
vaccination in children with asthma. Expert Rev Vaccines, 11(4), 461-468. doi:
10.1586/erv.12.2
Peasah, S. K., Azziz-Baumgartner, E., Breese, J., Meltzer, M. I., & Widdowson, M. A.
(2013). Influenza cost and cost-effectiveness studies globally--a review. Vaccine,
31(46), 5339-5348. doi: 10.1016/j.vaccine.2013.09.013
Perrotta, D. M., Decker, M., & Glezen, W. P. (1985). Acute respiratory disease
hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol,
122(3), 468-476.
Puig-Barbera, J., Tormos, A., Sominina, A., Burtseva, E., Launay, O., Ciblak, M. A., . . .
Mahe, C. (2014). First-year results of the Global Influenza Hospital Surveillance
Network: 2012-2013 Northern hemisphere influenza season. BMC Public Health,
14(1), 564. doi: 10.1186/1471-2458-14-564
Radin, J. M., Katz, M. A., Tempia, S., Talla Nzussouo, N., Davis, R., Duque, J., . . .
Widdowson, M. A. (2012). Influenza surveillance in 15 countries in Africa, 20062010. J Infect Dis, 206 Suppl 1, S14-21. doi: 10.1093/infdis/jis606
Reber, A. J., Chirkova, T., Kim, J. H., Cao, W., Biber, R., Shay, D. K., & Sambhara, S.
(2012). Immunosenescence and Challenges of Vaccination against Influenza in
the Aging Population. Aging Dis, 3(1), 68-90.
Reed, C., Angulo, F. J., Swerdlow, D. L., Lipsitch, M., Meltzer, M. I., Jernigan, D., &
Finelli, L. (2009). Estimates of the prevalence of pandemic (H1N1) 2009, United
States, April-July 2009. Emerg Infect Dis, 15(12), 2004-2007. doi:
10.3201/eid1512.091413
Rizzo, C., Bella, A., Viboud, C., Simonsen, L., Miller, M. A., Rota, M. C., . . . Ciofi degli
Atti, M. L. (2007). Trends for influenza-related deaths during pandemic and
epidemic seasons, Italy, 1969-2001. Emerg Infect Dis, 13(5), 694-699. doi:
10.3201/eid1305.061309
Rothberg, M. B., Haessler, S. D., & Brown, R. B. (2008). Complications of Viral
Influenza. The American Journal of Medicine, 121(4), 258-264. doi:
http://dx.doi.org/10.1016/j.amjmed.2007.10.040
Ryan, J., Zoellner, Y., Gradl, B., Palache, B., & Medema, J. (2006). Establishing the
health and economic impact of influenza vaccination within the European Union
25 countries. Vaccine, 24(47-48), 6812-6822. doi: 10.1016/j.vaccine.2006.07.042

71
Samaan, G., McPherson, M., & Partridge, J. (2013). A review of the evidence to support
influenza vaccine introduction in countries and areas of WHO's Western Pacific
Region. PLoS ONE, 8(7), e70003. doi: 10.1371/journal.pone.0070003
Sambhara, S., & McElhaney, J. E. (2009). Immunosenescence and influenza vaccine
efficacy. Curr Top Microbiol Immunol, 333, 413-429. doi: 10.1007/978-3-54092165-3_20
Savy, V., Ciapponi, A., Bardach, A., Glujovsky, D., Aruj, P., Mazzoni, A., . . . Colindres,
R. E. (2013). Burden of influenza in Latin America and the Caribbean: a
systematic review and meta-analysis. Influenza Other Respir Viruses, 7(6), 10171032. doi: 10.1111/irv.12036
Sawatwong, P., Chittaganpitch, M., Hall, H., Peruski, L. F., Xu, X., Baggett, H. C., . . .
Olsen, S. J. (2012). Serology as an adjunct to polymerase chain reaction assays
for surveillance of acute respiratory virus infections. Clin Infect Dis, 54(3), 445446. doi: 10.1093/cid/cir710
Schanzer, D. L., Langley, J. M., & Tam, T. W. S. (2008a). Co-morbidities associated
with influenza-attributed mortality, 1994–2000, Canada. Vaccine, 26(36), 46974703. doi: http://dx.doi.org/10.1016/j.vaccine.2008.06.087
Schanzer, D. L., Langley, J. M., & Tam, T. W. S. (2008b). Role of influenza and other
respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other
Respir Viruses, 2(1), 1-8. doi: 10.1111/j.1750-2659.2008.00035.x
Schanzer, D. L., Sevenhuysen, C., Winchester, B., & Mersereau, T. (2013). Estimating
influenza deaths in Canada, 1992-2009. PLoS ONE, 8(11), e80481. doi:
10.1371/journal.pone.0080481
Schotsaert, M., & Garcia-Sastre, A. (2014). Influenza vaccines: a moving
interdisciplinary field. Viruses, 6(10), 3809-3826. doi: 10.3390/v6103809
Schoub, B. D. (2010). Surveillance and management of influenza on the African
continent. Expert Rev Respir Med, 4(2), 167-169. doi: 10.1586/ers.10.10
Shrestha, S., Foxman, B., Weinberger, D. M., Steiner, C., Viboud, C., & Rohani, P.
(2013). Identifying the interaction between influenza and pneumococcal
pneumonia using incidence data. Sci Transl Med, 5(191), 191ra184. doi:
10.1126/scitranslmed.3005982
Simmerman, J. M., & Uyeki, T. M. (2008). The burden of influenza in East and SouthEast Asia: a review of the English language literature. Influenza Other Respir
Viruses, 2(3), 81-92. doi: 10.1111/j.1750-2659.2008.00045.x
Simonsen, L., Clarke, M. J., Stroup, D. F., Williamson, G. D., Arden, N. H., & Cox, N. J.
(1997). A method for timely assessment of influenza-associated mortality in the
United States. Epidemiology, 8(4), 390-395.

72
Simonsen, L., Fukuda, K., Schonberger, L. B., & Cox, N. J. (2000). The Impact of
Influenza Epidemics on Hospitalizations. Journal of Infectious Diseases, 181(3),
831-837. doi: 10.1086/315320
Siriwardena, A. N. (2012). Increasing Evidence That Influenza Is a Trigger for
Cardiovascular Disease. Journal of Infectious Diseases, 206(11), 1636-1638. doi:
10.1093/infdis/jis598
Smeeth, L., Thomas, S. L., Hall, A. J., Hubbard, R., Farrington, P., & Vallance, P.
(2004). Risk of Myocardial Infarction and Stroke after Acute Infection or
Vaccination. New England Journal of Medicine, 351(25), 2611-2618. doi:
doi:10.1056/NEJMoa041747
Steffen, C., Debellut, F., Gessner, B. D., Kasolo, F. C., Yahaya, A. A., Ayebazibwe, N., .
. . Mounts, A. W. (2012). Improving influenza surveillance in sub-Saharan Africa.
Bull World Health Organ, 90(4), 301-305. doi: 10.2471/blt.11.098244
Stohr, K. (2003). Overview of the WHO Global Influenza Programme. Dev Biol (Basel),
115, 3-8.
Sutanto, A., Gessner, B. D., Djlantik, I., Steinhoff, M., Murphy, H., Nelson, C., . . .
Arjoso, S. (2002). Acute respiratory illness incidence and death among children
under two years of age on Lombok Island, Indonesia. Am J Trop Med Hyg, 66(2),
175-179.
Szucs, T. (1999). The socio-economic burden of influenza. J Antimicrob Chemother, 44
Suppl B, 11-15.
Takahashi, K., Suzuki, M., Minh le, N., Anh, N. H., Huong, L. T., Son, T. V., . . .
Yoshida, L. M. (2013). The incidence and aetiology of hospitalised communityacquired pneumonia among Vietnamese adults: a prospective surveillance in
Central Vietnam. BMC Infect Dis, 13, 296. doi: 10.1186/1471-2334-13-296
Talbot, H. K., & Falsey, A. R. (2010). The Diagnosis of Viral Respiratory Disease in
Older Adults. Clinical Infectious Diseases, 50(5), 747-751. doi: 10.1086/650486
Taylor, R. M. (1951). A further note on 1233 (“influenza C”) virus. Archiv für die
gesamte Virusforschung, 4(4), 485-500. doi: 10.1007/BF01241168
Tempia, S., Walaza, S., Viboud, C., Cohen, A. L., Madhi, S. A., Venter, M., . . . Cohen,
C. (2014). Mortality Associated with Seasonal and Pandemic Influenza and
Respiratory Syncytial Virus among Children less than 5 Years of Age in a High
HIV-Prevalence Setting – South Africa, 1998-2009. Clinical Infectious Diseases.
doi: 10.1093/cid/ciu095
Thompson, D. L., Baumbach, J., Jungk, J., Sewell, C. M., Smelser, C., & Landen, M.
(2013). Does outpatient laboratory testing represent influenza burden and
distribution in a rural state? Influenza Other Respir Viruses, 7(5), 686-693. doi:
10.1111/irv.12097

73
Thompson, W. W., Comanor, L., & Shay, D. K. (2006). Epidemiology of seasonal
influenza: use of surveillance data and statistical models to estimate the burden of
disease. J Infect Dis, 194 Suppl 2, S82-91. doi: 10.1086/507558
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., &
Fukuda, K. (2003). Mortality associated with influenza and respiratory syncytial
virus in the United States. Jama, 289(2), 179-186.
Thompson, W. W., Shay, D. K., Weintraub, E., & et al. (2004). Influenza-associated
hospitalizations in the united states. Jama, 292(11), 1333-1340. doi:
10.1001/jama.292.11.1333
Thompson, W. W., Weintraub, E., Dhankhar, P., Cheng, P. Y., Brammer, L., Meltzer, M.
I., . . . Shay, D. K. (2009). Estimates of US influenza-associated deaths made
using four different methods. Influenza Other Respir Viruses, 3(1), 37-49. doi:
10.1111/j.1750-2659.2009.00073.x
van der Vries, E., Stittelaar, K. J., van Amerongen, G., Veldhuis Kroeze, E. J. B., de
Waal, L., Fraaij, P. L. A., . . . Osterhaus, A. D. M. E. (2013). Prolonged Influenza
Virus Shedding and Emergence of Antiviral Resistance in Immunocompromised
Patients and Ferrets. PLoS Pathog, 9(5), e1003343. doi:
10.1371/journal.ppat.1003343
Verani, J. R., McCracken, J., Arvelo, W., Estevez, A., Lopez, M. R., Reyes, L., . . .
Lindblade, K. A. (2013). Surveillance for hospitalized acute respiratory infection
in Guatemala. PLoS ONE, 8(12), e83600. doi: 10.1371/journal.pone.0083600
Viboud, C., Alonso, W. J., & Simonsen, L. (2006). Influenza in Tropical Regions. PLoS
Med, 3(4), e89. doi: 10.1371/journal.pmed.0030089
Viboud, C., Boelle, P. Y., Pakdaman, K., Carrat, F., Valleron, A. J., & Flahault, A.
(2004). Influenza epidemics in the United States, France, and Australia, 19721997. Emerg Infect Dis, 10(1), 32-39. doi: 10.3201/eid1001.020705
Wang, X. L., Yang, L., Chan, K. P., Chiu, S. S., Chan, K. H., Peiris, J. S., & Wong, C. M.
(2012). Model selection in time series studies of influenza-associated mortality.
PLoS ONE, 7(6), e39423. doi: 10.1371/journal.pone.0039423
Weinstein, R. A., Bridges, C. B., Kuehnert, M. J., & Hall, C. B. (2003). Transmission of
Influenza: Implications for Control in Health Care Settings. Clinical Infectious
Diseases, 37(8), 1094-1101. doi: 10.1086/378292
Weinstock, D. M., Gubareva, L. V., & Zuccotti, G. (2003). Prolonged Shedding of
Multidrug-Resistant Influenza A Virus in an Immunocompromised Patient. New
England Journal of Medicine, 348(9), 867-868. doi:
doi:10.1056/NEJM200302273480923
White, D. O., & Fenner, F. J. (1994). Medical Virology (fourth ed.). San Diego,
California, USA: Academic Press.

74
WHO Collaborating Center for Surveillance, E., and Control of Influenza, Uyeki, T.,
Teates, K., Brammer, L., Klimov, A., Fukuda, K., & Cox, N. (2004). Update:
influenza activity--United States and worldwide, 2003-04 season, and
composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep,
53(25), 547-552.
WHO, World Health Organization (2005). Vaccine Introduction Guidelines Adding a
vaccine to a national immunization programme: decision and implementation
Retrieved from
http://www.who.int/immunization/hpv/plan/vaccine_introduction_guidelines_who
_2005.pdf
WHO, World Health Organization (2009). Pandemic influenza preparedness and
response, WHO guidance document (pp. 64). Retrieved from
http://whqlibdoc.who.int/publications/2009/9789241547680_eng.pdf?ua=1
WHO, World Health Organization (2010, May 23, 2010). Pandemic (H1N1) 2009 update 112, Weekly update. Global Alert and Response (GAR), Disease Outbreak
News. Retrieved April 2, 2014, 2014, from
http://www.who.int/csr/don/2010_08_06/en/#
WHO, World Health Organization (2011a). The use of PCR in surveillane and diagnosis
of influenza (W. w. g. o. p. c. r. p. f. d. s. i. A. viruses, Trans.). Geneva,
Switzerland: World Health Organization.
WHO, World Health Organization (2011b). WHO Global Influenza Surveillance
Network: Manual for the laboratory diagnosis and virological surveillance of
influenza Retrieved from
http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
WHO, World Health Organization (2012a, April 2012). Background Paper on Influenza
Vaccines and Immunization SAGE Working Group. Paper presented at the
Working Group on Influenza Vaccines and Immunization Geneva, Switzerland.
WHO, World Health Organization (2012b, November 23, 2012). Vaccines against
influenza WHO position paper - November 2012. Weekly epidemiological record,
87, 461-476.
WHO, World Health Organization (2013). Global epidemiology surveillance standards
for influenza Retrieved from
http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influ
enza_Surveillance_Standards_2014.pdf?ua=1
WHO, World Health Organization (2014a). Definition of region groupings. Health
statistics and information systems. Retrieved December 5, 2014, 2014, from
http://www.who.int/healthinfo/global_burden_disease/definition_regions/en/

75
WHO, World Health Organization (2014b, March 2014). Influenza (Seasonal) fact sheet.
Retrieved April 5, 2014, 2014, from
http://www.who.int/mediacentre/factsheets/fs211/en/
WHO, World Health Organization (2014c). WHO recommendations on the composition
of influenza virus vaccines. Retrieved December 5, 2014, 2014, from
http://www.who.int/influenza/vaccines/virus/recommendations/en/
Widmer, K., Zhu, Y., Williams, J. V., Griffin, M. R., Edwards, K. M., & Talbot, H. K.
(2012). Rates of hospitalizations for respiratory syncytial virus, human
metapneumovirus, and influenza virus in older adults. J Infect Dis, 206(1), 56-62.
doi: 10.1093/infdis/jis309
Wong, C.-M., Chan, K.-P., Hedley, A. J., & Peiris, J. S. M. (2004). Influenza-Associated
Mortality in Hong Kong. Clinical Infectious Diseases, 39(11), 1611-1617. doi:
10.1086/425315
Wong, C. M., Peiris, J. S., Yang, L., Chan, K. P., Thach, T. Q., Lai, H. K., . . . Chow, A.
(2012). Effect of influenza on cardiorespiratory and all-cause mortality in Hong
Kong, Singapore and Guangzhou. Hong Kong Med J, 18 Suppl 2, 8-11.
Wong, C. M., Yang, L., Chan, E., Chan, K. H., Hedley, A. J., & Peiris, J. S. (2009).
Influenza-associated hospitalisation. Hong Kong Med J, 15 Suppl 9, 35-37.
Yang, L., Chiu, S. S., Chan, K.-P., Chan, K.-H., Wong, W. H.-S., Peiris, J. S. M., &
Wong, C.-M. (2011). Validation of Statistical Models for Estimating
Hospitalization Associated with Influenza and Other Respiratory Viruses. PLoS
ONE, 6(3), e17882. doi: 10.1371/journal.pone.0017882
Yang, L., Ma, S., Chen, P. Y., He, J. F., Chan, K. P., Chow, A., . . . Peiris, J. S. M.
(2011). Influenza associated mortality in the subtropics and tropics: Results from
three Asian cities. Vaccine, 29(48), 8909-8914. doi:
http://dx.doi.org/10.1016/j.vaccine.2011.09.071
Yu, H., Huang, J., Huai, Y., Guan, X., Klena, J., Liu, S., . . . Varma, J. K. (2014). The
substantial hospitalization burden of influenza in central China: surveillance for
severe, acute respiratory infection, and influenza viruses, 2010-2012. Influenza
Other Respir Viruses, 8(1), 53-65. doi: 10.1111/irv.12205
Zhou, H., Thompson, W. W., Viboud, C. G., Ringholz, C. M., Cheng, P. Y., Steiner, C., .
. . Shay, D. K. (2012). Hospitalizations associated with influenza and respiratory
syncytial virus in the United States, 1993-2008. Clin Infect Dis, 54(10), 14271436. doi: 10.1093/cid/cis211

Appendices
Appendix 1. Literature Search Methodology by Database
(Web appendix from Lafond et al., 2014)
Pubmed: 3596 results
1. influenza, human[sh] OR influenza A virus[majr] OR influenza B virus[majr] OR influenza C
virus[majr] OR influenza[all] OR viral etiology[all]
2. respiratory tract infections[sh] OR respiratory tract diseases[sh]
3. pneumonia[majr] OR pneumonia, viral[sh]
4. bronchiolitis[sh] OR bronchiolitis, viral[sh] OR bronchopneumonia[sh]
5. influenza-like illness[all]
6. acute respiratory[all] OR acute lower respiratory[all] OR lower respiratory[all]
7. ILI[all] OR SARI[all] OR ALRI[all] OR LRTI[all] OR CAP[all]
8. 1 AND (2 OR 3 OR 4 OR 5 OR 6 OR 7)
9. Limit 8 to ("1996/01/01"[PDAT] : "3000/12/31"[PDAT]) AND "humans"[MeSH Terms])
Embase (Ovid): 34349 results
1. exp influenza/ OR exp influenza virus/ OR exp influenza A/ OR exp influenza B/ OR exp influenza C/
OR exp influenza virus A / OR exp influenza virus B / OR exp influenza virus C / OR exp seasonal
influenza/ OR influenza.mp OR viral etiology.mp
2. exp respiratory tract infection/ OR exp acute respiratory tract disease/
3. exp pneumonia/ OR exp virus pneumonia/
4. exp bronchiolitis/ OR exp viral bronchiolitis/ OR exp bronchitis/
5. exp flu like syndrome/ OR influenza-like illness.mp
6. ILI.mp OR SARI.mp OR ARI.mp OR ALRI.mp OR LRTI.mp OR CAP.mp
7. 1 AND (2 OR 3 OR 4 OR 5 OR 6)
8. Limit 7 to (human and yr=”1996-Current”)
Global Health (Ovid): 4068 results
1. exp influenza/ OR exp influenza viruses/ OR exp Influenzavirus A/ OR exp Influenzavirus B/ OR exp
Influenzavirus C/ OR influenza.mp OR viral etiology.mp
2. exp respiratory diseases/ or exp lower respiratory tract infections
3. exp pneumonia/
4. exp bronchiolitis/ OR exp bronchitis/
5. influenza-like illness.mp OR ILI.mp OR SARI.mp OR ARI.mp OR ALRI.mp OR LRTI.mp OR
CAP.mp
6. 1 AND (2 OR 3 OR 4 OR 5)
7. Limit to yr=”1996-Current”
CINAHL via EBSCOhost: 630 results
(TX influenza OR TX influenza virus OR TX viral etiology)
AND
(TX respiratory infections OR TX pneumonia OR TX influenza-like illness OR TX acute respiratory OR
TX lower respiratory OR TX "ILI" OR TX "SARI" OR TX "ALRI" OR TX "ARI" OR TX "LRTI" OR TX
"CAP")
Limiters: 1996-2012; human
WHOLIS: 10
(influenza OR influenza virus OR viral etiology)

76

77

CINAHL via EBSCOhost (continued)
AND
(respiratory infection OR respiratory disease OR respiratory illness OR acute respiratory OR lower
respiratory OR pneumonia OR bronchiolitis OR bronchitis OR SARI OR ILI OR ARI OR ALRI OR LRTI
OR CAP)
Publication year: 1996-2012

Web of Science via Web of Knowledge: (SCI-EXPANDED): 6018
(TS= (Influenza) OR TS=(viral etiology))
AND
(TS=(Acute Respiratory Infections) OR TS=(respiratory diseases) OR TS=(respiratory illnesses) OR
TS=(Pneumonia) OR TS=(influenza-like illness) OR TS=(lower respiratory tract infections) OR
TS=(bronchiolitis) OR TS=(bronchitis))
Time span= 1996-2012
LILACS and IndMed: 275, 4
(Influenza)
AND
(respiratory disease OR respiratory infection OR OR pneumonia)

CNKI: 883 results
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 呼吸系统感染 (respiratory infection)
甲流 or 流感 or 病毒病原学(influenza group keywords )And 呼吸系统疾病 ( another name of respiratory
infection)
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 肺炎 or下支气管炎 (pneumonia or
bronchiolitis )
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 肺炎 or 上支气管炎 (pneumonia or
bronchitis )
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 流感病样病例 (ILI Chinesename) or ILI
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 急性呼吸道感染( sari chinese name) or
SARI
甲流 or 流感 or 病毒病原学 (influenza group keywords) And ARI
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 急性下呼吸道感染 (LRTI Chinese name)
or LRTI
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 急性上呼吸道感染 (LRTI Chinese name)
or LRTI
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 非典型肺炎 (SARS Chinese name) or
SARS
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 社区活动感染 (CAP Chinese name) or
CAP
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Appendix 2. Summary of Published Datasets Used in Analyses
Location

Years

Study
Population

Case Definition

Age
Range

Diagnostic Test

%
Influenza
Positive
≥14

%
Influenza
Positive
15-64

%
Influenza
Positive
≥45

%
Influenza
Positive
≥65

Total %
Influenza
Positive

Multiple Sites,
Kuwait1

2000-2001

general

Pneumonia

>=18

Enzyme-linked
Immunosorbent
Assay (Paired or
Single serum)
Polymerase Chain
Reaction, Viral
Culture (Respiratory
Specimen), and
Complement Fixation
(Paired Sera)
Polymerase Chain
Reaction,
Immunofluorescence
Assay (Respiratory
Specimen), and
Serology (Paired
Sera)

10.5

-

7.4

-

10.5

Shatin, Hong
Kong2

2004-2005

COPD

Acute
Exacerbations of
COPD with
Pneumonia

Adults

7.6

-

-

-

7.6

Noumea, New
Caledonia3

2006-2007

general

Pneumonia

>=18

19.0

-

-

-

19.0

Coast
Province,
Kenya4
Chiang Mai,
Thailand5

1994-1996

general

Pneumonia

>=18

Complement Fixation
(Paired Sera)

6.1

-

-

-

6.1

2006-2008

general

Pneumonia

>=18

Polymerase Chain
Reaction

5.9

-

-

-

5.9

Multiple Sites,
Thailand6

2001-2002

general

Acute Febrile
Illness

>=18

Enzyme-linked
Immunosorbent
Assay (Paired Sera)

-*

-

-

-

-

Santiago,
Chile7

2003-2004

general

Pneumonia

>=18

Immunofluorescence
Assay

6.9

-

-

-

6.9

Buenos Aires,
Argentina8

1998-2001

general

Pneumonia

>=18

2.0

-

-

-

2.0

Shenzhen,
China9

2003-2005

general

Pneumonia

>=18

Immunofluorescence
Assay, Viral Culture
(Multiple Respiratory
Specimens), and
Complement Fixation
(Sera)
Polymerase Chain
Reaction

22.8

-

-

-

22.8
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Location

Years

Study
Population

Case Definition

Age
Range

Diagnostic Test

%
Influenza
Positive
≥14
-*

%
Influenza
Positive
15-64
18.0*

%
Influenza
Positive
≥45
15.0*

%
Influenza
Positive
≥65
14.5*

Total %
Influenza
Positive

Dalian,
China10

1997-2000

general

Pneumonia

>=18

Enzyme-linked
Immunosorbent
Assay (Blood)

Shenzhen,
China11

2007-2008

general

Respiratory
Infection

>=18

Polymerase Chain
Reaction

17.3

18.2

19.0

15.8

17.3

Barcelona,
Spain12

1991-1995

Immunoco
mpromised

Cologne,
Germany13

2003-2004

Immunoco
mpromised

Acute
Respiratory
Infection
Pneumonia

Adults

Viral Culture

1.4

-

-

-

1.4

>=18

Polymerase Chain
Reaction, Viral
Culture, and Antigen
Detection
(Respiratory
Specimen)
Complement Fixation
(Paired Sera)

1.6

-

-

-

1.6

Multiple Sites,
Spain14

1992-1994

COPD

Pneumonia

Adults

-

-

-

-

-

Bochum,
Germany15

1998-1999

COPD

Beer-Sheva,
Israel16

1997-1999

COPD

Utrecht,
Netherlands17

2002-2004

general

Acute
Exacerbations of
COPD
Acute
Exacerbations of
COPD
Lower
Respiratory
Infection

>=18

Polymerase Chain
Reaction

22.4

-

-

-

22.4

>=65

Enzyme
Immunoassay (paired
sera)
Polymerase Chain
Reaction, Viral
Culture, and
Immunofluorescence
Assay (Multiple
Respiratory
Specimens)
Complement Fixation
(Paired Sera)

-

-

-

-

15.8

13.1

-

-

-

13.1

Beer-Sheva,
Israel18

1991-1992

general

Pneumonia

>=18

5.8

-

-

-

5.8

Leiden,
Netherlands19

1991-1993

general

Pneumonia

>=18

Complement Fixation
(Paired Sera)

5.9

-

-

-

5.9

Barcelona,
Spain20

1995-2001

general

Pneumonia

>=18

Enzyme
Immunoassay (Paired
Sera)

-*

-

-

-

-

>=18

-*
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Location

Years

Study
Population

Case Definition

Age
Range

Diagnostic Test

%
Influenza
Positive
≥14
20.8

%
Influenza
Positive
15-64
-

%
Influenza
Positive
≥45
-

%
Influenza
Positive
≥65
19.6

Total %
Influenza
Positive

Nottingham,
United
Kingdom21
Province of
Kuopia,
Finland22
Turku,
Finland23

1998-1999

general

Pneumonia

>=18

Complement Fixation
(Paired Sera)

1981-1982

general

Pneumonia

Adults

Complement Fixation
(Paired Sera)

2.2

6.7

0.9

-

2.2

1999-2004

general

Pneumonia

>=18

Polymerase Chain
Reaction,
Fluoroimmunoassay
(Multiple Respiratory
Specimens), and
Serology (Paired
Sera)

7.8

-

-

-

7.8

Alkmaar,
Netherlands24

1998-2000

general

Pneumonia

>=18

4.5

-

-

-

4.5

general

Pneumonia

>=18

9.8

-

-

-

9.8

general

Pneumonia

>=18

Polymerase Chain
Reaction
(Respiratory
Specimen) and
Enzyme-linked
Immunosorbent
Assay (Paired Sera)
Polymerase Chain
Reaction (Multiple
Respiratory
Specimens) and
Complement Fixation
(Paired Sera)
Polymerase Chain
Reaction,
Immunofluorescence
Assay, Viral Culture
(Respiratory
Specimen), and
Complement Fixation
(Paired Sera)

Leiden,
Netherlands25

2000-2002

Barcelona,
Spain26

2003-2004

8.1

-

-

-

8.1

20.8
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Location

Years

Study
Population

Case Definition

Age
Range

Diagnostic Test

%
Influenza
Positive
≥14

%
Influenza
Positive
15-64

%
Influenza
Positive
≥45

%
Influenza
Positive
≥65

Total %
Influenza
Positive

Stockholm,
Sweden27

2004-2005

general

Pneumonia

>=18

Polymerase Chain
Reaction, Viral
Culture (Respiratory
Specimen), and
Enzyme-linked
Immunosorbent
Assay (Paired Sera)

7.6

-

-

-

7.6

Schiedam,
Netherlands28

1998-1999

general

Pneumonia

>=18

Complement Fixation
and
Immunofluorescence
(Single or Paired
Sera)
Polymerase Chain
Reaction

21.7

-

-

-

21.7

Rome, Italy29

2004-2005

general

Pulmonary
Diseases

Adults

1.0

-

-

-

1.0

Turin, Italy30

2008-2008

general

Respiratory
Infection

>=18

Polymerase Chain
Reaction and Viral
Culture
Polymerase Chain
Reaction,
Immunofluorescence
Assay, and Viral
Culture
Polymerase Chain
Reaction,
Immunofluorescence
Assay, and Viral
Culture
Polymerase Chain
Reaction, Viral
Culture (Multiple
Respiratory
Specimens), and
Hemagglutination
Inhibition Assay
(Paired Sera)

0.6

-

-

-

0.6

Caen,
France31

2003-2004

other

Intubation in
ICU patients

Adults

3.7

-

-

-

3.7

St Louis,
Missouri,
United
States32

2005-2006

general

Acute
Respiratory
Infection

Adults

2.8

-

-

-

2.8

Houston,
Texas, United
States33

1993-1995

general

Acute
Respiratory
Infection

>=18

8.7

9.5

8.5

6.5

8.7
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Location

Years

Study
Population

Case Definition

Age
Range

Diagnostic Test

%
Influenza
Positive
≥14
3.6

%
Influenza
Positive
15-64
-

%
Influenza
Positive
≥45
-

%
Influenza
Positive
≥65
-

Total %
Influenza
Positive

Edmonton,
Canada34

2004-2006

general

Pneumonia

Adults

Polymerase Chain
Reaction and
Immunofluorescence
Assay

Singapore,
Singapore35

1995-1997

COPD

Adults

Melbourne,
Australia36

2003-2005

COPD

Acute
Exacerbations of
COPD
Acute
Exacerbations of
COPD

Complement Fixation
(Paired Sera)

24.4

-

-

-

24.4

>=65

Polymerase Chain
Reaction (Multiple
Respiratory
Specimens) and
Complement Fixation
(Paired Sera)
Complement Fixation
(Paired or Single
Serum)
Polymerase Chain
Reaction, Viral
Culture (Respiratory
Specimen),
Immunofluorescence
Assay, and
Complement Fixation
(Paired Sera)
Viral Culture
(Respiratory
Specimen) and
Complement Fixation
(Paired Sera)
Polymerase Chain
Reaction,
Immunofluorescence
Assay (Paired Sera),
and Viral Culture
(Multiple Respiratory
Specimens)

-

-

2.0

-

2.0

Multiple Sites,
Japan37

1994-1997

general

Pneumonia

>=18

1.4

-

-

-

1.4

Christchurch,
New
Zealand38

1999-2000

general

Pneumonia

>=18

9.5

-

-

-

9.5

Multiple Sites,
Japan39

1998-2000

general

Pneumonia

>=65

-

-

-

7.1

7.1

Newcastle,
Australia40

2000-2003

other

Acute
Exacerbations of
COPD

>=65

-

-

17.8

-

17.8

3.6
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Location

Years

Study
Population

Case Definition

Age
Range

Diagnostic Test

Melbourne,
Australia41

1993-1994

other

Acute
Exacerbation of
Asthma

>=18

Ljubljana,
Slovenia42

1996-1997

general

Pneumonia

>=18

Viral Culture
(Respiratory
Specimen) and
Complement Fixation
(Paired Sera)
Viral Culture
(Respiratory
Specimen) and
Complement Fixation
(Paired Sera)

* Estimates for Influenza A only

%
Influenza
Positive
≥14

%
Influenza
Positive
15-64

%
Influenza
Positive
≥45

%
Influenza
Positive
≥65

Total %
Influenza
Positive

25.3

-

-

-

25.3

1.9

-

-

-

1.9
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Appendix 3. Summary of unpublished (surveillance) datasets
Number of
Total number
Country
Years
inpatient sites
tested
Angola
2009 - 2011
2
111
Bangladesh
2007- 2011
12
3338
Cambodia
2009 - 2011
3
849
China(IEIP)
2010 - 2012
1
2178
China (Sentinel)
2011 - 2012
10
1462
Costa Rica
2006 - 2009
10
115
Cote d'Ivoire
2009 - 2011
3
53
DRC
2009 - 2011
3
359
El Salvador
2007 - 2011
1754
Ghana
2009 - 2011
4
695
Guatemala
2008 - 2011
3
1457
India (Ballabgarh)
2009 - 2011
33
651
India (Vadu)
2009 - 2011
38
1538
Indonesia
2011
11
179
Kenya
2006 - 2011
9
569
Kyrgyz
2009 - 2011
4
266
Lao
2008 - 2011
5
206
Mexico
2003 - 2010
1
205
Moldova
2009 - 2011
9
1394
Mongolia
2006 - 2011
35
3256
Morocco
2007 - 2011
16
720
Nigeria
2008 - 2011
4
317
Paraguay
2010 - 2011
4
1065
Philippines
2009 - 2011
6
626
South Africa
2009 - 2011
5
6370
Tanzania
2008 - 2011
5
205
Thailand (RPS)
2005 - 2011
20
12779
Thailand (MOPH)
2010 - 2011
3
218
Vietnam
2011 - 2012
8
800
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Appendix 4. Pandemic crude proportion of respiratory samples from hospitalized adults testing positive for
influenza by age group, study design, and population including all datasets*†
No. of
Median
studies
Median Percent Positive (IQR) p-value**
Number (IQR)
(n=)
Tested
Positive
Age group in years
≥14
9
501(123, 835)
162(52, 187) 23% (0.13, 0.34) 0.8651
18 to 64
8
567(229, 856)
113(11, 227) 22% (0.15, 0.30)
≥45
6
246(159, 332)
43(40, 56)
19% (0.14, 0.25)
≥65
4
147(110, 444)
23(20, 379)
18% (0.16, 0.60)
Diagnostic test
PCR only
3
95(70, 830)
13(9, 162)
14% (0.13, 0.20) 0.1213
Immunofluorescence
0
0
0
0%
only
Culture only
0
0
0
0%
Serology Only
0
0
0
0%
Multiple diagnostic
6
668(447, 1752) 180(103, 316) 29% (0.23, 0.38)
tests, incl. PCR
Multiple diagnostic
0
0
0
0%
tests, excl. PCR
Case definition
Acute Respiratory
0
0
0
0%
0.0404
Infection
Acute Lower
2
911(70, 1752)
98(9, 187)
12% (0.11, 0.13)
Respiratory Infection
Pneumonia
0
0
0
0%
Severe Acute
21
720(317, 1457)
162(52, 316) 24% (0.20, 0.38)
Respiratory Illness
Other
0
0
0
0%
WHO region
African
1
95
13
14%
0.3330
Eastern
1
501
172
34%
Mediterranean
European
1
123
52
42%
Americas
2
641(447, 835)
210(103, 316) 30%(0.23, 0.38)
Southeast Asian
1291(830,
2
175(162, 187) 15%(0.11, 0.20)
1752)
Western Pacific
2
969(70, 1869)
232(9, 454)
19% (0.13, 0.24)
World Bank Income Level
Low
4
109(83, 477)
33(11, 107)
17%(0.13, 0.31) 0.6242
Lower Middle
5
835(501, 1752) 187(172, 316) 24%(0.23, 0.34)
Upper Middle
0
0
0
0%
High
0
0
0
0%
*Six eligible articles provided data for influenza A only, and were excluded from the overall positive analyses
**Kruskal-Wallis/Wilcoxon rank sum test.
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. Since data was provided by year in
the unpublished datasets, three unpublished datasets were included in two timeframes; six unpublished datasets were in all three timeframes.
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Appendix 5. Assessment of the Impact of Dataset Quality on Positive Proportions
5a. Median Influenza-Positive Proportion for Respiratory Samples from Hospitalized Adults in Published Datasets only shown below by Bias Score
bias

low score

high score

KW p-value

No. of
datasets
(n=)

Median Percent
Positive (IQR)

6% (0.03, 0.10)

31

8% (0.04, 0.17)

0.8081

9

6% (0.02, 0.14)

32

8% (0.05, 0.18)

0.7528

14

9% (0.06, 0.13)

27

8% (0.04, 0.18)

0.9124

16

8% (0.04, 0.19)

0.9255

No. of datasets
(n=)

Median Percent
Positive (IQR)

10

comparability
outcome
total

8

8% (0.02, 0.13)

selection

medium score
No. of datasets
(n=)

17

Median Percent
Positive (IQR)

7% (0.05, 0.16)

Total bias = selection bias + comparability bias + outcome bias
Low score is a score of 1 or 0 for total and a score of 0 for individual bias.
Medium score is a score of 2 for total; no medium score used for individual bias.
High score is a score of 3 for total and score of 1 for individual bias.

5b. Median Influenza-Positive Proportion Stratified by PCR testing
5bi. PCR tested
Bias

low score

medium score

high score

KW p-value

No. of
datasets
(n=)

Median Percent
Positive (IQR)

5% (0.03, 0.10)

12

13% (0.08, 0.18)

0.0394

5

9% (0.04, 0.10)

13

10% (0.07, 0.18)

0.4597

outcome

3

10% (0.10, 0.13)

15

8% (0.05, 0.18)

0.3743

Total

4

10% (0.03, 0.13)

8

14% (0.08, 0.21)

0.1866

No. of datasets
(n=)

Median Percent
Positive (IQR)

selection

6

comparability

No. of datasets
(n=)

6

Median Percent
Positive (IQR)

5% (0.04, 0.09)
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5bii. No PCR
Bias

low score

KW pvalue

high score
No. of
datasets
(n=)

Median
Percent
Positive (IQR)

20% (0.02, 0.24)

18

6% (0.02, 0.10)

0.3657

3

2%(0.01, 0.25)

18

7% (0.02, 0.16)

0.763

11

7% (0.01, 0.16)

10

5% (0.02, 0.20)

0.7782

7

4% (0.02, 0.07)

0.5196

No. of datasets
(n=)

Median Percent
Positive (IQR)

selection

3

comparability
outcome
Total

medium score
Median
No. of
Percent
datasets
Positive
(n=)
(IQR)

3

2% (0.01, 0.25)

8% (0.06,
0.20)

11

5c. Median Influenza-Positive Proportion Stratified by Timeframe
5ci.Seasonal
bias

low score

high score

KW p-value

No. of
datasets
(n=)

Median Percent
Positive (IQR)

8% (0.03, 0.11)

32

8% (0.04, 0.17)

0.8081

9

9% (0.03, 0.11)

33

8% (0.05, 0.17)

0.7528

15

9% (0.06, 0.13)

27

8% (0.04, 0.18)

0.9124

16

8% (0.05, 0.18)

0.9255

No. of datasets
(n=)

Median Percent
Positive (IQR)

10

comparability
outcome
total

8

10% (0.02, 0.13)

selection

medium score
No. of datasets
(n=)

17

Median Percent
Positive (IQR)

7% (0.05, 0.16)
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Appendix 6. Evaluating Impact of pandemic H1N1 in 2010 calendar year
6a. Crude positive proportions for seasonal influenza by 2010 data
Datasets without 2010 Data
No. of studies
Median Percent
(n=)
Positive (IQR)
Age group in years
≥14
65
8% (0.04, 0.14)
18 to 64
30
11% (0.06, 0.15)
≥45
25
8% (0.02, 0.13)
≥65
19
11% (0.06, 0.15)
Type of study
Unpublished surveillance
30
10% (0.04, 0.14)
Published
39
8% (0.04, 0.17)
Diagnostic test
Polymerase Chain Reaction (PCR) only
13
11% (0.10, 0.17)
Immunofluorescence only
1
7%
Culture only
1
1%
Serology Only
10
6% (0.02, 0.16)
Multiple diagnostic tests, incl. PCR
39
8% (0.03, 0.11)
Multiple diagnostic tests, excl. PCR
5
20% (0.07, 0.22)
Case definition
Acute Respiratory Infection
4
6% (0.02, 0.11)
Acute Lower Respiratory Infection
6
12% (0.07, 0.14)
Pneumonia
24
7% (0.04, 0.10)
Severe Acute Respiratory Illness
24
9% (0.03, 0.12)
Other
11
16% (0.04, 0.22)
Study population
General adult population
58
8% (0.05, 0.13)
COPD
6
12% (0.02, 0.22)
Immunocompromised
2
1% (0.01, 0.02)
Other
3
18% (0.04, 0.25)
WHO region
African
8
8% (0.06, 0.12)
Eastern Mediterranean
1
10%
European
22
8% (0.02, 0.16)
Americas
9
7% (0.04, 0.10)
Southeast Asian
9
10% (0.06, 0.14)
Western Pacific
20
9% (0.03, 0.18)
World Bank income level
Low
10
10% (0.06, 0.14)
Lower Middle
19
6% (0.03, 0.14)
Upper Middle
8
12% (0.08, 0.19)
High
32
8% (0.03, 0.14)
Development Status
Developing
39
10% (0.06, 0.14)
Industrialized
30
7% (0.02, 0.13)
*Thirteen eligible articles provided data for influenza A only, and were excluded from the overall positive analyses
**Kruskal-Wallis/Wilcoxon rank sum test.
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates.

p-value
0.902

0.8512

0.094

0.4646

0.1549

0.9827

0.436

0.2261
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6b. Pooled estimates for seasonal influenza without 2010
Datasets without 2010 Data
PCR
PCR tested
Tested
Pooled %
N*
Positive (95% CI)
Age group in years
≥14
18 to 64
≥45
≥65
Study population
General adult popn
Special population**
WHO region
African
Americas
Eastern Mediterranean
European
Southeast Asian
Western Pacific
Income level
Low Income
Lower Middle Income
Upper Middle Income
High Income
Development status†
Developing
Industrialized

N†

Pooled %
Positive (95%
CI)†

42
26
19
13

10% (0.08, 0.13)
11% (0.07, 0.17)
9% (0.09, 0.10)
did not converge

66
30
25
19

9% (0.08, 0.11)
11% (0.07, 0.17)
9% (0.09, 0.09)
did not converge

39
5

10% (0.08, 0.13)
9% (0.03, 0.30)

58
9

10% (0.08, 0.12)
12% (0.07, 0.22)

7
2
0
10
9
16

9% (0.07, 0.12)
6% (0.0001, 47)
0%
16% (0.07, 0.38)
did not converge
10% (0.08, 0.13)

8
9
1
22
9
20

9% (0.07, 0.11)
8% (0.05, 0.12)

9
15
5
15

8% (0.04, 0.14)
11% (0.04, 0.32)
10% (0.07, 0.15)
9% (0.06, 0.12)

10
19
8
32

8% (0.05, 0.13)
11% (0.05, 0.25)
10% (0.08, 0.14)
8% (0.06, 0.11)

31
13

10% (0.07, 0.15)
8% (0.06, 0.12)

39
30

10% (0.08, 0.13)
7% (0.5, 0.10)

10% (0.05, 0.18)
did not converge
10% (0.08, 0.13)

*Number of data points included in model, including multiple individual years from a single dataset, when available
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients
†All diagnostic tests included
‡no PCR data
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients
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Appendix 7. Evaluating Impact of Partial-year Influenza Testing
7a. Seasonal crude positive proportions for datasets stratified by partial-years
Datasets with partial-years
Datasets with full-years
No. of
studies
Median Percent
pNo. of studies
Median Percent
(n=)
Positive (IQR)
value
(n=)
Positive (IQR)
Age group in years
≥14
20
9% (0.06, 0.12)
0.4649
43
9% (0.04, 0.22)
18 to 64
7
10% (0.06, 0.21)
12
10% (0.04, 0.15)
≥45
7
11% (0.09, 0.19)
19
9% (0.04, 0.14)
≥65
5
10% (0.06, 0.11)
26
10% (0.07, 0.15)
Type of study
Unpublished surveillance
5
10% (0.08, 0.21) 0.3676
20
11% (0.06, 0.15)
Published
17
10% (0.06, 0.13)
22
7% (0.02, 0.20)
Timeframe for outcome data
Pre-2009†
18
10% (0.6, 0.14)
0.2571
29
8% (0.02, 0.17)
Post-2009
6
13% (0.08, 0.18)
20
12% (0.08, 0.20)
Diagnostic test
Polymerase Chain Reaction (PCR)
only
6
19% (0.10, 0.22) 0.1751
16
11% (0.07, 0.15)
Immunofluorescence only
1
7%
0
0%
Culture only
0
0%
1
1%
Serology Only
5
6% (0.6, 0.10)
5
6% (0.02, 0.21)
Multiple diagnostic tests, incl.
PCR
10
9% (0.08, 0.10)
42
8% (0.03, 0.14)
Multiple diagnostic tests, excl.
PCR
0
0%
5
20% (0.07, 0.22)
Case definition
Acute Respiratory Infection
2
6% (0.03, 0.09)
0.032
3
13% (0.01, 0.17)
Acute Lower Respiratory Infection
2
17% (0.13, 0.21)
6
12% (0.07, 0.14)
Pneumonia
9
7% (0.06, 0.10)
15
7% (0.02, 0.20)
Severe Acute Respiratory Illness
2
9% (0.08, 0.10)
39
10% (0.05, 0.15)
Other
7
17% (0.16, 0.22)
6
6% (0.02, 0.24)
Study population
General adult population
18
9% (0.06, 0.10)
0.4309
35
10% (0.05, 0.15)
COPD
3
16% (0, 0.22)
3
8% (0.02, 0.24)
Immunocompromised
0
0%
2
1% (0.01, 0.02)
Other
1
18%
2
15% (0.04, 0.25)
WHO region
African
1
6%
0.4022
14
9% (0.06, 0.14)
Eastern Mediterranean
1
10%
0
0%
European
8
10% (0.07, 0.14)
16
7% (0.02, 0.17)
Americas
5
7% (0.04, 0.09)
7
12% (0.06, 0.18)
Southeast Asian
2
14% (0.04, 0.23)
12
12% (0.07, 0.16)
Western Pacific
5
17% (0.10, 0.18)
21
9% (0.03, 0.17)
World Bank income level
Low
2
13% (0.06, 0.21) 0.9284
8
10% (0.07, 0.14)
Lower Middle
3
10% (0.04, 0.23)
11
11% (0.04, 0.15)
Upper Middle
3
8% (0.07, 0.17)
5
13% (0.08, 0.20)
High
14
10% (0.06, 0.13)
18
6% (0.02, 0.19)
Development Status
Developing
9
10% (0.07, 0.17) 0.4425
25
11% (0.06, 0.15)
Industrialized
13
10% (0.06, 0.13)
17
5% (0.02, 0.08)
*Thirteen eligible articles provided data for influenza A only, and were excluded from the overall positive analyses
**Kruskal-Wallis/Wilcoxon rank sum test.
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates.

pvalue
0.4765

0.2709

0.038

0.3086

0.9681

0.2257

0.7672

0.4374

0.0464
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7b. Influenza-positive pooled estimates for datasets stratified by partial-years
Datasets with partial-years
PCR tested
PCR
Pooled %
Tested
Positive (95%
Pooled % Positive
N*
CI)
N†
(95% CI)†
Age group in years
≥14
14
12% (0.08, 0.16) 20 11% (0.08, 0.14)
18 to 64
7
13% (0.07, 0.24)
7
13% (0.07, 0.24)
≥45
6
11% (0.08, 0.15)
7
11% (0.08, 0.15)
≥65
5
11% (0.08, 0.14)
5
11% (0.08, 0.14)
Study population
General adult population
13
11% (0.08, 0.16) 18 11% (0.08, 0.14)
Special population**
2
20% (0.05, 0.86)
4
14% (0.05, 0.37)
WHO region
African
1
Americas
3
9% (0.03, 0.23)
5
8% (0.05, 0.14)
Eastern Mediterranean
1
European
5
11% (0.07, 0.18)
8
10% (0.07, 0.16)
17% (0.0002,
Southeast Asian
2
143)
2
17% (0.0002, 143)
Western Pacific
5
10% (0.06, 0.18)
5
10% (0.06, 0.18)
Income level
Low Income
1
2
12% (0.00005, 254)
Lower Middle Income
3
14% (0.03, 0.72)
3
14% (0.03, 0.72)
Upper Middle Income
2
9% (0.002, 5.6)
3
9% (0.03, 0.24)
High Income
9
10% (0.07, 0.14) 14 9% (0.07, 0.12)
Development status†
Developing
6
13% (0.07, 0.24)
9
12% (0.08, 0.19)
Industrialized
9
10% (0.07, 0.14) 13 9% (0.06, 0.13)
*Number of data points included in model, including multiple individual years from a single dataset, when available
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients
†All diagnostic tests included
‡no PCR data
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients

Datasets with full-years

PCR Tested N*

PCR tested Pooled %
Positive (95% CI)

N†

Pooled % Positive
(95% CI)†

48
37
27
18

11%(0.09, 0.14)
12% (0.09, 0.16)
10% (0.09, 0.11)
10%

68
43
34
26

11% (0.09, 0.13)
12% (0.09, 0.16)
10% (0.09, 0.11)
10%

46
3

11% (0.09, 0.14)
4% (0.008, 0.17)

62
5

11% (0.09, 0.13)
10% (0.03, 0.39)

14

9% (0.07, 0.12)

14
7

9% (0.07, 0.12)
14% (0.07, 0.30)

7

21% (0.06, 0.68)

16

10% (0.04, 0.23)

12
16

11% (0.08, 0.16)
11% (0.08, 0.16)

12
20

11% (0.08, 0.16)
11% (0.08, 0.15)

16
22
5
6

13% (0.10, 0.17)
12% (0.07, 0.19)
10% (0.04, 0.26)
7% (0.03, 0.17)

16
28
7
18

13% (0.10, 0.17)
12% (0.08, 0.17)
10% (0.06, 0.17)
7% (0.04, 0.12)

45
4

11% (0.09, 0.14)
5% (0.02, 0.10)

52
17

11% (0.09, 0.14)
6% (0.3, 0.11)
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Appendix 8. Evaluating Impact of Multipathogen Detection
8a. Crude positive proportions
Studies with Multipathogen detection
No. of studies
Median Percent
(n=)
Positive (IQR)
p-value
Age group in years
≥14
18 to 64
≥45
≥65
Type of study
Unpublished surveillance
Published
Timeframe for outcome data
Pre-2009†
During 2009 ("pandemic")
Post-2009
Diagnostic test
Polymerase Chain Reaction (PCR)
only
Immunofluorescence only
Culture only
Serology Only
Multiple diagnostic tests, incl. PCR
Multiple diagnostic tests, excl. PCR
Case definition
Acute Respiratory Infection
Acute Lower Respiratory Infection
Pneumonia
Severe Acute Respiratory Illness
Other
Study population
General adult population
COPD
Immunocompromised
Other
WHO region
African
Eastern Mediterranean
European
Americas
Southeast Asian
Western Pacific
World Bank income level
Low
Lower Middle
Upper Middle
High
Development Status
Developing
Industrialized

37
2
6
5

8% (0.04, 0.15)
14%(0.09, 0.18)
8% (0.02, 0.18)
7% (0.06, 0.16)

0.4386

0
41

0%
8% (0.04, 0.17)

41
0
0

8% (0.04, 0.17)
0%
0%

5
1
1
10
17
5

17% (0.10, 0.22)
7%
1%
6% (0.02, 0.16)
8% (0.04, 0.10)
20% (0.07, 0.22)

0.1922

3
1
24
0
11

3% (0.01, 0.09)
13%
7% (0.04, 0.10)
0%
16% (0.04, 0.22)

0.2715

28
6
2
3

8% (0.05, 0.12)
12% (0.02, 0.22)
1% (0.01, 0.02)
18% (0.04, 0.25)

0.1751

1
1
20
5
1
11

6%
10%
7% (0.02, 0.12)
7% (0.04, 0.09)
6%
17% (0.07, 0.23)

0.5452

1
1
5
32

6%
6%
17% (0.07, 0.20)
8% (0.03, 0.14)

0.7587

10
30

10% (0.07, 0.19)
7% (0.02, 0.13)

0.1252

*Thirteen eligible articles provided data for influenza A only, and were excluded from the overall positive analyses
**Kruskal-Wallis/Wilcoxon rank sum test.
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates.
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8b.Pooled estimates
Studies with Multipathogen detection
PCR tested
PCR
Pooled %
Tested
Positive (95%
N*
CI)
N†
Age group in years
≥14
18 to 64
≥45
≥65
Study population
General adult population
Special population**
WHO region
African
Americas
Eastern Mediterranean
European
Southeast Asian
Western Pacific
Income level
Low Income
Lower Middle Income
Upper Middle Income
High Income
Development status
Developing
Industrialized

Pooled % Positive
(95% CI)†

16
2
4
2

10% (0.07, 0.13)
13% (0.002, 8.3)
11% (0.03, 0.34)
12% (0.001, 19)

36
2
6
5

8% (0.06, 0.11)
13% (0.002, 8.3)
9% (0.04, 0.22)
10% (0.04, 0.28)

13
5

10% (0.07, 0.13)
9% (0.3, 0.30)

28
11

8% (0.06, 0.11)
7% (0.03, 0.16)

0
2
0
8
1
7

0%
6% (0.0001, 47)
0%
9% (0.06, 0.13)
13% (0.08, 0.21)

1
5
1
20
2
11

12% (0.07, 0.19)

0
0
2
15

0%
0%
19% (0.03, 1.0)
9% (0.06, 0.12)

1
2
5
32

12% (0.05, 0.30)
8% (0.06, 0.11)

5
13

15% (0.09, 0.26)
8% (0.06, 0.12)

10
30

12% (0.09, 0.19)
7% (0.05, 0.10)

7% (0.02, 0.18)
7% (0.05, 0.11)

*Number of data points included in model, including multiple individual years from a single dataset, when available
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients
†All diagnostic tests included
‡no PCR data
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients
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Appendix 9. Glossary
Terms or abbreviation followed by definition
Surface antigens of influenza virus type A
 HA – hemagglutinin
 NA – neuraminidase
Public Health Agencies
 WHO – World Health Organization
 CDC – Centers for Disease Control and Prevention
Study Timeframe
 Pre-pandemic – conducting study, collection and testing specimens prior to the 2009-calendar year
 Pandemic – collecting and testing specimens during the 2009-calendar year
 Post-pandemic – conducting study, collecting and testing specimens in 2010-calendar year and
later
Diagnostic Test
 PCR – Polymerase Chain Reaction
 Multiple diagnostic tests incl. PCR – study using more than one tests including polymerase chain
reaction to detect and confirm influenza
 Multiple diagnostic tests excl. PCR – study using more than one tests excluding polymerase chain
reaction to detect and confirm influenza
 Immunofluorescence – a microscopy technique used to detect the presence of a protein
specifically targeted by fluorescent-labeled antibodies
 Complement Fixation – immunological assay which includes serum complement for the binding
of antigen-antibody complexes
Case Definitions
 SARI – Severe acute respiratory infection
 ILI – Influenza-like illness
 ARI – Acute respiratory illness
 ARLI – Acute respiratory like illness
 LRTI – Lower respiratory tract illness
 CAP – Community acquired pneumonia
 Other – includes acute febrile illness, respiratory infection, acute exacerbation of chronic illness
Study Populations
 COPD – Chronic obstructive pulmonary disease
 ICU – Intensive care unit
 Other – includes ICU patients (only), acute exacerbation of chronic illness
 Popn – population
Regional Groupings
 WHO region – six regions that WHO member states are grouped into
 World Bank income level –
http://siteresources.worldbank.org/DATASTATISTICS/Resources/OGHIST.xls
 Development status – United Nations Population Division (UNPD), 2012 World Population
Prospects Report

97

Statistical Terms
 CI – confidence intervals
 IQR – interquartile range; statistic dispersion
Exploratory Analysis
 Partial-year data - datasets which completed ongoing influenza testing beyond a 12-month period,
such as 15 and 26 months
 Multipathogen detection – datasets which tested for other pathogens in addition to influenza type
A and B
o RSV – Respiratory syncytial virus
o M.pna – Mycoplasma pneumoniae
Vaccines and immune status
 LAIV – Live Attenuated Influenza Vaccine
 HIV – human immunodeficiency virus
 Immunosenescence – decreased immune functionality observed or associated with aging

